[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 331
1. Youm HS, Cha DS, Han KH, Park EY, Hyon NN, Chong Y: A case of huge sclerosing stromal tumor of the ovary weighing 10 kg in a 71-year-old postmenopausal woman. J Gynecol Oncol; 2008 Dec;19(4):270-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of huge sclerosing stromal tumor of the ovary weighing 10 kg in a 71-year-old postmenopausal woman.
  • Sclerosing stromal tumor (SST) is a rare benign neoplasm of ovarian stromal origin and predominantly affects young women in the second and third decades.
  • This tumor characteristically differentiates itself histologically and clinically from both thecomas and fibromas.
  • We present a case of huge SST of the ovary weighing 10 kg in a 71-year-old postmenopausal woman with a brief review of the literature.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virchows Arch. 2003 Oct;443(4):549-60 [12910419.001]
  • [Cites] Gynecol Oncol. 2001 May;81(2):318-9 [11330969.001]
  • [Cites] Obstet Gynecol. 1975 Jun;45(6):675-9 [1143729.001]
  • [Cites] Adv Anat Pathol. 2007 Sep;14(5):305-19 [17717430.001]
  • [Cites] AJR Am J Roentgenol. 2005 Jul;185(1):207-15 [15972425.001]
  • [Cites] Ultrasound Obstet Gynecol. 2003 Nov;22(5):531-4 [14618669.001]
  • [Cites] Gynecol Oncol. 1976 Sep;4(3):335-9 [964703.001]
  • [Cites] Cancer. 1973 Mar;31(3):664-70 [4348335.001]
  • [Cites] Clin Radiol. 2000 Dec;55(12):899-911 [11124069.001]
  • [Cites] Int J Gynaecol Obstet. 2003 Dec;83(3):319-21 [14643050.001]
  • [Cites] Histopathology. 1979 Sep;3(5):367-76 [488921.001]
  • (PMID = 19471655.001).
  • [ISSN] 2005-0380
  • [Journal-full-title] Journal of gynecologic oncology
  • [ISO-abbreviation] J Gynecol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2676485
  • [Keywords] NOTNLM ; Ovary / Sclerosing stromal tumor
  •  go-up   go-down


2. Iravanloo G, Nozarian Z, Sarrafpour B, Motahhary P: Sclerosing stromal tumor of the ovary. Arch Iran Med; 2008 Sep;11(5):561-2
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sclerosing stromal tumor of the ovary.
  • Sclerosing stromal tumors are benign ovarian neoplasms of the sex cord stromal category which occur predominantly in the second and third decades of life.
  • Herein, we report a 26-year-old woman who developed a sclerosing stromal tumor of the ovary with irregular menses but normal hormonal status.
  • She was suspected to have a malignant tumor and underwent bilateral oophorectomy.
  • Other ovarian stromal tumors include fibroma and thecoma which tend to occur in the fifth and sixth decades of life.
  • It is, therefore, necessary to keep in mind the possibility of a sclerosing stromal tumor in a young woman.
  • [MeSH-major] Ovarian Neoplasms. Sex Cord-Gonadal Stromal Tumors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18759528.001).
  • [ISSN] 1735-3947
  • [Journal-full-title] Archives of Iranian medicine
  • [ISO-abbreviation] Arch Iran Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Iran
  •  go-up   go-down


3. Ziadi S, Trimeche M, Hammedi F, Hidar S, Sriha B, Mestiri S, Korbi S: Bilateral proliferating Brenner tumor of the ovary associated with recurrent urothelial carcinoma of the urinary bladder. N Am J Med Sci; 2010 Jan;2(1):39-41

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral proliferating Brenner tumor of the ovary associated with recurrent urothelial carcinoma of the urinary bladder.
  • CONTEXT: Brenner tumors of ovary are relatively uncommon neoplasm.
  • Most of them are benign and less than 5% are proliferating or borderline.
  • The association between Brenner tumor of the ovary and papillary urothelial carcinoma of bladder is extremely rare.
  • CASE REPORT: We describe an unusual case of proliferating bilateral Brenner tumor of the ovary with a highly recurrent low-grade papillary urothelial carcinoma of bladder.
  • CONCLUSION: The immunohistopathological similarities of ovarian and bladder tumors and their association in the current case, may be coincidental but may reflect a common initiating event inducing similar pathogenesis changes in the epithelium of both organs.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Obstet Gynecol. 1961 Apr;81:743-51 [13684151.001]
  • [Cites] Urology. 2003 Mar;61(3):634-7; discussion 637 [12639661.001]
  • [Cites] Virchows Arch. 2006 Aug;449(2):268-71 [16832656.001]
  • [Cites] Cancer. 1979 May;43(5):1830-9 [445369.001]
  • [Cites] Pathologica. 1990 Jan-Feb;82(1077):101-8 [2194158.001]
  • [Cites] Int J Gynecol Pathol. 1988;7(3):197-211 [2846458.001]
  • [Cites] Eur J Gynaecol Oncol. 2007;28(3):233-4 [17624095.001]
  • [Cites] Eur J Gynaecol Oncol. 1999;20(4):318-20 [10475132.001]
  • [Cites] Ann Pathol. 1998 Apr;18(2):103-9 [9608862.001]
  • [Cites] Mod Pathol. 1995 May;8(4):384-8 [7567935.001]
  • [Cites] Cancer. 1984 Jun 15;53(12):2692-7 [6722728.001]
  • [Cites] Acta Pathol Microbiol Scand Suppl. 1972;233:56-66 [5074634.001]
  • [Cites] Cancer. 1972 Jul;30(1):174-86 [5040741.001]
  • [Cites] Cancer. 1985 Aug 1;56(3):582-91 [4005815.001]
  • (PMID = 22624111.001).
  • [ISSN] 2250-1541
  • [Journal-full-title] North American journal of medical sciences
  • [ISO-abbreviation] N Am J Med Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3354386
  • [Keywords] NOTNLM ; Brenner tumor / ovary / urinary bladder / urothelial carcinoma
  •  go-up   go-down


Advertisement
4. Bonome T, Lee JY, Park DC, Radonovich M, Pise-Masison C, Brady J, Gardner GJ, Hao K, Wong WH, Barrett JC, Lu KH, Sood AK, Gershenson DM, Mok SC, Birrer MJ: Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res; 2005 Nov 15;65(22):10602-12
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary.
  • Papillary serous low malignant potential (LMP) tumors are characterized by malignant features and metastatic potential yet display a benign clinical course.
  • The role of LMP tumors in the development of invasive epithelial cancer of the ovary is not clearly defined.
  • The aim of this study is to determine the relationships among LMP tumors and invasive ovarian cancers and identify genes contributing to their phenotypes.
  • Affymetrix U133 Plus 2.0 microarrays (Santa Clara, CA) were used to interrogate 80 microdissected serous LMP tumors and invasive ovarian malignancies along with 10 ovarian surface epithelium (OSE) brushings.
  • Gene expression profiles for each tumor class were used to complete unsupervised hierarchical clustering analyses and identify differentially expressed genes contributing to these associations.
  • The majority of low-grade tumors clustered with LMP tumors.
  • Comparing OSE with high-grade and LMP expression profiles revealed enhanced expression of genes linked to cell proliferation, chromosomal instability, and epigenetic silencing in high-grade cancers, whereas LMP tumors displayed activated p53 signaling.
  • The expression profiles of LMP, low-grade, and high-grade papillary serous ovarian carcinomas suggest that LMP tumors are distinct from high-grade cancers; however, they are remarkably similar to low-grade cancers.
  • Prominent expression of p53 pathway members may play an important role in the LMP tumor phenotype.
  • [MeSH-major] Carcinoma, Papillary / genetics. Carcinoma, Papillary / pathology. Cystadenocarcinoma, Serous / genetics. Cystadenocarcinoma, Serous / pathology. Ovarian Neoplasms / genetics. Ovarian Neoplasms / pathology
  • [MeSH-minor] Cluster Analysis. Female. Gene Expression Profiling. Humans. Neoplasm Staging. Oligonucleotide Array Sequence Analysis / methods. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16288054.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50CA165009; United States / NCI NIH HHS / CA / R33CA103595
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


5. Zhang LL, Shao SL, Wu Y: [Expressions of osteopontin and B7-H4 in epithelial ovarian neoplasm and their significance]. Chin J Cancer; 2010 Jan;29(1):25-9
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expressions of osteopontin and B7-H4 in epithelial ovarian neoplasm and their significance].
  • BACKGROUND AND OBJECTIVE: Epithelial ovarian cancer involves a number of factors.
  • Recent studies have shown that osteopontin (OPN) is related to the occurrence and development of a variety of tumors, but few studies are on ovarian cancer.
  • B7-H4 is a newly identified tumor marker in ovarian cancer.
  • This study explored the expression of OPN and B7-H4 and their clinical significance in epithelial ovarian tumors.
  • METHODS: The expression of OPN and B7-H4 in 15 cases of normal ovarian tissue, 20 of benign ovarian tumor tissue, 20 of borderline ovarian tumor tissue, and 40 of ovarian cancer tissue were detected by immunohistochemistry, and the relationship of OPN and B7-H4 expression to clinical and pathologic features of ovarian cancer was analyzed.
  • RESULTS: The expression of OPN and B7-H4 were significantly higher in ovarian cancer than in borderline and benign tumors (P<0.05).
  • The positive rates of OPN and B7-H4 were significantly higher in poorly differentiated ovarian cancer than in medium and highly differentiated ovarian cancer (P<0.05), and the levels of expression were significantly lower in tissue at stages I and III of ovarian cancer than in stages III and IV (P<0.05).
  • The positive rate of B7-H4 were significantly higher in ovarian serous carcinoma than in the mucinous carcinoma (P<0.05), but did not relate to age and lymph node metastasis.
  • CONCLUSION: The expression of OPN and B7-H4 increased in epithelial ovarian cancer, which could be referenced in the diagnosis of ovarian malignant tumors.
  • [MeSH-major] Cystadenocarcinoma, Serous / metabolism. Neoplasms, Glandular and Epithelial / metabolism. Osteopontin / metabolism. Ovarian Neoplasms / metabolism. V-Set Domain-Containing T-Cell Activation Inhibitor 1 / metabolism
  • [MeSH-minor] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Adolescent. Adult. Aged. Female. Gene Expression Regulation, Neoplastic. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Ovary / metabolism. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20038306.001).
  • [ISSN] 1000-467X
  • [Journal-full-title] Chinese journal of cancer
  • [ISO-abbreviation] Chin J Cancer
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / SPP1 protein, human; 0 / V-Set Domain-Containing T-Cell Activation Inhibitor 1; 106441-73-0 / Osteopontin; Ovarian epithelial cancer
  •  go-up   go-down


6. Jeoung HY, Choi HS, Lim YS, Lee MY, Kim SA, Han SJ, Ahn TG, Choi SJ: The efficacy of sonographic morphology indexing and serum CA-125 for preoperative differentiation of malignant from benign ovarian tumors in patients after operation with ovarian tumors. J Gynecol Oncol; 2008 Dec;19(4):229-35

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The efficacy of sonographic morphology indexing and serum CA-125 for preoperative differentiation of malignant from benign ovarian tumors in patients after operation with ovarian tumors.
  • OBJECTIVE: To evaluate the value of sonographic morphology indexing (MI) system and serum CA-125 levels in the assessment of the malignancy risk in patients with ovarian tumors.
  • METHODS: From September 2000 to July 2006, 202 patients who underwent surgery for ovarian tumors were reviewed retrospectively.
  • The association of the final pathologic diagnosis with the MI score and serum CA-125 level were examined.
  • RESULTS: There were 26 malignant tumors out of 141 ovarian tumors with a MI >/=5 (18%).
  • There were 22 malignant tumors out of 54 ovarian tumors with serum CA-125 >30 u/ml (41%).
  • CONCLUSION: The sonographic MI system is an accurate and simple method to differentiate a malignant tumor from a benign ovarian tumor.
  • The accuracy of the sonographic MI system improved when the serum CA-125 level was considered and ovarian teratomas were excluded.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 1985 May;155(2):477-8 [3885313.001]
  • [Cites] Int J Gynecol Pathol. 1982;1(1):3-16 [7184889.001]
  • [Cites] Gynecol Oncol. 2003 Oct;91(1):46-50 [14529661.001]
  • [Cites] Radiol Clin North Am. 2003 Jul;41(4):799-811 [12899493.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2001 May;96(1):80-4 [11311766.001]
  • [Cites] Radiographics. 2001 Mar-Apr;21(2):475-90 [11259710.001]
  • [Cites] CA Cancer J Clin. 1999 Sep-Oct;49(5):297-320 [11198956.001]
  • [Cites] Gynecol Oncol. 2000 Jun;77(3):454-9 [10831359.001]
  • [Cites] Gynecol Oncol. 2000 Jun;77(3):410-2 [10831351.001]
  • [Cites] Gynecol Oncol. 2000 Jun;77(3):350-6 [10831341.001]
  • [Cites] Clin Cancer Res. 2008 Feb 15;14(4):1065-72 [18258665.001]
  • [Cites] Radiology. 1999 Jul;212(1):19-27 [10405715.001]
  • [Cites] Gynecol Oncol. 1998 Apr;69(1):3-7 [9570990.001]
  • [Cites] Obstet Gynecol. 1995 Jan;85(1):48-52 [7800323.001]
  • [Cites] Gynecol Oncol. 1994 Nov;55(2):174-8 [7959280.001]
  • [Cites] Gynecol Oncol. 1993 Oct;51(1):7-11 [8244178.001]
  • [Cites] Obstet Gynecol. 1991 Jul;78(1):70-6 [2047071.001]
  • [Cites] Gynecol Oncol. 1990 Oct;39(1):69-71 [2227575.001]
  • [Cites] Br J Obstet Gynaecol. 1990 Oct;97(10):922-9 [2223684.001]
  • (PMID = 19471578.001).
  • [ISSN] 2005-0380
  • [Journal-full-title] Journal of gynecologic oncology
  • [ISO-abbreviation] J Gynecol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2676475
  • [Keywords] NOTNLM ; CA-125 antigen / ROC curve / Teratoma / Ultrasonogram (morphology indexing)
  •  go-up   go-down


7. Van Calster B, Valentin L, Van Holsbeke C, Testa AC, Bourne T, Van Huffel S, Timmerman D: Polytomous diagnosis of ovarian tumors as benign, borderline, primary invasive or metastatic: development and validation of standard and kernel-based risk prediction models. BMC Med Res Methodol; 2010;10:96
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polytomous diagnosis of ovarian tumors as benign, borderline, primary invasive or metastatic: development and validation of standard and kernel-based risk prediction models.
  • BACKGROUND: Hitherto, risk prediction models for preoperative ultrasound-based diagnosis of ovarian tumors were dichotomous (benign versus malignant).
  • We develop and validate polytomous models (models that predict more than two events) to diagnose ovarian tumors as benign, borderline, primary invasive or metastatic invasive.
  • However, discrimination between primary and metastatic invasive tumors decreased to near random levels.
  • CONCLUSIONS: We have developed models that successfully discriminate between benign, borderline, and invasive ovarian tumors.
  • The random discrimination between primary and metastatic invasive tumors on temporal/external validation demonstrated once more the necessity of validation studies.
  • [MeSH-major] Algorithms. Models, Statistical. Ovarian Neoplasms / ultrasonography. Risk Assessment / methods

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2001 Feb;80(2):162-7 [11161854.001]
  • [Cites] Ultrasound Obstet Gynecol. 2010 Aug;36(2):226-34 [20455203.001]
  • [Cites] Neural Comput. 2002 May;14(5):1115-47 [11972910.001]
  • [Cites] Oncology. 2003;65(1):29-36 [12837980.001]
  • [Cites] Stat Med. 2000 Apr 30;19(8):1059-79 [10790680.001]
  • [Cites] Med Decis Making. 2001 Jan-Feb;21(1):45-56 [11206946.001]
  • [Cites] Lancet. 2001 Jan 20;357(9251):176-82 [11213094.001]
  • [Cites] Med Decis Making. 1999 Jan-Mar;19(1):78-89 [9917023.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8794-801 [16314639.001]
  • [Cites] Gynecol Oncol. 2006 Jan;100(1):185-91 [16216320.001]
  • [Cites] Int J Gynaecol Obstet. 2006 Nov;95 Suppl 1:S161-92 [17161157.001]
  • [Cites] Ultrasound Obstet Gynecol. 2007 May;29(5):496-504 [17444557.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2007 Aug;133(2):218-22 [16797823.001]
  • [Cites] Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4440-7 [17671128.001]
  • [Cites] J Clin Oncol. 2007 Sep 20;25(27):4194-200 [17698805.001]
  • [Cites] J Clin Epidemiol. 2008 Feb;61(2):125-34 [18177785.001]
  • [Cites] J Clin Epidemiol. 2008 Feb;61(2):135-41 [18177786.001]
  • [Cites] Neural Netw. 2008 Mar-Apr;21(2-3):437-49 [18343309.001]
  • [Cites] Obstet Gynecol. 2009 Feb;113(2 Pt 1):384-94 [19155910.001]
  • [Cites] BMJ. 2009;338:b605 [19477892.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Lancet. 2009 Oct 17;374(9698):1371-82 [19793610.001]
  • [Cites] Epidemiology. 2010 Jan;21(1):128-38 [20010215.001]
  • [Cites] Ultrasound Obstet Gynecol. 2000 Oct;16(5):500-5 [11169340.001]
  • (PMID = 20961457.001).
  • [ISSN] 1471-2288
  • [Journal-full-title] BMC medical research methodology
  • [ISO-abbreviation] BMC Med Res Methodol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2988009
  •  go-up   go-down


8. Tamada T, Sone T, Tanimoto D, Higashi H, Miyoshi H, Egashira N, Yamamoto A, Imai S: MRI appearance of primary giant ovarian leiomyoma in a hysterectomised woman. Br J Radiol; 2006 Oct;79(946):e126-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MRI appearance of primary giant ovarian leiomyoma in a hysterectomised woman.
  • Primary leiomyoma is a rare, benign tumour of the ovary.
  • We describe the MRI features of an ovarian leiomyoma identified in a 51-year-old woman after hysterectomy.
  • The tumour appeared as a well-circumscribed low signal intensity mass on T(1) weighted imaging, with mixed signal intensity on T2 weighted imaging.
  • This case suggests the potential usefulness of dynamic contrast-enhanced MRI for the diagnosis of ovarian leiomyoma.
  • [MeSH-major] Leiomyoma / diagnosis. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Female. Humans. Hysterectomy. Magnetic Resonance Imaging. Middle Aged. Uterine Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16980667.001).
  • [ISSN] 1748-880X
  • [Journal-full-title] The British journal of radiology
  • [ISO-abbreviation] Br J Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 16
  •  go-up   go-down


9. Downs LS Jr, Lima PH, Bliss RL, Blomquist CH: Cathepsins B and D activity and activity ratios in normal ovaries, benign ovarian neoplasms, and epithelial ovarian cancer. J Soc Gynecol Investig; 2005 Oct;12(7):539-44
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cathepsins B and D activity and activity ratios in normal ovaries, benign ovarian neoplasms, and epithelial ovarian cancer.
  • OBJECTIVE: Cathepsins B (CB) and D (CD) belong to a family of proteases felt to be important in tumor metastasis and invasion.
  • It has been suggested that both enzymes play a role the progression of epithelial ovarian cancer and they have been investigated as potential biomarkers for ovarian cancer.
  • METHODS: Ovarian cancer cell lines and snap-frozen archived tissue samples were sonicated and cathepsin activities were assayed fluorometrically with cathepsin-specific peptide substrates in combination with specific inhibitors.
  • Tissue specimens were divided into four groups: normal ovary, benign neoplasm, early-stage (I/II) cancer, and late-stage (III/IV) cancer.
  • CONCLUSIONS: CB activity is associated with invasive ovarian neoplasm.
  • [MeSH-major] Cathepsin B / metabolism. Cathepsin D / metabolism. Ovarian Neoplasms / enzymology. Ovary / enzymology
  • [MeSH-minor] Female. Humans. Isoenzymes. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16202931.001).
  • [ISSN] 1556-7117
  • [Journal-full-title] Journal of the Society for Gynecologic Investigation
  • [ISO-abbreviation] J. Soc. Gynecol. Investig.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Isoenzymes; EC 3.4.22.1 / Cathepsin B; EC 3.4.23.5 / Cathepsin D
  •  go-up   go-down


10. Bar JK, Słomska I, Rabczyńki J, Noga L, Gryboś M: Expression of p53 protein phosphorylated at serine 20 and serine 392 in malignant and benign ovarian neoplasms: correlation with clinicopathological parameters of tumors. Int J Gynecol Cancer; 2009 Nov;19(8):1322-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of p53 protein phosphorylated at serine 20 and serine 392 in malignant and benign ovarian neoplasms: correlation with clinicopathological parameters of tumors.
  • The study investigated the expression of p53 protein phosphorylated at serine 20 (Ser20) and Ser392 and the association between clinicopathological parameters of ovarian neoplasms with respect to p53 protein overexpression.
  • METHODS: p53 protein expression was evaluated on tissues from malignant and benign ovarian tumors.
  • RESULTS: The correlation between p53 protein overexpression and p53-Ser392 phosphorylation was found in ovarian carcinomas (P = 0.001, r = +0.27).
  • In the total group of ovarian carcinomas, significant differences were observed in p53 protein overexpression between well (G1) and poor (G3) tumor grades (P = 0.005) and between serous and endometrioid types of tumor (P = 0.04), whereas p53-Ser20 phosphorylation was associated with advanced International Federation of Gynecology and Obstetrics stage (P = 0.004) and high tumor grade (P = 0.02).
  • In p53-positive ovarian carcinomas, p53-Ser392 phosphorylation was associated with advanced tumor stage (P = 0.02) and high tumor grade (P = 0.049).
  • p53-Ser20 phosphorylation was associated with low tumor grade of p53-positive ovarian carcinomas (P = 0.02) and with high tumor grade of p53-negative ovarian carcinomas (P = 0.02).
  • CONCLUSIONS: These results revealed that p53 phosphorylation at Ser20 and Ser392 is an early event in ovarian tumor development.
  • The authors suggest that the expression of p53 protein phosphorylated at Ser20 and Ser392 in ovarian carcinomas determines their individual clinical features depending on p53 protein status and may be useful biological biomarkers characterizing their behavior.
  • [MeSH-major] Adenocarcinoma, Mucinous / metabolism. Cystadenocarcinoma, Serous / metabolism. Endometrial Neoplasms / metabolism. Neoplasms / metabolism. Ovarian Neoplasms / metabolism. Serine / metabolism. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Adult. Aged. Female. Humans. Immunoenzyme Techniques. Middle Aged. Neoplasm Staging. Phosphorylation. Prognosis. Young Adult

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • PhosphoSitePlus. gene/protein/disease-specific - PhosphoSitePlus® - comprehensive post-translational modification resource .
  • Hazardous Substances Data Bank. L-SERINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20009884.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; 452VLY9402 / Serine
  •  go-up   go-down


11. Tam KF, Liu VW, Liu SS, Tsang PC, Cheung AN, Yip AM, Ngan HY: Methylation profile in benign, borderline and malignant ovarian tumors. J Cancer Res Clin Oncol; 2007 May;133(5):331-41
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methylation profile in benign, borderline and malignant ovarian tumors.
  • PURPOSE: Promoter hypermethylation is a common phenomenon in neoplasm.
  • The aims of this study were (a) to compare the methylation profiles in different types of ovarian tumors and (b) to determine the possible relationship between the methylation status and different clinicopathologic characteristics.
  • METHODS: We examined the promoter methylation status of 9 tumor suppressor genes (RARbeta2, TMS1, RIZ1, P15, P16, PTEN, MINT31, APC and HIC1) in 89 ovarian cancers, 16 borderline ovarian tumors, 19 benign ovarian tumors, 16 normal ovarian tissue and 5 ovarian cancer cell lines.
  • The methylation status was examined with respect to clinicopathologic characteristics of the ovarian cancer patients.
  • RESULTS: Methylation indices for ovarian cancer, borderline ovarian tumor, benign ovarian tumor, normal ovarian tissue and ovarian cancer cell lines were 28.8, 20.1, 10.5, 11.8 and 42.2%, respectively.
  • It was significantly higher in ovarian cancer, borderline ovarian tumor and ovarian cancer cell lines (X (2) test, P < 0.001, P = 0.01 and P < 0.001, respectively) than benign or normal ovarian tissues.
  • In ovarian cancer, concurrent methylation of at least two genes (CM2) was associated with early stage disease (X (2) test, P = 0.035) and less recurrence (X (2) test, P = 0.020).
  • CONCLUSION: CM2 was an independent predictor for survival in ovarian cancer.
  • [MeSH-major] DNA Methylation. Ovarian Neoplasms / genetics
  • [MeSH-minor] Cell Line, Tumor. Female. Genes, Tumor Suppressor. Humans. Middle Aged. Neoplasm Recurrence, Local. Ovary / metabolism. Survival Analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 1998 May 1;93(3):309-12 [9590162.001]
  • [Cites] Cancer Lett. 2004 Apr 30;207 (2):215-20 [15072831.001]
  • [Cites] Cancer Res. 2000 Nov 15;60(22):6236-42 [11103776.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8681-6 [10411935.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] Cancer Res. 2001 May 1;61(9):3573-7 [11325821.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):795-800 [11891178.001]
  • [Cites] Oncogene. 1999 Apr 8;18(14 ):2335-41 [10327053.001]
  • [Cites] Cancer Res. 1999 Nov 1;59(21):5438-42 [10554013.001]
  • [Cites] Clin Cancer Res. 2003 Mar;9(3):1033-8 [12631603.001]
  • [Cites] Clin Cancer Res. 2004 Mar 15;10(6):2000-6 [15041718.001]
  • [Cites] Nat Genet. 1999 Feb;21(2):163-7 [9988266.001]
  • [Cites] Cancer Lett. 2000 May 29;153(1-2):175-82 [10779647.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2912-9 [12912936.001]
  • [Cites] Clin Cancer Res. 2005 Aug 1;11(15):5365-9 [16061849.001]
  • [Cites] Am J Pathol. 2002 Sep;161(3):1015-22 [12213730.001]
  • [Cites] Clin Cancer Res. 2001 Jul;7(7):1982-6 [11448914.001]
  • [Cites] J Natl Cancer Inst. 2003 Feb 19;95(4):327-30 [12591989.001]
  • [Cites] Nat Genet. 1994 Aug;7(4):536-40 [7951326.001]
  • [Cites] BMC Cancer. 2002 Mar 21;2:4 [11945179.001]
  • [Cites] Curr Opin Genet Dev. 1999 Apr;9(2):158-63 [10322130.001]
  • [Cites] Adv Cancer Res. 1998;72:141-96 [9338076.001]
  • [Cites] Oncogene. 2004 Jun 3;23 (26):4646-54 [15064707.001]
  • [Cites] Clin Cancer Res. 2002 Nov;8(11):3324-31 [12429618.001]
  • [Cites] Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):656-63 [15701853.001]
  • [Cites] Am J Pathol. 2001 Mar;158(3):1121-7 [11238060.001]
  • [Cites] J Biol Chem. 2000 Jan 28;275(4):2727-32 [10644736.001]
  • [Cites] Nat Genet. 1996 Apr;12(4):363-7 [8630488.001]
  • [Cites] Cancer Res. 1998 Feb 15;58(4):591-3 [9485004.001]
  • (PMID = 17177027.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


12. Badiglian Filho L, Oshima CT, De Oliveira Lima F, De Oliveira Costa H, De Sousa Damião R, Gomes TS, Gonçalves WJ: Canonical and noncanonical Wnt pathway: a comparison among normal ovary, benign ovarian tumor and ovarian cancer. Oncol Rep; 2009 Feb;21(2):313-20
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Canonical and noncanonical Wnt pathway: a comparison among normal ovary, benign ovarian tumor and ovarian cancer.
  • In ovarian cancer, the role played by Wnts and its pathways is not clearly defined.
  • In order to analyze the canonical and noncanonical Wnt pathway in normal ovary, benign ovarian tumor and ovarian cancer, we evaluated the immunohistochemical expression of Wnt1, Frizzled-1 (FZD1), Wnt5a, Frizzled-5 (FZD5) and beta-catenin.
  • Ovarian specimens were obtained from surgeries performed between 1993 and 2004.
  • The patients were divided in three groups: group A, epithelial ovarian cancer (n=38); group B, benign epithelial neoplasia (n=28); and group C, normal ovaries (n=26).
  • Our findings suggest that the pathways related to Wnt5a have an important role in ovarian malignant neoplasia.
  • Furthermore, Wnt5a was found to be a predictor of poor prognosis for ovarian cancer.
  • [MeSH-major] Biomarkers, Tumor / analysis. Frizzled Receptors / biosynthesis. Neoplasms, Glandular and Epithelial / metabolism. Ovarian Neoplasms / metabolism. Wnt Proteins / biosynthesis. beta Catenin / biosynthesis
  • [MeSH-minor] Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Neoplasm Staging. Ovary. Prognosis. Signal Transduction / physiology

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19148501.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Frizzled Receptors; 0 / Wnt Proteins; 0 / beta Catenin
  •  go-up   go-down


13. Mrochem J, Sodowski K, Deja R, Walaszek-Gruszka A, Wojcieszek A, Kołosza Z, Chmura A, Czernik E, Masłyk B, Bartnik W, Cnota W: [Evaluation of selected serum protein markers as early detectors of ovarian cancer]. Ginekol Pol; 2008 Apr;79(4):271-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Evaluation of selected serum protein markers as early detectors of ovarian cancer].
  • OBJECTIVE: an attempt to determine the value of the simultaneous quantization of osteopontin (OPN), insulin-growth factor II (IGF II), leptin, prolactin and CA 125 for early detection of ovarian cancer.
  • MATERIALS AND METHODS: Prospective study of 69 women including: 15 females with ovarian cancer; 33 females with benign ovarian neoplasm; 21 disease-free females; The levels of IGF II, prolactin, leptin and CA 125 were determined in serum, while the level of OPN was checked in plasma.
  • RESULTS: The concentrations of IGF II, leptin and prolactin do not let us distinguish among disease-free females, females with ovarian cancer and those with benign ovarian neoplasms on the basis of biochemical markers.
  • The comparison of OPN and CA 125 levels showed significant differences in the concentrations of the biomarkers between disease-free females and females with ovarian cancer, as well as between females with benign ovarian neoplasms and females with ovarian cancer.
  • The ROC curves for two groups: disease-free females and females with ovarian cancer, proved the diagnostic value of OPN and CA 125.
  • CONCLUSIONS: The simultaneous quantization of OPN, IGF II leptin and prolactin has not been proved useful for the early detection of ovarian cancer.
  • Statistically significant increase of OPN & CA 125 levels was noted in case of women with ovarian cancer diagnosed through microscopic examination.
  • Quantization of OPN may have an additional value for treatment monitoring of women diagnosed with ovarian cancer but with concentration of CA 125 within the reference value.
  • [MeSH-major] Biomarkers, Tumor / blood. Ovarian Neoplasms / blood. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Adult. CA-125 Antigen / blood. Early Diagnosis. Female. Humans. Insulin-Like Growth Factor II / analysis. Leptin / blood. Middle Aged. Osteopontin / blood. Poland. Prolactin / blood. Prospective Studies. ROC Curve. Reference Values. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18592865.001).
  • [ISSN] 0017-0011
  • [Journal-full-title] Ginekologia polska
  • [ISO-abbreviation] Ginekol. Pol.
  • [Language] pol
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / IGF2 protein, human; 0 / Leptin; 106441-73-0 / Osteopontin; 67763-97-7 / Insulin-Like Growth Factor II; 9002-62-4 / Prolactin
  •  go-up   go-down


14. Tomsová M, Krepinská E, Spacek J: [Sclerosing stromal tumor--a rare benign ovarian neoplasm]. Ceska Gynekol; 2008 Jun;73(3):188-91
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Sclerosing stromal tumor--a rare benign ovarian neoplasm].
  • [Transliterated title] Sklerozující stromální tumor--vzácný gonadostromální nádor ovaria.
  • Sclerosing stromal tumor (SST) is a rare benign ovarian neoplasm of the sex cord-stromal category occurring predominantly in young women (usually younger than 30 years of age).
  • Histologically, the tumor is characterized by cellular heterogenity, prominent vascularisation, and a pseudolobular appearance composed of cellular and hypocellular areas.
  • We report a case of the ovarian SST in a 17-year-old girl.
  • Clinical, microscopic, immunohistochemical, ultrastructural findings and differential diagnosis are disscussed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18646673.001).
  • [ISSN] 1210-7832
  • [Journal-full-title] Ceska gynekologie
  • [ISO-abbreviation] Ceska Gynekol
  • [Language] CZE
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


15. Serin IS, Tanriverdi F, Ata CD, Akalin H, Ozcelik B, Ozkul Y, Kelestimur F: GnRH-II mRNA expression in tumor tissue and peripheral blood mononuclear cells (PBMCs) in patients with malignant and benign ovarian tumors. Eur J Obstet Gynecol Reprod Biol; 2010 Mar;149(1):92-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] GnRH-II mRNA expression in tumor tissue and peripheral blood mononuclear cells (PBMCs) in patients with malignant and benign ovarian tumors.
  • OBJECTIVE: To investigate the expression of the second form of GnRH (GnRH-II) in tumor tissue and peripheral blood mononuclear cells (PBMCs) in malignant and benign ovarian tumors in humans.
  • STUDY DESIGN: Sixty-six women were studied: 24 with epithelial ovarian carcinomas, 22 with benign ovarian tumors and 20 in the control group undergoing surgery.
  • Malignant, benign and normal ovarian tissue and PBMCs were obtained for measurement of GnRH-II mRNA levels using quantitative real-time RT-PCR.
  • RESULT(S): The expression of GnRH-II was found to be 1.5 times higher in malignant ovarian tumors compared with benign ovarian tumors and the control group in post-menopausal patients (P<0.01).
  • In the post-menopausal patient group with malignant ovarian tumors, there were significant positive correlations between serum FSH level and ovarian tissue GnRH-II mRNA expression (r=0.68; P=0.03), and serum LH level and ovarian tissue GnRH-II mRNA expression (r=0.71; P=0.02).
  • Controls, benign and malignant groups were similar in terms of GnRH-II expression in PBMCs in the pre- and post-menopausal periods.
  • There was no significant correlation between ovarian tissue GnRH-II mRNA expression vs. PBMC GnRH-II mRNA expression in patient and control groups.
  • CONCLUSION(S): We have shown increased GnRH-II expression in human ovarian cancer tissue in post-menopausal women in vivo.
  • Expression of GnRH-II in PBMCs did not reflect the local GnRH-II expression levels in ovarian tissue.
  • These preliminary data suggest that local GnRH-II may participate in the regulation of ovarian tumor growth in post-menopausal women.
  • [MeSH-major] Carcinoma / metabolism. Gonadotropin-Releasing Hormone / analogs & derivatives. Leukocytes, Mononuclear / metabolism. Ovarian Neoplasms / metabolism. Ovary / metabolism
  • [MeSH-minor] Adult. Aged. Analysis of Variance. Female. Gene Expression Regulation, Neoplastic. Humans. Middle Aged. Neoplasm Staging. Postmenopause / genetics. Postmenopause / metabolism. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20018426.001).
  • [ISSN] 1872-7654
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / RNA, Messenger; 33515-09-2 / Gonadotropin-Releasing Hormone; 91097-16-4 / LHRH, His(5)-Trp(7)-Tyr(8)-
  •  go-up   go-down


16. Markowska A, Ziółkowska A, Jaszczyńska-Nowinka K, Madry R, Malendowicz LK: Elevated blood plasma concentrations of active ghrelin and obestatin in benign ovarian neoplasms and ovarian cancers. Eur J Gynaecol Oncol; 2009;30(5):518-22
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevated blood plasma concentrations of active ghrelin and obestatin in benign ovarian neoplasms and ovarian cancers.
  • The two peptides are secreted into the blood but circulating levels of these peptides have not been assessed in women with ovarian tumours.
  • Therefore, the purpose of this study was to evaluate peripheral blood concentrations of active and total ghrelin and obestatin in patients with benign ovarian tumours and those with ovarian cancer.
  • The studies were conducted on 22 patients operated due to benign ovarian tumours, and 31 patients operated due to ovarian cancer.
  • Both in women with benign ovarian tumours and those with ovarian cancer blood concentrations of active ghrelin and obestatin were higher than in the control group (active ghrelin: 90 +/- 4, 84 +/- 4 and 56 +/- 9 pg/ml, respectively, obestatin: 660 +/- 36; 630 +/- 30 and 538 +/- 31 ng/ml (x +/- SE), respectively).
  • The alterations resulted in increased values of active to total ghrelin concentration ratio in the peripheral blood of patients with benign ovarian tumours or with ovarian cancer (0.79 +/- 0.02 and 0.93 +/- 0.05, respectively vs 0.58 +/- 0.02 in the control group).
  • Due to the absence of any convincing proof for the presence of a functional GHS-R-1a receptor for ghrelin in human ovaries it did not seem probable that the observed elevated levels of active ghrelin and obestatin were directly linked to development of ovarian tumours.
  • [MeSH-major] Ghrelin / blood. Ovarian Neoplasms / blood. Ovarian Neoplasms / pathology. Peptide Hormones / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19899406.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Ghrelin; 0 / Peptide Hormones; 0 / obestatin, human
  •  go-up   go-down


17. Zou JF, Li JY, Wu XW, Chen SY: [Effects of different anesthesia and analgesia on erythrocyte immune function of patients with ovarian benign tumor treated by laparoscopic therapeutic]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2010 Dec;26(12):1252-4
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effects of different anesthesia and analgesia on erythrocyte immune function of patients with ovarian benign tumor treated by laparoscopic therapeutic].
  • AIM: To investigate the effects of different anesthesia and analgesia on erythrocyte immune function of patients with ovarian benign tumor treated by laparoscopic therapeutic.
  • METHODS: 120 patients with ovarian benign tumor treated by laparoscopic therapeutic were randomly divided into two groups with 60 cases each.In group A, patients received general anesthesia eombined with thoracic epidural anesthesia during surgery, patients in group B received general anesthesia.
  • CONCLUSION: Anesthesia may harm on erythroeyte immune function of patients with ovarian benign tumor treated by laparoscopic therapeutic.
  • [MeSH-major] Analgesia / adverse effects. Anesthesia / adverse effects. Erythrocytes / immunology. Laparoscopy. Ovarian Neoplasms / immunology. Ovarian Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Anesthesia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21138693.001).
  • [ISSN] 1007-8738
  • [Journal-full-title] Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology
  • [ISO-abbreviation] Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] China
  •  go-up   go-down


18. Zaman S, Majid S, Hussain M, Chughtai O, Mahboob J, Chughtai S: A retrospective study of ovarian tumours and tumour-like lesions. J Ayub Med Coll Abbottabad; 2010 Jan-Mar;22(1):104-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A retrospective study of ovarian tumours and tumour-like lesions.
  • Objective of the study was to determine the nature of various ovarian lesions and to ascertain the frequency and distribution of the various non-neoplastic and neoplastic lesions.
  • METHODS: The study was a retrospective review of all cases of ovarian cancer, benign ovarian neoplasm and functional ovarian cysts received during Jan-Dec 2008 at Chughtai's Lahore Laboratory.
  • Among the neoplastic tumours 78.70% were benign and 21.29% were malignant.
  • Benign serous cysts were the commonest benign tumour followed by mature cystic teratoma and mucinous cyst.
  • Serous cystadenocarcinoma was the commonest malignant tumour followed closely by endometrioid carcinoma and granulosa cell tumour.
  • Krukenberg tumour, tumour metastatic to ovaries and non-Hodgkins lymphoma was also diagnosed during this period.
  • CONCLUSION: The morphologic diversity of ovarian masses poses many challenges.
  • A specific diagnosis can usually be made by evaluating routinely stained slides but sometimes immunohistochemistry is required in difficult cases.
  • [MeSH-major] Ovarian Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Middle Aged. Ovarian Cysts / epidemiology. Ovarian Cysts / pathology. Pakistan / epidemiology. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21409917.001).
  • [ISSN] 1025-9589
  • [Journal-full-title] Journal of Ayub Medical College, Abbottabad : JAMC
  • [ISO-abbreviation] J Ayub Med Coll Abbottabad
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


19. Coronado Martín PJ, Fasero Laiz M, García Santos J, Ramírez Mena M, Vidart Aragón JA: [Overexpression and prognostic value of p53 and HER2/neu proteins in benign ovarian tissue and in ovarian cancer]. Med Clin (Barc); 2007 Jan 13;128(1):1-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Overexpression and prognostic value of p53 and HER2/neu proteins in benign ovarian tissue and in ovarian cancer].
  • [Transliterated title] Grado de expresión y valor pronóstico de las proteínas p53 y HER2/neu en el tejido ovárico benigno y en el cáncer de ovario.
  • BACKGROUND AND OBJECTIVE: To investigate the prognostic value of p53 and HER2/neu overexpression in epithelial ovarian cancer (EOC).
  • PATIENTS AND METHOD: p53 and HER2/neu immunostaining were performed in 198 tissue samples, 124 EOC, 44 benign ovarian tumors and 30 normal ovaries.
  • RESULTS: Neither p53 nor HER2/neu overexpression was seen in the benign ovarian tumors.
  • HER2/neu immunostaining was observed in one normal ovary.
  • [MeSH-major] Cystadenoma, Mucinous / genetics. Cystadenoma, Serous / genetics. Ovarian Neoplasms / genetics. Receptor, ErbB-2 / genetics. Teratoma / genetics. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] Aged. Biomarkers, Tumor. Confidence Intervals. Endometriosis / genetics. Endometriosis / pathology. Endometriosis / surgery. Female. Follow-Up Studies. Genes, p53. Humans. Immunohistochemistry. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local. Neoplasm Staging. Ovarian Diseases / genetics. Ovarian Diseases / pathology. Ovarian Diseases / surgery. Prognosis. Proportional Hazards Models. Risk. Survival Analysis. Time Factors

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17266884.001).
  • [ISSN] 0025-7753
  • [Journal-full-title] Medicina clínica
  • [ISO-abbreviation] Med Clin (Barc)
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


20. Popovska S, Popovski K, Gorchev G, Marinov E: [Sclerosing stromal ovarial tumor--a case report and review]. Akush Ginekol (Sofiia); 2005;44(4):42-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Sclerosing stromal ovarial tumor--a case report and review].
  • Sclerosing stromal tumor (SST) is a rare benign ovarian neoplasm of stromal origin with less than 100 cases reported in the literature.
  • Unlike the other stromal tumors, the comas and fibromas, which tend to occur in the fifth and sixth decades, sclerosing stromal tumors predominantly affect females in the second and third decades.
  • Several unique histologic features including pseudolobulation, sclerosis and prominent vascularity of the tumor are clearly reflected at ultrasonography.
  • We present a case of SST of the ovary in a 26-year-old female, and describe the ultrasound findings with pathologic correlation.
  • [MeSH-major] Ovarian Neoplasms / pathology. Sex Cord-Gonadal Stromal Tumors / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16028379.001).
  • [ISSN] 0324-0959
  • [Journal-full-title] Akusherstvo i ginekologii︠a︡
  • [ISO-abbreviation] Akush Ginekol (Sofiia)
  • [Language] bul
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Bulgaria
  •  go-up   go-down


21. Mülayim B, Gürakan H, Dagli V, Mülayim S, Aydin O, Akkaya H: Unaware of a giant serous cyst adenoma: a case report. Arch Gynecol Obstet; 2006 Mar;273(6):381-3
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A case of 36-year-old nonmarried virgin woman presenting a giant ovarian serous cyst adenoma weighing 9.5 kg is reported here.
  • Ovarian neoplasms may be divided by origin cell type into three main groups: epithelial, stromal and germ cell.
  • Taken as a group, the epithelial tumors are by far the most common type.
  • The single most common benign ovarian neoplasm is the benign cystic teratoma; however, according to some studies it is serous cyst adenoma.
  • At laparotomy, a giant, totally cystic, vascularized and smooth mass attached to the right ovary was encountered, lying between the symphysis and the xiphoid.
  • This is the largest ovarian cyst that ever reported from our hospital and one of the largest among the reported cases in the literature.
  • [MeSH-major] Cystadenoma, Serous / pathology. Ovarian Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16249904.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


22. Chang YW, Hong SS, Jeen YM, Kim MK, Suh ES: Bilateral sclerosing stromal tumor of the ovary in a premenarchal girl. Pediatr Radiol; 2009 Jul;39(7):731-4
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral sclerosing stromal tumor of the ovary in a premenarchal girl.
  • Sclerosing stromal tumor (SST) is a rare benign ovarian neoplasm classified as a type of sex cord stromal tumor that occurs predominantly in young patients.
  • We present a case of a bilateral SST of the ovary with calcification in a 12-year-old premenarchal girl and describe the US, CT, MR and pathological findings.
  • [MeSH-major] Diagnostic Imaging / methods. Endometrial Stromal Tumors / diagnosis. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Child. Female. Humans. Menarche. Sclerosis / diagnosis

  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Comput Assist Tomogr. 1999 Jul-Aug;23(4):555-7 [10433285.001]
  • [Cites] Korean J Radiol. 2003 Jul-Sep;4(3):194-9 [14530650.001]
  • [Cites] Eur Radiol. 1999;9(7):1335-8 [10460370.001]
  • [Cites] J Comput Assist Tomogr. 2001 Mar-Apr;25(2):201-6 [11242213.001]
  • [Cites] Gynecol Oncol. 2006 May;101(2):342-5 [16403568.001]
  • [Cites] Cancer. 1973 Mar;31(3):664-70 [4348335.001]
  • [Cites] Abdom Imaging. 2002 Sep-Oct;27(5):588-91 [12173003.001]
  • [Cites] Pediatr Radiol. 2003 Jan;33(1):56-8 [12497242.001]
  • (PMID = 19283376.001).
  • [ISSN] 1432-1998
  • [Journal-full-title] Pediatric radiology
  • [ISO-abbreviation] Pediatr Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


23. Schem Ch, Bauerschlag DO, Meinhold-Heerlein I, Fischer D, Friedrich M, Maass N: [Benign and borderline tumors of the ovary]. Ther Umsch; 2007 Jul;64(7):369-74
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Benign and borderline tumors of the ovary].
  • [Transliterated title] Benigne und Borderline-Tumoren des Ovars.
  • Palpable or sonographic ovarian tumors are reason for various differential diagnoses.
  • Therefore the clarification of ovarian lesions is one of the main duties in daily gynaecological practice.
  • Although diagnostic procedures might be supplemented by CT-Scan or MRI techniques, classical bimanual examination and vaginal ultrasound scan will determine the diagnosis in most cases comparably accurate.
  • The suspected diagnosis concerning benign or malignant lesions, should take the palpable and sonographic feature, as well as the information from the patients medical history (e.g. family history of malignant diseases (BRCA 1/2 mutations) into account.
  • They are mostly normal follicle cysts, but may also be a tumor of low malignant potential (LMP-tumor) or even an invasive cancerous lesion.
  • 20-30% of all ovarian tumors are malignant and by the time of primary diagnosis already in a about 60-70% incurable due to intraabdominal dissemination.
  • Benign or malignant lesions may occur in every age group.
  • Ovarian tumors at infantile age are malignant in about 15%.
  • Most malignant tumors occur between the age of 50 to 70.
  • The LMP-tumors occur in average 10 years earlier.
  • Malignant ovarian lesions represent about 15-30% of all genital malignant tumors.
  • The persistence of ovarian cysts and tumors will be mostly examined by laparoscopic surgery.
  • In that respect the diagnosis of LMP-tumors might be incidentally and will then have a substantial impact on the extent of the surgery and the follow up.
  • This compilation overviews the spectrum of benign and low malignant potential tumors of the ovary and their different tissues of origin.
  • [MeSH-major] Ovarian Neoplasms
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Middle Aged. Neoplasm Recurrence, Local. Ovarian Cysts / diagnosis. Ovarian Cysts / radiography. Ovarian Cysts / ultrasonography. Ovary / pathology. Palpation. Time Factors. Tomography, X-Ray Computed. Ultrasonography, Doppler

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17948753.001).
  • [ISSN] 0040-5930
  • [Journal-full-title] Therapeutische Umschau. Revue thérapeutique
  • [ISO-abbreviation] Ther Umsch
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 22
  •  go-up   go-down


24. Zhao SJ, Liu JY, Ren FR, Feng YJ: [Expression of glucose transporter-1 and its correlation with basic fibroblast growth factor and proliferating cell nuclear antigen in epithelial ovarian neoplasm]. Zhonghua Fu Chan Ke Za Zhi; 2005 Apr;40(4):264-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of glucose transporter-1 and its correlation with basic fibroblast growth factor and proliferating cell nuclear antigen in epithelial ovarian neoplasm].
  • OBJECTIVE: To study the expression of glucose transporter-1 (GLUT1) and its correlation with basic fibroblast growth factor (bFGF) and proliferating cell nuclear antigen (PCNA) in epithelial ovarian neoplasm.
  • METHODS: Streptavidin-peroxidase complex technique was used to examine the expression of GLUT1, bFGF and PCNA protein in six cases of normal ovarian tissue, 20 cases of benign epithelial tumors, seven cases of borderline tumor and 44 cases of epithelial ovarian carcinoma.
  • RESULTS: In normal ovary and benign ovarian tumor, GLUT1 was not detected, but in borderline ovarian tumor and cancer, the positive expression ratio of GLUT1 was 6/7 and 91% (40/44), respectively.
  • The intensity of GLUT1 in ovarian epithelial neoplasm was significantly higher than in borderline tumors.
  • The staining intensity of GLUT1 was significantly correlated with the histological grade of the tumor (r(S) = 0.499, P = 0.001), and was positively correlated with the clinical stage, cancer invasion and lymph node metastasis.
  • bFGF positive rate in tumor was 57% (25/44).
  • CONCLUSIONS:. (1) The expression of GLUT1 may be closely related to malignant transformation of ovarian epithelial tumors.
  • Both of them play important roles in the carcinogenesis and progression of ovarian epithelial carcinoma.
  • [MeSH-major] Epithelium / metabolism. Fibroblast Growth Factor 2 / metabolism. Glucose Transporter Type 1 / genetics. Ovarian Neoplasms / genetics. Ovarian Neoplasms / metabolism. Proliferating Cell Nuclear Antigen / metabolism
  • [MeSH-minor] Female. Gene Expression Regulation, Neoplastic. Humans. Ovary / metabolism. Ovary / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15924676.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Glucose Transporter Type 1; 0 / Proliferating Cell Nuclear Antigen; 0 / SLC2A1 protein, human; 103107-01-3 / Fibroblast Growth Factor 2
  •  go-up   go-down


25. Trifonov I: [Registry of patients with advanced ovary carcinoma in the province of Stara Zagora]. Akush Ginekol (Sofiia); 2007;46(7):35-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Registry of patients with advanced ovary carcinoma in the province of Stara Zagora].
  • A representative inquiry has been conducted including the most important parameters from the medical files of 61 out-patients with ovarian carcinoma in III or IV stage in the province of Stara Zagora for the period 1997, 1998 and 1999.
  • In 9.83% of the patients benign tumours were found, in 6.55% malignant as concomitant diseases.
  • Histological screening of ovarian tumours showed predominance of the serous carcinoma in the papilliferum--/40.98%/.
  • A combined chemotherapy. including mostly cys-platinum, is used in the treatment of patients with tumour in the ovary in the Clinic of Oncological Diseases of Stara Zagora.
  • [MeSH-major] Ovarian Neoplasms / epidemiology. Registries. Surveys and Questionnaires
  • [MeSH-minor] Bulgaria / epidemiology. Female. Humans. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18333420.001).
  • [ISSN] 0324-0959
  • [Journal-full-title] Akusherstvo i ginekologii︠a︡
  • [ISO-abbreviation] Akush Ginekol (Sofiia)
  • [Language] bul
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Bulgaria
  •  go-up   go-down


26. Hayashi M, Shibazaki M, Sohma R, Inaba N: Effects of histologic type on levels of macrophage colony-stimulating factor in liquid contents of benign ovarian tumors. Am J Med Sci; 2006 Oct;332(4):181-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of histologic type on levels of macrophage colony-stimulating factor in liquid contents of benign ovarian tumors.
  • BACKGROUND: Normal ovarian tissue is rich in cytokines.
  • Cytokines are important in the physiology of ovarian function.
  • Most of the same cytokines that are found in normal ovarian tissue are also found in association with benign and malignant tumors in contrast to their functions in normal tissues.
  • Thus, we measured macrophage colony-stimulating factor (M-CSF) levels in the liquid contents of benign ovarian tumors--serous cystadenoma, mucinous cystadenoma, and mature cystic teratoma--and investigated whether M-CSF levels were associated with the histologic type of the ovarian tumors.
  • METHODS: We enrolled 65 patients, 52 with benign ovarian tumor and 13 in the early postmenopausal period with symptoms of a menopausal disorder.
  • Among the 52 patients with benign ovarian tumor, 16 had serous cystadenoma, 21 had mucinous cystadenoma, and 15 had mature cystic teratoma.
  • Immediately after surgery, the liquid content was drawn from the ovarian tumor, then centrifuged, and the separated supernatant was stored at -30 degrees C.
  • The serum M-CSF levels were 308 to 499 U/mL in patients with benign ovarian tumor.
  • CONCLUSIONS: Elevation of levels of M-CSF varies according to histologic type in benign ovarian tumors.
  • [MeSH-major] Extracellular Fluid / metabolism. Macrophage Colony-Stimulating Factor / metabolism. Neoplasm Proteins / metabolism. Neoplasms / metabolism. Neoplasms / pathology. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17031243.001).
  • [ISSN] 0002-9629
  • [Journal-full-title] The American journal of the medical sciences
  • [ISO-abbreviation] Am. J. Med. Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 81627-83-0 / Macrophage Colony-Stimulating Factor
  •  go-up   go-down


27. Bunyavejchevin S, Phupong V: Laparoscopic surgery for presumed benign ovarian tumor during pregnancy. Cochrane Database Syst Rev; 2006;(4):CD005459
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic surgery for presumed benign ovarian tumor during pregnancy.
  • BACKGROUND: The surgical management of ovarian tumors in pregnancy is similar to that of non-pregnant women.
  • The procedures include resection of the tumor (enucleation), removal of an ovary or ovaries (oophorectomy), or surgical excision of the fallopian tube and ovary (salpingo-oophorectomy).
  • OBJECTIVES: To compare the effects of using laparoscopic surgery for benign ovarian tumor during pregnancy on maternal and fetal health and the use of healthcare resources.
  • SELECTION CRITERIA: Randomized controlled trials with reported data that compared outcomes of laparoscopic surgery for benign ovarian tumor in pregnancy to conventional laparotomy technique.
  • AUTHORS' CONCLUSIONS: The practice of laparoscopic surgery for benign ovarian tumour during pregnancy is associated with benefits and harms.
  • The available case series studies of laparoscopic surgery for benign ovarian tumour during pregnancy provide limited insight into the potential benefits and harms associated with this new surgical technique in pregnancy.
  • Randomized controlled trials are required to provide the most reliable evidence regarding the benefits and harms of laparoscopic surgery for benign ovarian tumour during pregnancy.
  • [MeSH-major] Laparoscopy. Ovarian Neoplasms / surgery. Pregnancy Complications, Neoplastic / surgery

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [UpdateIn] Cochrane Database Syst Rev. 2013;1:CD005459 [23440802.001]
  • (PMID = 17054259.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 26
  •  go-up   go-down


28. Daneshbod Y, Daneshbod K, Rasekhi AR, Mosayebi Z, Negahban S, Hodjati SR, Bedayat GR, Ganjei-Azar P: Cytologic differentiation of struma ovarii from other ovarian neoplasms. Acta Cytol; 2008 Jan-Feb;52(1):72-6
Hazardous Substances Data Bank. THYROGLOBULIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytologic differentiation of struma ovarii from other ovarian neoplasms.
  • OBJECTIVE: To present the cytologic findings of struma ovarii and value of cytology and immunocytochemistry (ICC) using thyroglobulin (TGB) and thyroid transcription factor-1 (TTF-1) in evaluation of this unusual ovarian neoplasm, together with the diagnostic pitfalls.
  • RESULTS: The cases were divided in to 3 groups: group 1--diagnosis of struma ovarii was made by cytology and confirmed by ICC (1 case); group 2--diagnosis was suggestive on cytology or cell block and confirmed by ICC staining (4 cases); group 3--on cytologic diagnosis indistinguishable from other cystic ovarian neoplasms (2 cases).
  • Cytologic findings were typically colloid with mosaic pattern, follicles, follicular cells only, sheets of follicular cells, both colloid and follicular cells, proteinaceous background or degenerated epithelial cells indistinguishable from other cystic ovarian neoplasms.
  • CONCLUSION: Cytologic findings of struma ovarii are distinct enough to be suggested intraoperatively, and ICC for TGB or TTF-1 is a valuable tool for preoperative fine needle aspiration biopsy and intraoperative diagnosis of this benign ovarian neoplasm.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Ovarian Neoplasms / diagnosis. Struma Ovarii / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Diagnosis, Differential. Female. Humans. Middle Aged. Nuclear Proteins / metabolism. Thyroglobulin / metabolism. Transcription Factors / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18323278.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1; 9010-34-8 / Thyroglobulin
  •  go-up   go-down


29. Osterberg L, Akeson M, Levan K, Partheen K, Zetterqvist BM, Brännström M, Horvath G: Genetic alterations of serous borderline tumors of the ovary compared to stage I serous ovarian carcinomas. Cancer Genet Cytogenet; 2006 Jun;167(2):103-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic alterations of serous borderline tumors of the ovary compared to stage I serous ovarian carcinomas.
  • Borderline tumors of the ovary comprise 10-20% of all epithelial ovarian tumors, and are placed between clearly benign and obviously malignant ovarian tumors.
  • The issue of whether borderline tumors are precursors of invasive carcinoma or distinct clinical entities, however, is still the subject of discussion.
  • To increase our understanding in relation to this issue, the aim of our study was to analyze both serous borderline and invasive ovarian tumors, and to investigate early carcinogenesis in serous ovarian tumors.
  • Using comparative genomic hybridization, we compared cytogenetic changes in borderline ovarian tumors and stage I invasive tumors.
  • The average number of genetic alterations differed significantly between the borderline and the invasive tumors (1.9 and 9.2, respectively).
  • The most common genetic alterations among the borderline tumors were loss of chromosome 17, 20q, and 18p, and gain of 12p13 approximately q23.
  • These changes were also found among the invasive tumors in a similar percentage.
  • In conclusion, we found four distinct cytogenetic alterations that might be early events in serous ovarian tumors, and that might also characterize a subgroup of borderline ovarian tumors that may have the potential to progress and develop malignancy.
  • [MeSH-major] Aneuploidy. Carcinoma / genetics. Ovarian Neoplasms / genetics. Serous Membrane
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. DNA, Neoplasm / analysis. Female. Humans. Middle Aged. Neoplasm Staging. Nucleic Acid Hybridization

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16737908.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


30. Medeiros LR, Rosa DD, Bozzetti MC, Fachel JM, Furness S, Garry R, Rosa MI, Stein AT: Laparoscopy versus laparotomy for benign ovarian tumour. Cochrane Database Syst Rev; 2009;(2):CD004751
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopy versus laparotomy for benign ovarian tumour.
  • BACKGROUND: Over the last 10 years laparoscopy and minilaparotomy have become increasingly common approaches for the surgical removal of benign ovarian tumours.
  • However, in the event that a tumour is found to be malignant, laparotomy is the appropriate procedure.
  • OBJECTIVES: To determine the benefits, harms, and cost of laparoscopy or minilaparotomy compared with laparotomy in women with benign ovarian tumours.
  • SELECTION CRITERIA: All randomised controlled trials comparing either laparoscopy or minilaparotomy with laparotomy for benign ovarian tumours.
  • AUTHORS' CONCLUSIONS: In women undergoing surgery for benign ovarian tumours, laparoscopy was associated with a reduction in fever, urinary tract infection, postoperative complications, postoperative pain, number of days in hospital, and total cost.
  • [MeSH-major] Laparoscopy. Laparotomy. Ovarian Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [UpdateOf] Cochrane Database Syst Rev. 2005;(3):CD004751 [16034946.001]
  • (PMID = 19370607.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] England
  • [Number-of-references] 78
  •  go-up   go-down


31. Spannuth WA, Rocconi RP, Kirby TO, Huh WK, Conner MG: Gamma mode of infiltration associated with poor prognosis in malignant teratoma of the ovary: A case report. Gynecol Oncol; 2005 Jul;98(1):155-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gamma mode of infiltration associated with poor prognosis in malignant teratoma of the ovary: A case report.
  • BACKGROUND: Although mature cystic teratoma is the most common tumor of the ovary, squamous cell carcinoma arising from a mature teratoma is a rare event.
  • Prognosis depends on clinical stage, grade, and recently described mode of tumor infiltration.
  • CASE: This case involves a 52-year-old woman with stage II squamous cell carcinoma arising in a mature cystic teratoma of the left ovary.
  • Final pathology demonstrated poorly differentiated squamous cell carcinoma with gamma mode of tumor infiltration.
  • CONCLUSION: Squamous cell carcinoma arising from a benign cystic teratoma is a rare event.
  • This case supports the growing evidence linking the mode of tumor infiltration with overall prognosis of survival.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Ovarian Neoplasms / pathology. Teratoma / pathology
  • [MeSH-minor] Chemotherapy, Adjuvant. Female. Humans. Middle Aged. Neoplasm Staging. Prognosis

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15922442.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Tamai K, Koyama T, Saga T, Kido A, Kataoka M, Umeoka S, Fujii S, Togashi K: MR features of physiologic and benign conditions of the ovary. Eur Radiol; 2006 Dec;16(12):2700-11
MedlinePlus Health Information. consumer health - Ovarian Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MR features of physiologic and benign conditions of the ovary.
  • In reproductive women, various physiologic conditions can cause morphologic changes of the ovary, resembling pathologic conditions.
  • Benign ovarian diseases can also simulate malignancies.
  • Magnetic resonance imaging (MRI) can play an important role in establishing accurate diagnosis.
  • Functional cysts should not be confused with cystic neoplasms.
  • Multicystic lesions that may mimic cystic neoplasms include hyperreactio luteinalis, ovarian hyperstimulation syndrome, and polycystic ovary syndrome.
  • Recognition of clinical settings can help establish diagnosis.
  • In endometrial cysts, MRI usually provides specific diagnosis; however, decidual change during pregnancy should not be confused with secondary neoplasm.
  • Peritoneal inclusion cysts can be distinguished from cystic neoplasms by recognition of their characteristic configurations.
  • Ovarian torsion and massive ovarian edema may mimic solid malignant tumors.
  • In pelvic inflammatory diseases, transfascial spread of the lesion should not be confused with invasive malignant tumors.
  • Many benign tumors, including teratoma, Brenner tumor, and sex-cord stromal tumor, frequently show characteristic MRI features.
  • Knowledge of MRI features of these conditions is essential in establishing accurate diagnosis and determining appropriate treatment.
  • [MeSH-major] Magnetic Resonance Imaging / methods. Ovarian Diseases / diagnosis. Ovary / anatomy & histology
  • [MeSH-minor] Diagnosis, Differential. Female. Humans

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Radiol. 1999 Oct;72(862):1006-11 [10673954.001]
  • [Cites] J Comput Assist Tomogr. 2000 Jan-Feb;24(1):72-6 [10667663.001]
  • [Cites] J Comput Assist Tomogr. 1999 Jul-Aug;23(4):555-7 [10433285.001]
  • [Cites] J Magn Reson Imaging. 2004 Sep;20(3):451-62 [15332253.001]
  • [Cites] Eur Radiol. 2001;11(7):1151-4 [11471603.001]
  • [Cites] Radiology. 1993 Feb;186(2):489-94 [8421756.001]
  • [Cites] Hum Reprod. 2001 Jun;16(6):1261-3 [11387302.001]
  • [Cites] Obstet Gynecol. 1977 Jul;50(1):120-8 [195239.001]
  • [Cites] Magn Reson Imaging. 1998 Dec;16(10):1147-53 [9858270.001]
  • [Cites] Eur Radiol. 1999;9(7):1335-8 [10460370.001]
  • [Cites] J Clin Ultrasound. 1981 Jul-Aug;9(6):275-80 [6454699.001]
  • [Cites] J Comput Assist Tomogr. 2001 Mar-Apr;25(2):201-6 [11242213.001]
  • [Cites] Radiology. 1991 Jul;180(1):73-8 [2052726.001]
  • [Cites] J Comput Assist Tomogr. 1990 Sep-Oct;14 (5):833-4 [2398172.001]
  • [Cites] Gynecol Oncol. 2003 Dec;91(3):648-50 [14675693.001]
  • [Cites] Gynecol Oncol. 2004 Jul;94(1):223-5 [15262147.001]
  • [Cites] AJR Am J Roentgenol. 2000 Jun;174(6):1559-63 [10845480.001]
  • [Cites] Radiology. 1996 Dec;201(3):751-5 [8939226.001]
  • [Cites] Radiographics. 2004 Oct;24 Suppl 1:S147-66 [15486238.001]
  • [Cites] Radiographics. 2002 Mar-Apr;22(2):283-94 [11896219.001]
  • [Cites] Radiographics. 2004 Nov-Dec;24(6):1575-89 [15537966.001]
  • [Cites] J Thorac Imaging. 2003 Apr;18(2):100-3 [12700485.001]
  • [Cites] AJR Am J Roentgenol. 2000 Aug;175(2):353-8 [10915674.001]
  • [Cites] J Comput Assist Tomogr. 1993 May-Jun;17 (3):477-9 [8491915.001]
  • [Cites] Eur Radiol. 2000;10(12):1954-7 [11305578.001]
  • [Cites] Radiology. 1996 Feb;198(2):397-402 [8596839.001]
  • [Cites] Korean J Radiol. 2005 Jan-Mar;6(1):44-6 [15782020.001]
  • [Cites] J Magn Reson Imaging. 1998 Nov-Dec;8(6):1203-6 [9848729.001]
  • [Cites] Eur Radiol. 2004 May;14 (5):798-804 [14504904.001]
  • [Cites] Radiographics. 2001 Mar-Apr;21(2):475-90 [11259710.001]
  • [Cites] AJR Am J Roentgenol. 2003 May;180(5):1288-90 [12704039.001]
  • [Cites] Radiographics. 2005 Jan-Feb;25(1):69-85 [15653588.001]
  • [Cites] Radiology. 1999 Jan;210(1):209-16 [9885610.001]
  • [Cites] Magn Reson Imaging. 2002 Apr;20(3):301-4 [12117613.001]
  • [Cites] AJR Am J Roentgenol. 1999 Feb;172(2):445-9 [9930800.001]
  • [Cites] AJR Am J Roentgenol. 1994 Sep;163(3):613-6 [8079854.001]
  • [Cites] Hum Reprod. 2002 Sep;17(9):2219-27 [12202405.001]
  • [Cites] Int J Gynecol Pathol. 1984;3(2):153-78 [6490313.001]
  • [Cites] AJR Am J Roentgenol. 2000 Nov;175(5):1423-30 [11044056.001]
  • [Cites] Top Magn Reson Imaging. 2001 Apr;12(2):131-46 [11296805.001]
  • [Cites] Radiology. 1996 Nov;201(2):549-52 [8888256.001]
  • [Cites] Radiol Clin North Am. 2003 Jul;41(4):799-811 [12899493.001]
  • (PMID = 16736136.001).
  • [ISSN] 0938-7994
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 44
  •  go-up   go-down


33. Paşaoğlu O, Ciftçi E, Tel N, Ozalp S, Acikalin MF: Benign clear cell adenofibroma of the ovary. A case report with literature review. Gynecol Obstet Invest; 2007;64(1):36-9
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for clear cell adenofibroma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign clear cell adenofibroma of the ovary. A case report with literature review.
  • Most clear cell neoplasms of the ovaries are carcinomas; benign and borderline clear cell tumors are uncommon.
  • To date, only 12 cases of benign clear cell adenofibroma have been reported in the literature.
  • Here we report a case of benign clear cell adenofibroma of the left ovary in a 51-year-old postmenopausal woman.
  • In this article we discussed the criteria for the diagnosis of benign and borderline clear cell adenofibromas and reviewed the literature.
  • [MeSH-major] Adenofibroma / pathology. Adenofibroma / surgery. Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery
  • [MeSH-minor] Biopsy, Needle. Female. Follow-Up Studies. Humans. Hysterectomy / methods. Immunohistochemistry. Middle Aged. Neoplasm Staging. Ovariectomy / methods. Pelvic Pain / diagnosis. Pelvic Pain / etiology. Postmenopause. Risk Assessment. Treatment Outcome. Uterine Hemorrhage / diagnosis. Uterine Hemorrhage / etiology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for adenofibroma .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 S. Karger AG, Basel.
  • (PMID = 17202822.001).
  • [ISSN] 1423-002X
  • [Journal-full-title] Gynecologic and obstetric investigation
  • [ISO-abbreviation] Gynecol. Obstet. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 8
  •  go-up   go-down


34. Wilczyńqski JR, Nowińska A, Szpakowski M, Nowak M, Szpakowski A, Władziński J, Kufelnicka M, Znojek W: [Laparoscopic treatment of benign ovarian tumors]. Ginekol Pol; 2006 Jan;77(1):40-7
MedlinePlus Health Information. consumer health - Women's Health.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Laparoscopic treatment of benign ovarian tumors].
  • BACKGROUND: laparoscopic surgery is one of the most common procedures performed in the presence of benign ovarian tumor.
  • THE AIM OF THE STUDY: The purpose of our study was to analyze clinical findings, operative procedures, size and histopathologic type of tumors, time of hospitalization and surgical complications.
  • MATERIAL AND METHODS: 102 female patients operated for benign adnexal masses by laparoscopic approach, in 3rd Department of Gynecology and Obstetrics, University of Medicine, Lódź, between 2001-2004.
  • RESULTS: the most frequent laparoscopic procedure was excision of the tumor (59.8%), and the most common histopathologic type was teratoma adultum (25%), endometroid cyst (21.1%) and serous cyst (20.2%), of 5-7 cm median size.
  • CONCLUSIONS: in the case of benign ovarian tumor laparoscopy is recommended procedure due to sparing ovarian function by small tissue traumatisation, shorter time of hospitalization, faster return to the health and low risk of complications.
  • Because of the possibility of encountering an unexpected ovarian malignancy, the laparoscopy should be executed only in the centers where the intraoperative histopathologic examination is a routine procedure.
  • [MeSH-major] Laparoscopy / methods. Ovarian Cysts / surgery. Ovarian Neoplasms / surgery. Women's Health

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cysts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16736959.001).
  • [ISSN] 0017-0011
  • [Journal-full-title] Ginekologia polska
  • [ISO-abbreviation] Ginekol. Pol.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


35. Nowak M, Klink M, Glowacka E, Sulowska Z, Kulig A, Szpakowski M, Szyllo K, Tchorzewski H: Production of cytokines during interaction of peripheral blood mononuclear cells with autologous ovarian cancer cells or benign ovarian tumour cells. Scand J Immunol; 2010 Feb;71(2):91-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Production of cytokines during interaction of peripheral blood mononuclear cells with autologous ovarian cancer cells or benign ovarian tumour cells.
  • Cytokines produced by tumour and immune cells may play a significant role in a modulation of immune cells response against tumour.
  • We investigated an ability of peripheral blood mononuclear cells (PBMC) of patients with early and advanced stages of ovarian cancer and from non-cancer patients to produce various cytokines in the presence or absence of autologous ovarian cancer (OC) cells or benign ovarian tumour (BOT) cells.
  • PBMC of patients with ovarian cancer or benign ovarian tumour generated comparable amounts of interleukin 6 and 10 (IL-6, IL-10), and transforming growth factor beta1 (TGF-beta1).
  • PBMC of the patients with cancer produced higher amount of tumour necrosis factor alpha (TNF-alpha) than PBMC of non-cancer patients.
  • [MeSH-major] Cell Communication / immunology. Cytokines / biosynthesis. Leukocytes, Mononuclear / immunology. Ovarian Neoplasms / immunology

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20384860.001).
  • [ISSN] 1365-3083
  • [Journal-full-title] Scandinavian journal of immunology
  • [ISO-abbreviation] Scand. J. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cytokines
  •  go-up   go-down


36. Dede M, Gungor S, Yenen MC, Alanbay I, Duru NK, Haşimi A: CA19-9 may have clinical significance in mature cystic teratomas of the ovary. Int J Gynecol Cancer; 2006 Jan-Feb;16(1):189-93
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CA19-9 may have clinical significance in mature cystic teratomas of the ovary.
  • The objective of this study was to evaluate size, bilaterality, histopathologic origin, and the serum levels of some tumor markers in patients with mature cystic teratomas (MCTs) of the ovary.
  • The mean tumor diameter was 7.2 +/- 4.5 cm (median 5; range 3-20).
  • Ovarian MCTs were diagnosed especially during the reproductive period.
  • CA19-9 may be the only important marker in the diagnosis of MCTs.
  • Since levels of CA19-9 and CA125 may be elevated in both benign and malignant conditions, interpretation of these findings must be made in light of the clinical condition of the patient.
  • [MeSH-major] Biomarkers, Tumor / analysis. CA-19-9 Antigen / genetics. Ovarian Neoplasms / genetics. Ovarian Neoplasms / pathology. Teratoma / genetics. Teratoma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Biopsy, Needle. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Ovariectomy / methods. Predictive Value of Tests. Preoperative Care. Probability. Prognosis. Retrospective Studies. Risk Assessment. Sensitivity and Specificity. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16445632.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen
  •  go-up   go-down


37. Kato N, Sasou S, Motoyama T: Expression of hepatocyte nuclear factor-1beta (HNF-1beta) in clear cell tumors and endometriosis of the ovary. Mod Pathol; 2006 Jan;19(1):83-9
MedlinePlus Health Information. consumer health - Ovarian Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of hepatocyte nuclear factor-1beta (HNF-1beta) in clear cell tumors and endometriosis of the ovary.
  • Clear cell tumors of the ovary are frequently associated with ovarian endometriosis.
  • Clinicopathologically, it has been suggested that clear cell tumors develop from endometriosis, but there has been little molecular evidence supporting this speculation.
  • Microarray analysis revealed recently that hepatocyte nuclear factor-1beta (HNF-1beta) was significantly upregulated in clear cell carcinoma of the ovary.
  • In the present study, we examined 30 clear cell tumors (26 malignant, three borderline, and one benign) and 40 endometriotic cysts to clarify if differentiation into the clear cell lineage already begins in ovarian endometriosis.
  • All of the 30 clear cell tumors, including borderline and benign ones, showed immunohistochemical expression of HNF-1beta in the nucleus, while other types of ovarian epithelial tumors (endometrioid, serous, mucinous, and Brenner tumors) rarely expressed it.
  • Among 30 clear cell tumors, 17 (56%) cases were associated with endometriosis, and endometriotic epithelium was identified in 12 cases.
  • In nine of the 12 cases, distinct nuclear immunostaining for HNF-1beta was detected in the endometriotic epithelium, as well as in the clear cell tumor.
  • Furthermore, 16 of 40 (40%) endometriotic cysts without a neoplasm also expressed HNF-1beta, and the expression was almost exclusively observed in the epithelium showing inflammatory atypia.
  • Our results indicate that HNF-1beta is an excellent molecular marker for ovarian clear cell tumors, including benign, borderline and malignant lesions.
  • Early differentiation into the clear cell lineage takes place in ovarian endometriosis, not only in atypical endometriosis, but also in endometriosis with degenerative and regenerative changes, and this is probably responsible for the frequent occurrence of clear cell carcinoma in ovarian endometriosis.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Endometriosis / pathology. Hepatocyte Nuclear Factor 1-beta / biosynthesis. Ovarian Diseases / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Epithelial Cells / chemistry. Epithelial Cells / pathology. Female. Humans. Immunohistochemistry. Middle Aged. Ovarian Cysts / metabolism. Ovarian Cysts / pathology

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16258507.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 138674-15-4 / Hepatocyte Nuclear Factor 1-beta
  •  go-up   go-down


38. Wertel I, Polak G, Bednarek W, Barczyński B, Roliński J, Kotarski J: Dendritic cell subsets in the peritoneal fluid and peripheral blood of women suffering from ovarian cancer. Cytometry B Clin Cytom; 2008 Jul;74(4):251-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dendritic cell subsets in the peritoneal fluid and peripheral blood of women suffering from ovarian cancer.
  • BACKGROUND: Evaluation of immature myeloid and lymphoid dendritic cells (DCs) in the peritoneal fluid (PF) and peripheral blood (PB) mononuclears of women with ovarian carcinoma (n = 47) and benign ovarian tumors (n = 37).
  • RESULTS: The percentage of PF myeloid DC (MDC) in mononuclears was significantly lower in patients with ovarian cancer in comparison to the group of nonmalignant ovarian tumors (0.65% and 6.95%).
  • The percentage of PF lymphoid DCs (LDCs) was higher in patients with ovarian cancer than in the reference group (0.64% and 0.09%).
  • In women suffering from ovarian cancer the percentage of both MDCs and LDCs was higher in the PF than in the PB.
  • In women with ovarian cancer, PF MDCs/LDCs ratio was lower in comparison to patients with serous cystadenoma.
  • LDC subsets may have influence on the local immune response in the PF of women with malignant tumors of the ovary. (c) 2008 Clinical Cytometry Society.
  • [MeSH-major] Ascitic Fluid / cytology. Dendritic Cells / metabolism. Ovarian Neoplasms
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cystadenoma, Serous / immunology. Cystadenoma, Serous / pathology. Disease Progression. Female. Flow Cytometry. Humans. Leukocytes, Mononuclear / immunology. Middle Aged. Neoplasm Metastasis

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18302193.001).
  • [ISSN] 1552-4957
  • [Journal-full-title] Cytometry. Part B, Clinical cytometry
  • [ISO-abbreviation] Cytometry B Clin Cytom
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Qiao YH, Cheng J, Guo RX: [Expression of phosphorylated protein kinase B and PTEN protein in ovarian epithelial cancer]. Zhonghua Fu Chan Ke Za Zhi; 2007 May;42(5):325-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of phosphorylated protein kinase B and PTEN protein in ovarian epithelial cancer].
  • OBJECTIVE: To analyze the expression of phosphorylated protein kinase B (pAKT) and PTEN protein in ovarian epithelial cancer and to investigate the correlations between their expression and prognosis of ovarian epithelial cancers.
  • METHODS: Expression of pAKT and PTEN in 12 normal ovarian tissues, 20 benign tumors, 12 borderline tumors and 80 cases of ovarian epithelial cancers were detected by immunohistochemical method, and their correlations were analyzed.
  • RESULTS: The positive expression of pAKT in normal ovarian and benign tumor tissues were significantly lower than that in ovarian epithelial cancers (8%, 10% vs 55%; P < 0.01), respectively.
  • However, loss of PTEN expression in ovarian epithelial cancers was significantly higher than that in normal ovarian and benign tumor tissues, and the positive rate of PTEN expression were respectively, 45%, 100%, and 80% (P < 0.01).
  • In ovarian cancers, a negative correlation between expression of pAKT and PTEN was observed (r = -0.444, P < 0.01).
  • CONCLUSIONS: The overexpression of pAKT and absence of PTEN are related to ovarian carcinogenesis and development.
  • Loss of PTEN expression is the independent risk factor of poor prognosis in patients with ovarian epithelial cancers.
  • [MeSH-major] Ovarian Neoplasms / metabolism. PTEN Phosphohydrolase / biosynthesis. Proto-Oncogene Proteins c-akt / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Ovary / metabolism. Ovary / pathology. Phosphorylation. Prognosis. Survival Analysis. Tumor Suppressor Proteins / biosynthesis


40. Min H, Wei-hong Z: Constitutive activation of signal transducer and activator of transcription 3 in epithelial ovarian carcinoma. J Obstet Gynaecol Res; 2009 Oct;35(5):918-25
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Constitutive activation of signal transducer and activator of transcription 3 in epithelial ovarian carcinoma.
  • AIM: To investigate the expressions of signal transducer and activator of transcription 3 (Stat3) and tyrosine-activated Stat3 (p-Stat3) in epithelial ovarian carcinoma (EOC) and their relationships with clinical pathological parameters or prognosis.
  • METHODS: Immunohistochemical methods were used to detect the expressions of Stat3 and p-Stat3 in EOC, benign ovarian tumors and normal ovarian tissues, after which an analysis of results with clinical pathological or prognosis was given.
  • RESULTS: The expressions of Stat3 and p-Stat3 in EOC were significantly higher than in normal ovarian epithelial tissues or benign ovarian tumor tissues (P < 0.0125) and the expression of Stat3 protein was highly correlated with the expression of p-Stat3 protein (P < 0.01).
  • [MeSH-major] Carcinoma / metabolism. Ovarian Neoplasms / metabolism. STAT3 Transcription Factor / metabolism
  • [MeSH-minor] Adult. Aged. Chi-Square Distribution. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Lymphatic Metastasis / pathology. Middle Aged. Neoplasm Staging. Phosphorylation. Prognosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20149042.001).
  • [ISSN] 1447-0756
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / STAT3 Transcription Factor
  •  go-up   go-down


41. Attia L, Chachia A, Ben Temime R, Bennour G, Makhlouf T, Koubâa A: [Benign ovarian tumors during pregnancy. A review of 26 cases]. Tunis Med; 2008 Jul;86(7):680-4
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Benign ovarian tumors during pregnancy. A review of 26 cases].
  • [Transliterated title] Tumeurs de l'ovaire au cours de la grossesse: a propos de 26 cas.
  • OBJECTIVE: To identify the particularities of ovarian tumors during pregnancy.
  • METHODS: A retrospective study of 26 patients who underwent surgical treatment for ovarian tumors during pregnancy between January 1993 and December 2005.
  • The circumstances under which the ovarian tumors were discovered consisted of adnexal torsion in 57% of cases, chronic pelvic pain in 15% of cases and at routine ultrasonographic scan in 26% of cases.
  • CONCLUSION: Ovarian tumors during pregnancy are rare.
  • Laparoscopic ovarian cystectomy offers significant advantages with respect to laparotomy for the pregnant patient.
  • [MeSH-major] Ovarian Cysts / diagnosis. Ovarian Cysts / surgery. Pregnancy Complications, Neoplastic / diagnosis. Pregnancy Complications, Neoplastic / surgery

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Ovarian Cysts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19472731.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


42. Zhang J, Ye F, Chen HZ, Ye DF, Lu WG, Xie X: [Deletion of OPCML gene and promoter methylation in ovarian epithelial carcinoma]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2006 Apr;28(2):173-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Deletion of OPCML gene and promoter methylation in ovarian epithelial carcinoma].
  • OBJECTIVE: To investigate the expression of OPCML gene in ovarian epithelial carcinoma and determine the relationship between mRNA expression and methylation of their promoters.
  • METHOD: Twenty normal ovarian tissues and 89 ovarian epithelial tumor specimens (72 malignant, 17 benign), as well as 3 ovarian carcinoma cell lines (SKOV-3, CAOV3, and 3AO), were collected for detection of OPCML gene expression by reverse transcription-polymerase chain reaction and for detection of promoter methylation by restriction enzyme cut analysis from 7.
  • RESULTS: Among ovarian epithelial carcinoma 19.4% expressed OPCML mRNA, while 85% of normal ovarian tissue and 76.5% of benign ovarian tumor.
  • The ratio of expression of OPCML mRNA in ovarian epithelial carcinoma was significantly lower than those of normal (chi2 = 30.108, P = 0.0000) and benign tumors (chi2 = 21.162, P = 0.000).
  • Methylations were detected in 44.4% of cancer cells promoter, while 0% in normal ovarian tissue and benign ovarian tumors.
  • The ratio of methylation of ovarian epithelial carcinoma was significantly higher than those of normal (chi2 = 13.630, P = 0.0000) and benign tumors (chi2 = 11.797, P = 0.000).
  • CONCLUSION: Deletion of OPCML gene exists in ovarian epithelial carcinoma cell.
  • [MeSH-major] Cell Adhesion Molecules / genetics. CpG Islands / genetics. DNA Methylation. Gene Deletion. Ovarian Neoplasms / genetics. Promoter Regions, Genetic / genetics
  • [MeSH-minor] Adult. Aged. Cell Line, Tumor. Female. GPI-Linked Proteins. Humans. Middle Aged. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16733898.001).
  • [ISSN] 1000-503X
  • [Journal-full-title] Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
  • [ISO-abbreviation] Zhongguo Yi Xue Ke Xue Yuan Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cell Adhesion Molecules; 0 / GPI-Linked Proteins; 0 / OPCML protein, human; 0 / RNA, Messenger
  •  go-up   go-down


43. Inai K, Shimizu Y, Kawai K, Tokunaga M, Soda M, Mabuchi K, Land CE, Tokuoka S: A pathology study of malignant and benign ovarian tumors among atomic-bomb survivors--case series report. J Radiat Res; 2006 Mar;47(1):49-59
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A pathology study of malignant and benign ovarian tumors among atomic-bomb survivors--case series report.
  • The present article describes the series of incident primary ovarian tumors in the Life Span Study (LSS) cohort of the Radiation Effects Research Foundation, with particular emphasis on case ascertainment and characterization of histological features of the tumors.
  • We identified 723 ovarian tumors (260 malignant, 463 benign) in 648 individuals of about 70,000 female LSS subjects; 71 cases had more than one ovarian tumor.
  • We histologically confirmed 601 tumors (182 malignant, 419 benign tumors).
  • The most frequent histological type was common epithelial tumor (90.7% for malignant and 59.7% for benign tumors).
  • The distributions of ovarian tumors by histological type were similar to those from other studies.
  • Among malignancies, the frequency of common epithelial types relative to other tumor types increased with radiation dose (p = 0.02).
  • Among benign tumors, the relative frequency of sex-cord stromal tumors increased with radiation dose (p = 0.04).
  • Within tumor types, there was no consistent pattern of survival by radiation dose.
  • Variations in histological types of ovarian tumors in response to radiation dose, suggested by the case series data need to be followed up by population-based incidence analysis.
  • [MeSH-major] Neoplasms, Radiation-Induced / mortality. Neoplasms, Radiation-Induced / pathology. Nuclear Warfare / statistics & numerical data. Ovarian Neoplasms / mortality. Ovarian Neoplasms / pathology. Risk Assessment / methods. Survivors / statistics & numerical data

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16571918.001).
  • [ISSN] 0449-3060
  • [Journal-full-title] Journal of radiation research
  • [ISO-abbreviation] J. Radiat. Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CP / N01-CP-31012; United States / NCI NIH HHS / CP / N01-CP-71015
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Japan
  •  go-up   go-down


44. Medeiros LR, Rosa DD, Edelweiss MI, Stein AT, Bozzetti MC, Zelmanowicz A, Pohlmann PR, Meurer L, Carballo MT: Accuracy of frozen-section analysis in the diagnosis of ovarian tumors: a systematic quantitative review. Int J Gynecol Cancer; 2005 Mar-Apr;15(2):192-202
PubMed Health. DARE review .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accuracy of frozen-section analysis in the diagnosis of ovarian tumors: a systematic quantitative review.
  • A quantitative systematic review was performed to estimate the diagnostic accuracy of frozen sections in ovarian tumors.
  • Studies that compared frozen sections and paraffin sections within subjects for diagnosis of ovarian tumors were included.
  • For benign ovarian vs borderline/malignant tumor cases, the occurrence of a positive frozen-section result for benignity (pooled likelihood ratio [LR], 8.7; 95% confidence interval [CI], 7.3-10.4) and posttest probability for benign diagnosis was 95% (95% CI, 94-96%).
  • A positive frozen-section result for malignant vs benign diagnosis (pooled LR, 303; 95% CI, 101-605) increased the probability of ovarian cancer to 98% (95% CI, 97-99%).
  • In borderline vs benign ovarian tumor cases, a positive frozen-section result (pooled LR, 69; 95% CI, 45-106) increased the probability of borderline tumors to 79% (95% CI, 71-85%).
  • In borderline vs malignant ovarian tumor cases, a positive frozen-section result (pooled LR, 18; 95% CI, 13-26) increased the probability of borderline tumors to 51% (95% CI, 42-60%).
  • We conclude that diagnostic accuracy rates for frozen-section analysis is high for malignant and benign ovarian tumors, but the accuracy rates in borderline tumors remain relatively low.
  • [MeSH-major] Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / pathology. Quality Assurance, Health Care
  • [MeSH-minor] Cryopreservation. Diagnosis, Differential. Female. Humans. Observer Variation. Sensitivity and Specificity. Specimen Handling

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15823099.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] United States
  • [Number-of-references] 34
  •  go-up   go-down


45. Krishnamurti U, Sasatomi E, Swalsky PA, Jones MW, Finkelstein SD: Microdissection-based mutational genotyping of serous borderline tumors of the ovary. Int J Gynecol Pathol; 2005 Jan;24(1):56-61
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microdissection-based mutational genotyping of serous borderline tumors of the ovary.
  • Mutational changes in a number of genetic foci were studied in 12 serous borderline tumors (SBTs) of the ovary including 2 with a micropapillary pattern.
  • The analysis was focused on chromosomal regions that have not been previously studied in these tumors.
  • The findings were correlated with the morphology and the FIGO stage of the tumors.
  • Six of the tumors were stage I, one was stage II, and five were stage III.
  • Loss of heterozygosity analysis in each tumor was performed with a panel of 12 polymorphic markers on chromosomes 1p, 5q, 9p, 9q, 10q, and 17p.
  • The ovarian tumors displayed allelic losses most frequently on 1p (83.3%), 9q (70%), and 17p (41.7%).
  • In five of six cases, allelic losses were 88% concordant between multiple tumor sites.
  • Only one case of stage III tumor displayed a discordant pattern of allelic loss at different tumor sites.
  • The pattern and cumulative allelic loss in the two cases with micropapillary architecture was similar to that of the other tumors.
  • Morphologically heterogenous areas including benign-appearing, typical borderline, and micropapillary areas had a similar pattern of allelic loss.
  • [MeSH-major] Cystadenocarcinoma, Papillary / genetics. Cystadenocarcinoma, Serous / genetics. Mutation / genetics. Ovarian Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Case-Control Studies. Female. Genotype. Humans. Loss of Heterozygosity / genetics. Microdissection. Microsatellite Repeats. Middle Aged. Neoplasm Staging. Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15626917.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Barwijuk AJ, Bonarek-Sztaba J: [Comparison of gas and gasless laparoscopy in the treatment of benign ovarian tumors]. Ginekol Pol; 2006 Jun;77(6):450-1, 454-7
Hazardous Substances Data Bank. Carbon dioxide .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparison of gas and gasless laparoscopy in the treatment of benign ovarian tumors].
  • OBJECTIVES: The aim of the study was to compare the outcomes of the gas and gasless laparoscopy in the treatment of benign ovarian tumors.
  • An ovarian tumor considered to be benign was the indication to operation.
  • Those assessments revealed that all tumors had been benign.
  • [MeSH-major] Laparoscopy / methods. Ovarian Neoplasms / surgery. Pneumoperitoneum, Artificial / methods

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16964696.001).
  • [ISSN] 0017-0011
  • [Journal-full-title] Ginekologia polska
  • [ISO-abbreviation] Ginekol. Pol.
  • [Language] pol
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 142M471B3J / Carbon Dioxide
  •  go-up   go-down


47. Lee YY, Kim TJ, Choi CH, Lee JW, Kim BG, Bae DS: Factors influencing the choice of laparoscopy or laparotomy in pregnant women with presumptive benign ovarian tumors. Int J Gynaecol Obstet; 2010 Jan;108(1):12-5
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors influencing the choice of laparoscopy or laparotomy in pregnant women with presumptive benign ovarian tumors.
  • OBJECTIVE: To evaluate the factors associated with physicians' choice of laparotomy or laparoscopy in pregnant women with presumptive benign ovarian tumors.
  • METHODS: Retrospective comparative analysis of pregnant women who underwent laparotomy or laparoscopy for ovarian tumors and who delivered at Samsung Medical Center, Seoul, Korea, between July 1995 and April 2008.
  • RESULTS: Univariate analysis revealed that the following factors had a significant or a borderline significant association with the choice of operation type: maternal age (P=0.044); surgeon type (professor vs clinical fellow; P=0.094); tumor mass size (P=0.081); gestational age (P=0.035); and time since surgery (P<0.001).
  • Multivariate analysis showed that tumor size (P=0.030), gestational age (P=0.027), and time since surgery (P=0.004) were independent factors associated with physicians' choice of laparoscopy or laparotomy for the management of presumptive benign ovarian tumors during pregnancy.
  • CONCLUSIONS: In the latter years of the present study, physicians at the study center preferred the laparoscopic approach for managing presumptive benign ovarian tumors during pregnancy.
  • Furthermore, they preferred this approach to laparotomy for pregnancies at a relatively early gestational age and for treating small tumors.
  • [MeSH-major] Laparoscopy / methods. Laparotomy / methods. Ovarian Neoplasms / diagnosis. Pregnancy Complications, Neoplastic / diagnosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19892330.001).
  • [ISSN] 1879-3479
  • [Journal-full-title] International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
  • [ISO-abbreviation] Int J Gynaecol Obstet
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Mittal S, Gupta N, Sharma AK, Dadhwal V: Laparoscopic management of a large recurrent benign mucinous cystadenoma of the ovary. Arch Gynecol Obstet; 2008 Apr;277(4):379-80
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic management of a large recurrent benign mucinous cystadenoma of the ovary.
  • INTRODUCTION: Benign mucinous cystadenomas account for 15% of all ovarian neoplasms and up to 80% of all mucinous tumors.
  • Laparoscopy has become an accepted method of management for ovarian cysts and its role is expanding as large benign adnexal masses more than 10 cm can be managed safely and effectively.
  • CASE REPORT: We report a 25-year-old nulliparous lady with a huge benign mucinous cystadenoma managed by laparoscopic cystectomy, followed by an early recurrence within 2 months.
  • Pathology revealed a benign cyst.
  • CONCLUSION: Since mucinous tumors are usually benign and multilocular, management of young patients is challenging, especially in the case of recurrence which is very rare.
  • [MeSH-major] Cystadenoma, Mucinous / surgery. Laparoscopy / methods. Neoplasm Recurrence, Local / surgery. Ovarian Neoplasms / surgery. Ovariectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18236062.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Germany
  •  go-up   go-down


49. Stanković ZB, Djukić MK, Sedlecki K, Djuricić S, Lukac BJ, Mazibrada I: Rapidly growing bilateral ovarian cystadenoma in a 6-year-old girl: case report and literature review. J Pediatr Adolesc Gynecol; 2006 Feb;19(1):35-8
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for ovarian cystadenoma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapidly growing bilateral ovarian cystadenoma in a 6-year-old girl: case report and literature review.
  • BACKGROUND: Benign ovarian neoplasms originating from epithelial tissue are common tumors in adult women.
  • Repeated ultrasonographic examinations revealed bilateral, cystic, rapidly growing ovarian masses.
  • Cysts were surgically removed, with preservation of normal ovarian tissue, and histopathologic findings showed a serous cystadenoma of both ovaries.
  • [MeSH-major] Cystadenoma, Serous / ultrasonography. Ovarian Neoplasms / ultrasonography

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16472727.001).
  • [ISSN] 1083-3188
  • [Journal-full-title] Journal of pediatric and adolescent gynecology
  • [ISO-abbreviation] J Pediatr Adolesc Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 16
  •  go-up   go-down


50. Hsu TL, Changchien CC, Huang CC, Lin H: Angioleiomyoma originating from the ovary of an eleven-year-old premenarchal girl. Gynecol Obstet Invest; 2008;65(4):262-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioleiomyoma originating from the ovary of an eleven-year-old premenarchal girl.
  • BACKGROUND: Angioleiomyoma (ALM) is a rare, benign neoplasm involving the peripheral soft tissues.
  • ALM has not previously been described to originate from the ovary.
  • We present a case herein of a premenarchal girl with a large ALM originating from the ovary.
  • A solid mass left ovarian was identified and resected.
  • The final pathologic report of the resected tumor was consistent with an ALM.
  • CONCLUSION: To our knowledge, this is the first report of an ALM arising from the ovary.
  • The treatment of choice for such an ovarian mass is surgical excision, which is usually a curative measure.
  • [MeSH-major] Angiomyoma / diagnosis. Angiomyoma / surgery. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 S. Karger AG, Basel
  • [CommentIn] Gynecol Obstet Invest. 2010;70(1):8-10 [20130412.001]
  • (PMID = 18196910.001).
  • [ISSN] 1423-002X
  • [Journal-full-title] Gynecologic and obstetric investigation
  • [ISO-abbreviation] Gynecol. Obstet. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


51. Green GE, Mortele KJ, Glickman JN, Benson CB: Brenner tumors of the ovary: sonographic and computed tomographic imaging features. J Ultrasound Med; 2006 Oct;25(10):1245-51; quiz 1252-4
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brenner tumors of the ovary: sonographic and computed tomographic imaging features.
  • OBJECTIVE: The purpose of this study was to describe the sonographic appearance of ovarian Brenner tumors with computed tomographic (CT) correlation.
  • METHODS: Twenty-two female patients (age range, 32-78 years; mean, 58 years) with 25 ovarian Brenner tumors were identified from pathologic records from 1990 to 2005.
  • RESULTS: Tumors ranged in size from 0.3 to 12 cm (mean, 2.5 cm); all were benign.
  • Eight (36%) of 22 patients had a total of 12 associated benign ovarian neoplasms (1 was contralateral); 3 patients had bilateral Brenner tumors.
  • Eight (47%) of 17 tumors were not seen on sonography, and 5 (36%) of 14 were not seen on CT.
  • Of the tumors seen on imaging, most were solid (67% on sonography and 78% on CT).
  • Four tumors appeared at least partially cystic, of which 3 had coexistent cystic ovarian lesions.
  • CONCLUSIONS: Brenner tumors are most often solid neoplasms found incidentally and frequently seen in association with other benign ovarian epithelial neoplasms.
  • [MeSH-major] Brenner Tumor / ultrasonography. Ovarian Neoplasms / ultrasonography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16998096.001).
  • [ISSN] 0278-4297
  • [Journal-full-title] Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  • [ISO-abbreviation] J Ultrasound Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Yan XJ, Tian Y, Wang C, Wang XL, Di JM, Cheng JX: [The expressions and clinical significance of IGFBP-2, -3 in both serum and tumor tissues in patients with epithelial ovarian cancer]. Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 Jul;40(4):639-43
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The expressions and clinical significance of IGFBP-2, -3 in both serum and tumor tissues in patients with epithelial ovarian cancer].
  • OBJECTIVE: To explore the serum levels of IGFBP-2, -3 and their proper roles in the regulation of IGF-II bioavailability in patients with ovarian tumor, and to investigate the correlation between the expressions of IGFBP-2 and IGFBP-3 in ovarian tumor tissues and related clinicopathological characteristics.
  • METHODS: Serum levels of IGFBP-2, -3 and big/mature IGF-II were measured by Western ligand blot (WLB) and Western blot (WB) in patients with ovarian tumor (10 cases of benign tumor, 6 cases of borderline tumor and 10 cases of malignant tumor) and 10 cases of normal control.
  • The expressions of IGFBP-2 and IGFBP-3 were examined in 39 specimens of ovarian tumor (8 cases of benign tumor, 8 cases of borderline tumor and 23 cases of malignant tumor) and 4 cases of normal ovarian tissues by immunohistochemical staining.
  • RESULTS: The serum levels of both big and mature IGF-II in epithelial ovarian cancer (ovarian cancer) patients were significantly decreased compared with those of normal control and benign and borderline tumor (P<0.001 or P<0.01).
  • The increased serum level of IGFBP-2 and decreased IGFBP-3 level were observed in patients with malignant ovarian tumors by comparing with those of patients with normal controls, benign and borderline tumor (P<0.001 or P<0.01).
  • The expression of IGFBP-2 was significantly higher in malignant ovarian tumor tissues than those in normal control and benign ovarian tumors tissues (P<0.0001, P<0.001, and the expression of IGFBP-3 decreased significantly in lower differentiated ovarian cancer tissues compared with that in high and moderate differentiated ovarian cancer tissues (P<0. 05).
  • CONCLUION: IGFBP-2 predominantly presents in the circulation of malignant patients in contrast to IGFBP-3, which may result in altered bioavailability of IGF-II in ovarian cancer, leading to the progress of tumor.
  • The serum levels of both IGFBP-2 and IGFBP-3 and their expressions in tumor tissues are correlated with the clinicopathological characteristics of ovarian cancer patients.
  • Our findings suggest that the presence of new mechanisms in the regulation of IGF-II bioavailability, and provide the evidence for the possibility to use IGFBP-2/IGFBP-3 as biological markers in diagnosis and prognosis of ovarian cancer.
  • [MeSH-major] Insulin-Like Growth Factor Binding Protein 2 / blood. Insulin-Like Growth Factor Binding Protein 3 / blood. Insulin-Like Growth Factor II / analysis. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19764562.001).
  • [ISSN] 1672-173X
  • [Journal-full-title] Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
  • [ISO-abbreviation] Sichuan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Insulin-Like Growth Factor Binding Protein 2; 0 / Insulin-Like Growth Factor Binding Protein 3; 67763-97-7 / Insulin-Like Growth Factor II
  •  go-up   go-down


53. Diamantopoulou S, Sikiotis K, Panayiotides J, Kassanos D: Serous cystadenoma with massive ovarian edema. A case report and review of the literature. Clin Exp Obstet Gynecol; 2009;36(1):58-61
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serous cystadenoma with massive ovarian edema. A case report and review of the literature.
  • BACKGROUND: Massive ovarian edema is an usual tumour-like condition.
  • It may be confused with an ovarian neoplasm.
  • Ultrasound revealed a mass of a non-echogenic cystic compartment of 13 cm maximum diameter, and an area of mixed echogenicity of 11 cm maximum diameter at the anatomic site of the right ovary.
  • The pathology examination revealed serous cystadenoma with massive ovarian edema.
  • CONCLUSIONS: Conservative treatment and ovarian suspension may be more appropriate, when histology on frozen section suggests a benign lesion.
  • [MeSH-major] Cystadenoma, Serous / pathology. Ovarian Neoplasms / pathology

  • Genetic Alliance. consumer health - Edema.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19400422.001).
  • [ISSN] 0390-6663
  • [Journal-full-title] Clinical and experimental obstetrics & gynecology
  • [ISO-abbreviation] Clin Exp Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 27
  •  go-up   go-down


54. Cho H, Hur HW, Kim SW, Kim SH, Kim JH, Kim YT, Lee K: Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol Immunother; 2009 Jan;58(1):15-23
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment.
  • PURPOSE: Inflammatory cells can both suppress and stimulate tumor growth, and the influence of inflammatory cells on clinical outcome has been the focus of many studies.
  • The purpose of this study was to evaluate the effectiveness of the neutrophil to lymphocyte ratio (NLR), a measure of the systemic inflammatory response, as an additional discriminative biomarker in epithelial ovarian cancer and to determine whether it predicts survival and recurrence.
  • METHODS: We studied 192 patients with epithelial ovarian cancer, 173 with benign ovarian tumors, 229 with benign gynecologic disease, and 405 healthy controls.
  • In epithelial ovarian cancer, the diagnostic usefulness of NLR, in combination with CA125, was evaluated.
  • RESULTS: Preoperative NLR in ovarian cancer subjects (mean 6.02) was significantly higher than that in benign ovarian tumor subjects (mean 2.57), benign gynecologic disease subjects (mean 2.55), and healthy controls (mean 1.98) (P < 0.001).
  • The sensitivity and specificity of NLR in detecting ovarian cancer was 66.1% (95% CI, 59.52-72.68%) and 82.7% (95% CI, 79.02-86.38%), respectively (cutoff value: 2.60).
  • In early stage ovarian cancer, CA125 was not elevated in 19 out of 49 patients.
  • CONCLUSIONS: Our findings provide evidence for the association between NLR and epithelial ovarian cancer.
  • Preoperative NLR, in combination with CA125, may represent a simple and cost-effective method of identifying ovarian cancers, and an elevated NLR may predict an adverse outcome in ovarian cancer.
  • [MeSH-major] Biomarkers, Tumor. Lymphocyte Count. Neoplasms, Glandular and Epithelial / pathology. Neutrophils / cytology. Ovarian Neoplasms / pathology

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18414853.001).
  • [ISSN] 1432-0851
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


55. Liguang Z, Peishu L, Hongluan M, Hong J, Rong W, Wachtel MS, Frezza EE: Survivin expression in ovarian cancer. Exp Oncol; 2007 Jun;29(2):121-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survivin expression in ovarian cancer.
  • AIM: To examine the expression of survivin in benign ovarian tumors, ovarian carcinomas of different stages.
  • METHODS: We screened the expression of survivin mRNA by reverse transcription polymerase chain reaction in 114 ovarian tissue samples.
  • RESULTS: No survivin mRNA was expressed in all normal ovarian specimens, while it appeared in 73% of ovarian carcinomas, 47% of borderline ovarian carcinomas and 19% of benign ovarian tumors.
  • In tissues with positive expression of survivin, we also found that mean survivin mRNA expression levels were higher in ovarian carcinomas than that in benign ovarian tumors and borderline ovarian carcinoma tissues (P < 0.001).
  • Among ovarian carcinomas, the high survivin mRNA expression levels correlated with the clinical stages, differentiation grade, lymph node metastasis, but not - with ascites and histological type.
  • CONCLUSION: Our study suggest that survivin is associated with progression of ovarian carcinoma.
  • [MeSH-major] Cystadenoma, Mucinous / metabolism. Cystadenoma, Serous / metabolism. Neoplasm Proteins / biosynthesis. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Carcinoma / metabolism. Carcinoma / pathology. Disease Progression. Female. Humans. Middle Aged. Neoplasm Staging. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Retrospective Studies. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17704744.001).
  • [ISSN] 1812-9269
  • [Journal-full-title] Experimental oncology
  • [ISO-abbreviation] Exp. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / RNA, Messenger
  •  go-up   go-down


56. Chauhan SC, Vinayek N, Maher DM, Bell MC, Dunham KA, Koch MD, Lio Y, Jaggi M: Combined staining of TAG-72, MUC1, and CA125 improves labeling sensitivity in ovarian cancer: antigens for multi-targeted antibody-guided therapy. J Histochem Cytochem; 2007 Aug;55(8):867-75
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined staining of TAG-72, MUC1, and CA125 improves labeling sensitivity in ovarian cancer: antigens for multi-targeted antibody-guided therapy.
  • Single antigen-targeted intraperitoneal radioimmunotherapy for ovarian cancer has shown limited success.
  • Due to the heterogeneous expression of tumor antigens on cancer cells, a multi-antigen targeting approach appears logical to augment the therapeutic efficacy of antibody-guided therapy.
  • In the interest of developing this novel approach, ovarian cancer tissue microarray slides containing cancer and benign/non-neoplastic tissue samples (n=92) were processed for single-, double-, and triple-antigen labeling using antibodies for the tumor-associated antigens TAG-72, MUC1, and CA125.
  • Among all ovarian cancer types, 72%, 61%, and 50% of the samples showed immunolabeling for TAG-72, MUC1, and CA125, respectively.
  • Of the 48 epithelial ovarian cancer samples, individual anti-TAG-72, MUC1, and CA125 antibody probing showed labeling in 89.5%, 87.5%, and 73.0% of the cases, respectively.
  • However, upon combining the three antigens (triple-antigen labeling), 98% of the epithelial ovarian cancer samples were labeled and >95% of the cancer cells within each sample were labeled.
  • Therapeutic efficacy of antibody-guided therapy for ovarian cancer treatment will be enhanced by the combined targeting of TAG-72, MUC1, and CA125.
  • [MeSH-major] Antibodies. Antigens, Neoplasm / metabolism. Biomarkers, Tumor / metabolism. CA-125 Antigen / metabolism. Glycoproteins / metabolism. Mucins / metabolism. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Drug Carriers. Female. Humans. Mucin-1. Neoplasms, Glandular and Epithelial / metabolism. Ovary / metabolism. Tissue Array Analysis

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17478446.001).
  • [ISSN] 0022-1554
  • [Journal-full-title] The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
  • [ISO-abbreviation] J. Histochem. Cytochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / Drug Carriers; 0 / Glycoproteins; 0 / MUC1 protein, human; 0 / Mucin-1; 0 / Mucins; 0 / tumor-associated antigen 72
  •  go-up   go-down


57. Kumar SR, Masood R, Spannuth WA, Singh J, Scehnet J, Kleiber G, Jennings N, Deavers M, Krasnoperov V, Dubeau L, Weaver FA, Sood AK, Gill PS: The receptor tyrosine kinase EphB4 is overexpressed in ovarian cancer, provides survival signals and predicts poor outcome. Br J Cancer; 2007 Apr 10;96(7):1083-91
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The receptor tyrosine kinase EphB4 is overexpressed in ovarian cancer, provides survival signals and predicts poor outcome.
  • We wanted to determine the biological role of EphB4 in ovarian cancer.
  • We studied the expression of EphB4 in seven normal ovarian specimens and 85 invasive ovarian carcinomas by immunohistochemistry.
  • EphB4 expression was largely absent in normal ovarian surface epithelium, but was expressed in 86% of ovarian cancers.
  • We also studied the biological significance of EphB4 expression in ovarian tumour cells lines in vitro and in vivo.
  • All five malignant ovarian tumour cell lines tested expressed higher levels of EphB4 compared with the two benign cell lines.
  • Treatment of malignant, but not benign, ovarian tumour cell lines with progesterone, but not oestrogen, led to a 90% reduction in EphB4 levels that was associated with 50% reduction in cell survival.
  • Inhibition of EphB4 expression by specific siRNA or antisense oligonucleotides significantly inhibited tumour cell viability by inducing apoptosis via activation of caspase-8, and also inhibited tumour cell invasion and migration.
  • Furthermore, EphB4 antisense significantly inhibited growth of ovarian tumour xenografts and tumour microvasculature in vivo.
  • Inhibition of EphB4 may hence have prognostic and therapeutic utility in ovarian carcinoma.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PROGESTERONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dev Biol. 2001 Feb 15;230(2):139-50 [11161568.001]
  • [Cites] Br J Cancer. 2007 Jan 15;96(1):151-6 [17179984.001]
  • [Cites] Ann Oncol. 2003 Feb;14(2):220-6 [12562648.001]
  • [Cites] Int J Cancer. 2003 May 1;104(5):603-10 [12594815.001]
  • [Cites] Pathol Oncol Res. 2004;10(1):26-33 [15029258.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 13;101(15):5583-8 [15067119.001]
  • [Cites] Cell. 1998 May 29;93(5):741-53 [9630219.001]
  • [Cites] Virchows Arch. 1998 Aug;433(2):103-11 [9737787.001]
  • [Cites] Mol Cell. 1999 Sep;4(3):403-14 [10518221.001]
  • [Cites] Cancer Res. 2005 Jun 1;65(11):4623-32 [15930280.001]
  • [Cites] BMC Cancer. 2005;5:119 [16171530.001]
  • [Cites] Oncogene. 2006 Feb 2;25(5):769-80 [16205642.001]
  • [Cites] Panminerva Med. 2006 Mar;48(1):13-7 [16633327.001]
  • [Cites] Gynecol Oncol. 2006 Jul;102(1):15-21 [16499955.001]
  • [Cites] Am J Pathol. 2006 Jul;169(1):279-93 [16816380.001]
  • [Cites] Int J Cancer. 2006 Sep 15;119(6):1236-48 [16615113.001]
  • [Cites] J Cell Sci. 2002 Jan 1;115(Pt 1):25-37 [11801721.001]
  • (PMID = 17353927.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA083639; United States / NCI NIH HHS / CA / R01 CA079218; United States / NCI NIH HHS / CA / R01CA79218
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Progestins; 0 / RNA, Small Interfering; 4G7DS2Q64Y / Progesterone; EC 2.7.10.1 / Receptor, EphB4; EC 3.4.22.- / Caspases
  • [Other-IDs] NLM/ PMC2360128
  •  go-up   go-down


58. Gao GL, Liu LD, Zou XS, Chen WX: [Expression of KiSS-1, matrix metalloproteinase-9, nuclear factor-kappaBp65 in ovarian tumour]. Zhonghua Fu Chan Ke Za Zhi; 2007 Jan;42(1):34-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of KiSS-1, matrix metalloproteinase-9, nuclear factor-kappaBp65 in ovarian tumour].
  • OBJECTIVE: To investigate the expression and correlation of KiSS-1, matrix metalloproteinase-9 (MMP-9) and nuclear factor (NF)-kappaBp65 proteins in primary epithelial ovarian tumors.
  • METHODS: Expression of KiSS-1, MMP-9, NF-kappaBp65 proteins in primary ovarian epithelial tumors (malignant n = 50, borderline tumor n = 20, benign adenoma n = 20, normal tissue n = 10) was evaluated by immunohistochemical staining.
  • RESULTS: Expression of metastin protein in primary epithelial ovarian cancers was significantly higher than that in ovarian benign adenoma (P < 0.05) and normal tissues (P < 0.05).
  • Expression of metastin protein in ovarian borderline tumors was significantly higher than that in normal tissues (P < 0.05).
  • Expression of metastin protein in ovarian cancer was significantly correlated with node metastasis (P < 0.05).
  • MMP-9 protein was positive in 68% (34/50) of the epithelial ovarian cancers, significantly higher than that in normal tissues (20%, 2/10; P < 0.05).
  • NF-kappaBp65 protein was positive in 72% (36/50) of the epithelial ovarian cancers, significantly higher than that in ovarian benign adenoma (30%, 6/20; P < 0.05) and normal tissues (10%, 1/10; P < 0.05).
  • The expression of MMP-9 protein in epithelial ovarian cancer was significantly correlated with FIGO stage (P < 0.05) and lymph node metastasis (P < 0.05).
  • The expression of NF-kappaBp65 protein in epithelial ovarian cancer was significantly correlated with FIGO stage (P < 0.05), differentiation grade (P < 0.05) and lymph node metastasis (P < 0.05).
  • There was obviously negative correlation between KiSS-1 and MMP-9 expression in ovarian cancer (rs = -0.547, P < 0.05), as well as between KiSS-1 and NF-kappaBp65 expression in ovarian cancer (rs = -0.414, P < 0.05), while there was obviously positive correlation between MMP-9 and NF-kappaBp65 expression in ovarian cancer (rs = 0.695, P < 0.05).
  • CONCLUSION: The results indicate that KiSS-1 plays some role in suppression of the metastasis of ovarian epithelial cancers, which may be through inhibiting the expression of MMP-9 and NF-kappaBp65.
  • [MeSH-major] Matrix Metalloproteinase 9 / biosynthesis. Ovarian Neoplasms / metabolism. Transcription Factor RelA / biosynthesis. Tumor Suppressor Proteins / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Immunohistochemistry. Kisspeptins. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Ovary / metabolism. Ovary / pathology. Prognosis. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17331419.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / KISS1 protein, human; 0 / Kisspeptins; 0 / Transcription Factor RelA; 0 / Tumor Suppressor Proteins; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


59. Baksu B, Akyol A, Davas I, Yazgan A, Ozgul J, Tanik C: Recurrent mucinous cystadenoma in a 20-year-old woman: was hysterectomy inevitable? J Obstet Gynaecol Res; 2006 Dec;32(6):615-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A recurrence of ovarian mucinous cysts is very rare.
  • Over a period of 21 months, a 20-year-old patient had three laparotomies resulting initially in the removal of one ovary with a mucinous cystadenoma and two cystectomies for the same pathology, but ultimately leading to hysterectomy and salphingo-oopherectomy.
  • Because mucinous tumors are usually benign and most of the time multilocular, management of young patients is challenging, especially in the case of recurrence.
  • Follow-up of these patients is very important and transvaginal ultrasound seems to be currently the most effective diagnostic tool for the follow-up of young patients treated with cystectomy for benign mucinous cystadenomas.
  • [MeSH-major] Cystadenoma, Mucinous / surgery. Hysterectomy. Neoplasm Recurrence, Local / surgery. Ovarian Neoplasms / surgery. Ovariectomy

  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17100827.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


60. Zhang S, Lin QD, DI W: Suppression of human ovarian carcinoma metastasis by the metastasis-suppressor gene, BRMS1. Int J Gynecol Cancer; 2006 Mar-Apr;16(2):522-31
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Suppression of human ovarian carcinoma metastasis by the metastasis-suppressor gene, BRMS1.
  • Expression of BRMS1 messenger RNA (mRNA) in multitissue including normal prostate, ovarian, testis, and colon has been detected by northern blot analysis.
  • We hypothesize that the role of BRMS1 in tumor progression may not be limited to breast cancer and melanoma.
  • We previously found that BRMS1 mRNA levels in primary ovarian epithelial carcinomas were significantly lower than that in normal ovarian and benign tumors (P < 0.05), and statistical analysis of BRMS1 mRNA levels revealed that BRMS1 mRNA levels were significantly higher in early tumor stages (I, II) compared with advanced tumor stages (III, IV) in which lymph node or distant metastases were present (P < 0.01).
  • Our data showed that reduced BRMS1 mRNA seems to influence ovarian carcinoma metastatic ability.
  • Therefore, we transfected BRMS1 plasmid into highly malignant ovarian carcinoma cell line, HO-8910PM, and examined cell biologic behaviors including proliferation, adhesion, invasion, and metastasis in vitro and in vivo.
  • BRMS1 expression did not alter the proliferation of HO-8910PM cells in vitro and primary tumor formation in vivo.
  • Also, BRMS1 transfectants form significantly less metastatic to organs of peritoneal cavity in orthotopically implanted ovarian tumor nude models.
  • These data suggested that in addition to its already described role in breast cancer and melanoma, BRMS1 functions as a metastasis-suppressor gene in ovarian carcinoma by modifying several metastatic-associated phenotypes, offering a new target for therapeutic intervention.
  • [MeSH-major] Gene Expression Regulation / physiology. Neoplasm Proteins / physiology. Ovarian Neoplasms / prevention & control
  • [MeSH-minor] Animals. Cell Movement. Cell Proliferation. Disease Models, Animal. Down-Regulation. Female. Humans. Mice. Mice, Inbred BALB C. Mice, Nude. Neoplasm Invasiveness. Neoplasms, Glandular and Epithelial / metabolism. Neoplasms, Glandular and Epithelial / prevention & control. Neoplasms, Glandular and Epithelial / secondary. Peritoneal Neoplasms / prevention & control. Peritoneal Neoplasms / secondary. RNA, Messenger / metabolism. Repressor Proteins. Reverse Transcriptase Polymerase Chain Reaction. Transfection. Tumor Cells, Cultured. Tumor Stem Cell Assay

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16681721.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BRMS1 protein, human; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / Repressor Proteins
  •  go-up   go-down


61. Ylisaukko-oja SK, Cybulski C, Lehtonen R, Kiuru M, Matyjasik J, Szymañska A, Szymañska-Pasternak J, Dyrskjot L, Butzow R, Orntoft TF, Launonen V, Lubiñski J, Aaltonen LA: Germline fumarate hydratase mutations in patients with ovarian mucinous cystadenoma. Eur J Hum Genet; 2006 Jul;14(7):880-3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Germline fumarate hydratase mutations in patients with ovarian mucinous cystadenoma.
  • HLRCC is characterized by benign leiomyomas of the skin and the uterus, renal cell carcinoma, and uterine leiomyosarcoma.
  • The aim of this study was to identify new families with FH mutations, and to further examine the tumor spectrum associated with FH mutations.
  • FH germline mutations were screened from 89 patients with RCC, skin leiomyomas or ovarian tumors.
  • Subsequently, 13 ovarian and 48 bladder carcinomas were analyzed for somatic FH mutations.
  • Two patients diagnosed with ovarian mucinous cystadenoma (two out of 33, 6%) were found to be FH germline mutation carriers.
  • These results suggest that benign ovarian tumors may be associated with HLRCC.
  • [MeSH-major] Cystadenoma, Mucinous / genetics. Fumarate Hydratase / genetics. Germ-Line Mutation. Neoplastic Syndromes, Hereditary / genetics. Ovarian Neoplasms / genetics
  • [MeSH-minor] Carcinoma, Renal Cell / genetics. Cystadenocarcinoma, Mucinous / genetics. Female. Genes, Dominant. Humans. Kidney Neoplasms / genetics. Leiomyoma / genetics. Male. Neoplasms / genetics. Skin Neoplasms / genetics. Urinary Bladder Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16639410.001).
  • [ISSN] 1018-4813
  • [Journal-full-title] European journal of human genetics : EJHG
  • [ISO-abbreviation] Eur. J. Hum. Genet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 4.2.1.2 / Fumarate Hydratase
  •  go-up   go-down


62. Athanassiadou P, Grapsa D: Fine needle aspiration of borderline ovarian lesions. Is It useful? Acta Cytol; 2005 May-Jun;49(3):278-85
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine needle aspiration of borderline ovarian lesions. Is It useful?
  • Borderline ovarian tumors are a low grade form of epithelial ovarian carcinoma with a low rate of growth and a low potential to invade or metastasize.
  • According to the new World Health Organization classification, these tumors are placed between clearly benign and obviously malignant tumors because they exhibit some, but not all, of the morphologic features of malignancy.
  • The pathologic subtype ofperitoneal implants is probably one of the main prognosticfactors in patients with serous tumors of low malignant potential, while the prognostic value of micropapillary serous carcinoma in patients with noninvasive implants remains debatable.
  • Although fine needle aspiration (FNA) is the most accurate diagnostic method in cytopathology, its value in the diagnosis of borderline lesions is limited, mainly because of its inability to establish the absence of stromal invasion.
  • [MeSH-major] Biopsy, Fine-Needle. Neoplasms, Glandular and Epithelial / pathology. Ovarian Neoplasms / pathology. Ovary / pathology
  • [MeSH-minor] Female. Humans. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15966290.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Luo J, Peng ZL, Yang KX, Wang H, Yang H, Dong DD, Yao XY: [Relation between the expression of hypoxia inducible factor-1alpha and angiogenesis in ovarian cancer using tissue microarray]. Zhonghua Fu Chan Ke Za Zhi; 2005 Jan;40(1):38-41
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Relation between the expression of hypoxia inducible factor-1alpha and angiogenesis in ovarian cancer using tissue microarray].
  • OBJECTIVE: To study the relation between the expression of hypoxia inducible factor-1alpha (HIF-1alpha)and angiogenesis in ovarian cancer.
  • METHODS: The expressions of HIF-1alpha mRNA, vascular endothelial growth factor (VEGF), and CD(34) in 295 patients with epithelial ovarian tumors were analyzed by tissue microarray technology, in situ hybridization and immunohistochemistry, and compared with those of 13 normal ovarian tissue samples.
  • RESULTS: The expressions of HIF-1alpha mRNA were observed in 0, 13.2%, 42.1% and 81.9% of normal ovarian tissue, benign, borderline and malignant ovarian tumors respectively.
  • Expression rates of HIF-1alpha mRNA in borderline and invasive tumors were significantly higher than those in normal ovarian tissues and benign tumors (P < 0.01).
  • Close positive relation was observed between the expression of HIF-1alpha mRNA and tumor histological grade (r = 0.246, P < 0.01).
  • CONCLUSION: HIF-1alpha may play a role in angiogenesis of ovarian carcinoma, and may promote the development of the carcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Hypoxia-Inducible Factor 1, alpha Subunit / biosynthesis. Neovascularization, Pathologic. Ovarian Neoplasms / metabolism. Ovary / metabolism
  • [MeSH-minor] Adult. Aged. Epithelium / metabolism. Epithelium / pathology. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Oligonucleotide Array Sequence Analysis. RNA, Messenger / biosynthesis. Vascular Endothelial Growth Factor A / metabolism

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15774091.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / RNA, Messenger; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


64. Wang E, Ngalame Y, Panelli MC, Nguyen-Jackson H, Deavers M, Mueller P, Hu W, Savary CA, Kobayashi R, Freedman RS, Marincola FM: Peritoneal and subperitoneal stroma may facilitate regional spread of ovarian cancer. Clin Cancer Res; 2005 Jan 1;11(1):113-22
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peritoneal and subperitoneal stroma may facilitate regional spread of ovarian cancer.
  • PURPOSE: Epithelial ovarian cancer (EOC) is characterized by early peritoneal involvement ultimately contributing to morbidity and mortality.
  • To study the role of the peritoneum in fostering tumor invasion, we analyzed differences between the transcriptional repertoires of peritoneal tissue lacking detectable cancer in patients with EOC versus benign gynecologic disease.
  • EXPERIMENTAL DESIGN: Specimens were collected at laparotomy from patients with benign disease (b) or malignant (m) ovarian pathology and comprised primary ovarian tumors, paired bilateral specimens from adjacent peritoneum and attached stroma (PE), subjacent stroma (ST), peritoneal washes, ascites, and peripheral blood mononuclear cells.
  • RESULTS: Principal component analysis and unsupervised clustering did not segregate specimens from patients with benign or malignant pathology.
  • Class comparison identified differences between benign and malignant PE and ST specimens deemed significant by permutation test (P = 0.027 and 0.012, respectively).
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Ovarian Neoplasms / pathology. Stromal Cells / pathology
  • [MeSH-minor] Computational Biology. DNA, Complementary / metabolism. Extracellular Matrix / metabolism. Female. Humans. Neoplasm Invasiveness. Neoplasm Metastasis. Oligonucleotide Array Sequence Analysis. Ovary / pathology. Peritoneum / pathology. RNA / metabolism. Transcription, Genetic. Up-Regulation

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15671535.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Complementary; 63231-63-0 / RNA
  •  go-up   go-down


65. Pan Y, Jiao J, Zhou C, Cheng Q, Hu Y, Chen H: Nanog is highly expressed in ovarian serous cystadenocarcinoma and correlated with clinical stage and pathological grade. Pathobiology; 2010;77(6):283-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nanog is highly expressed in ovarian serous cystadenocarcinoma and correlated with clinical stage and pathological grade.
  • We investigated whether the Nanog expression is associated with the occurrence and development of ovarian cancer.
  • METHODS: Immunohistochemistry was used to examine the expression of Nanog in 43 normal ovarian epithelia, 110 serous cystadenomas, 80 borderline serous cystadenomas, and 107 serous cystadenocarcinomas.
  • RESULTS: The expression intensity of Nanog in normal ovarian tissue, benign, borderline, and malignant tumors showed a gradual rising trend.
  • CONCLUSIONS: Nanog was highly expressed in ovarian serous cystadenocarcinoma, and showed a positive correlation with clinical stage and grade.
  • Nanog may play an important role in the development of dedifferentiation and progression of serous ovarian carcinoma.
  • [MeSH-major] Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / pathology. Homeodomain Proteins / metabolism. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Cell Dedifferentiation. Cystadenoma, Serous / metabolism. Cystadenoma, Serous / pathology. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Ovary / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2011 S. Karger AG, Basel.
  • (PMID = 21266826.001).
  • [ISSN] 1423-0291
  • [Journal-full-title] Pathobiology : journal of immunopathology, molecular and cellular biology
  • [ISO-abbreviation] Pathobiology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / NANOG protein, human
  •  go-up   go-down


66. Ahmed N, Latifi A, Riley CB, Findlay JK, Quinn MA: Neuronal transcription factor Brn-3a(l) is over expressed in high-grade ovarian carcinomas and tumor cells from ascites of patients with advanced-stage ovarian cancer. J Ovarian Res; 2010;3:17

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuronal transcription factor Brn-3a(l) is over expressed in high-grade ovarian carcinomas and tumor cells from ascites of patients with advanced-stage ovarian cancer.
  • OBJECTIVES: In view of the recent association of Brn-3 transcription factors with neuroblastomas, cervical, breast, and prostate cancers we examined the expression of Brn-3a(l) in normal ovaries and in different histological grades of ovarian tumors.
  • The expression of Brn-3a(l) was also evaluated in normal ovarian and cancer cell lines and tumor cells isolated from the ascites of advanced-stage ovarian cancer patients.
  • METHODS: Normal ovaries, benign, borderline, grades 1, 2 and 3 ovarian tumors were analyzed by immunohistochemistry for Brn-3a(l) expression.
  • A total of 46 ovarian specimens were included in the study.
  • Immunofluorescence was used to investigate the expression of Brn-3a in normal ovarian and cancer cell lines.
  • Brn-3a(l) expression was also evaluated by Western blot in tumor cells isolated from ascites of advanced-stage ovarian cancer patients and also in ovarian cancer cell lines.
  • RESULTS: Nearly 12% of normal and benign ovarian tissues and 57% of borderline ovarian tumors were positive for epithelial Brn-3a(l) expression.
  • Stromal staining was higher and it constituted 40% of normal non-cancerous ovaries compared to 50 and 86% in benign and borderline tumors.
  • On the other hand, 85-100% of grades 1, 2 & 3 ovarian tumors demonstrated nuclear and cytoplasmic Brn-3a(l) staining in the epithelium.
  • Stromal staining in grades1, 2 and 3 tumors constituted 71-88% of total staining.
  • Overall, immunoreactive Brn-3a was present in all grades of ovarian tumors.
  • The extent of epithelial and stromal Brn-3a staining was significantly different between the normal and histological grades of tumors (epithelial-chi2 = 41.01, df = 20, P = 0.004, stromal-chi2 = 24.66. df = 15, P = 0.05).
  • The extent of epithelial staining was significantly higher in grades 1 and 2 ovarian tumors compared to normal ovaries and benign ovarian tumors (p < 0.05).
  • In parallel, stromal staining was significantly higher in grade 3 tumors compared to normal ovaries (p < 0.05).
  • In addition, cytoplasmic and nuclear Brn-3a expression was evident in ovarian cancer cell lines while no such expression was observed in SV40 antigen immortalized normal ovarian cell lines.
  • CONCLUSION: These data suggest that like other cancers, Brn-3a(l) expression is enhanced in ovarian tumors and its expression is consistent with its known role in inhibiting apoptosis and enhancing tumorigenesis.
  • Specific targeting of Brn-3a may provide a useful strategy for regulating multiple tumor related genes involved with ovarian carcinomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2010 Aug 1;28(22):3555-61 [20547991.001]
  • [Cites] J Biol Chem. 2010 May 14;285(20):15286-95 [20228055.001]
  • [Cites] Blood. 2010 Mar 18;115(11):2264-73 [19965679.001]
  • [Cites] Nat Rev Cancer. 2009 Jun;9(6):415-28 [19461667.001]
  • [Cites] Br J Cancer. 2009 Jan 13;100(1):134-44 [19088723.001]
  • [Cites] Clin Cancer Res. 2008 Dec 1;14(23):7645-51 [19047089.001]
  • [Cites] Clin Exp Metastasis. 2008;25(6):643-55 [18398687.001]
  • [Cites] Br J Cancer. 2008 Apr 22;98(8):1415-24 [18349831.001]
  • [Cites] Cancer Sci. 2008 Mar;99(3):543-52 [18201274.001]
  • [Cites] J Neurochem. 2008 Apr;105(2):425-35 [18086126.001]
  • [Cites] J Cell Physiol. 2007 Dec;213(3):581-8 [17708542.001]
  • [Cites] Endocr Relat Cancer. 2006 Jun;13(2):641-51 [16728589.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2006;9(1):83-91 [16276351.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3072-80 [15833836.001]
  • [Cites] Br J Cancer. 2005 Apr 25;92(8):1475-85 [15798771.001]
  • [Cites] J Biol Chem. 2005 Mar 25;280(12):11851-8 [15598651.001]
  • [Cites] Differentiation. 2004 Apr;72(4):150-61 [15157238.001]
  • [Cites] Cancer Biol Ther. 2002 Jul-Aug;1(4):428-32 [12432261.001]
  • [Cites] Nucleic Acids Res. 2002 Nov 15;30(22):4872-80 [12433990.001]
  • [Cites] J Biol Chem. 2004 May 14;279(20):21617-27 [14970234.001]
  • [Cites] Nucleic Acids Res. 1993 Dec 25;21(25):5921-9 [8290353.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Jan;82(1):89-94 [8989239.001]
  • [Cites] Genes Dev. 1997 May 15;11(10):1207-25 [9171367.001]
  • [Cites] Verh Dtsch Ges Pathol. 1997;81:62-72 [9474856.001]
  • [Cites] Dev Biol. 1998 May 15;197(2):155-69 [9630743.001]
  • [Cites] J Biol Chem. 1998 Jul 3;273(27):16715-22 [9642226.001]
  • [Cites] Int J Biochem Cell Biol. 1998 Nov;30(11):1153-7 [9839440.001]
  • [Cites] J Biol Chem. 1999 Oct 1;274(40):28521-7 [10497216.001]
  • [Cites] Oncogene. 1999 Nov 18;18(48):6684-91 [10597274.001]
  • [Cites] Int J Gynecol Pathol. 2000 Jan;19(1):7-15 [10638449.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Australas J Dermatol. 1997 Jun;38 Suppl 1:S91-8 [10994482.001]
  • [Cites] Oncogene. 2001 Aug 9;20(35):4899-903 [11521202.001]
  • [Cites] Nucleic Acids Res. 2001 Nov 15;29(22):4530-40 [11713302.001]
  • [Cites] Carcinogenesis. 2002 Feb;23(2):237-44 [11872628.001]
  • [Cites] Mol Biotechnol. 2002 Oct;22(2):123-7 [12405260.001]
  • [Cites] Biochim Biophys Acta. 2002 Dec 12;1579(2-3):207-13 [12427558.001]
  • (PMID = 20670407.001).
  • [ISSN] 1757-2215
  • [Journal-full-title] Journal of ovarian research
  • [ISO-abbreviation] J Ovarian Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2920243
  •  go-up   go-down


67. Chiesa AG, Deavers MT, Veras E, Silva EG, Gershenson D, Malpica A: Ovarian intestinal type mucinous borderline tumors: are we ready for a nomenclature change? Int J Gynecol Pathol; 2010 Mar;29(2):108-12
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian intestinal type mucinous borderline tumors: are we ready for a nomenclature change?
  • At a National Cancer Institute-sponsored workshop it was proposed that the borderline category of ovarian intestinal-type mucinous tumors (OInMTs) could be eliminated if the apparent benign behavior of these tumors could be confirmed.
  • Optimal sampling and adequate sampling were defined as at least 1 section per centimeter of maximum tumor dimension and at least 1 section per 2 cm of maximum tumor dimension, respectively.
  • Tumor size ranged from 8 to 39 cm (mean 20 cm).
  • The sampling of the ovarian tumor was optimal in 28 cases and adequate in 5 cases.
  • The tumor was incompletely removed and recurred in the pelvis 1 year later.
  • Ten months later, the tumor re-recurred in the pelvis and could only be drained because of the patient's advanced age and her poor medical status.
  • The second patient with recurrent tumor had undergone a cystectomy and full staging for a borderline OInMT.
  • Fourteen months later, she developed a recurrence in the residual ovary.
  • [MeSH-major] Adenocarcinoma, Mucinous / classification. Adenocarcinoma, Mucinous / pathology. Ovarian Neoplasms / classification. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Histocytochemistry. Humans. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Retrospective Studies. Terminology as Topic. Young Adult

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Gynecol Pathol. 2010 Nov;29(6):552-3; author reply 553-4 [20881857.001]
  • (PMID = 20173495.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Kim JY, Lee YC, Kim C: Direct inhibition of Pumilo activity by Bam and Bgcn in Drosophila germ line stem cell differentiation. J Biol Chem; 2010 Feb 12;285(7):4741-6
SciCrunch. The Antibody Registry: Reagent: Antibodies .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The RNA-binding translational repressor Pumilio (Pum) in conjunction with Nanos (Nos) is required for self-renewal, whereas Bam (bag-of-marbles) and Bgcn (benign gonial cell neoplasm) promote differentiation of germ line stem cells in the Drosophila ovary.
  • Notably, the N-terminal region of Pum, which lacks the C-terminal RNA-binding Puf domain, mediates both the ternary protein interaction and the Bam inhibition of Pum function.

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • FlyBase. FlyBase .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Dev. 1999 Oct 15;13(20):2704-12 [10541556.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Jul 14;106(28):11623-8 [19556547.001]
  • [Cites] Development. 2000 Dec;127(23):5225-32 [11060247.001]
  • [Cites] Science. 2002 Jun 7;296(5574):1855-7 [12052957.001]
  • [Cites] Nat Rev Genet. 2002 Dec;3(12):931-40 [12459723.001]
  • [Cites] Curr Biol. 2003 Oct 14;13(20):1786-91 [14561403.001]
  • [Cites] Development. 2003 Dec;130(26):6625-34 [14660550.001]
  • [Cites] Development. 2004 Mar;131(6):1353-64 [14973291.001]
  • [Cites] Science. 2004 Mar 26;303(5666):2016-9 [14976263.001]
  • [Cites] Curr Biol. 2004 Jun 8;14(11):981-6 [15182671.001]
  • [Cites] J Bacteriol. 1983 Jan;153(1):163-8 [6336730.001]
  • [Cites] Anal Biochem. 1988 Jun;171(2):404-8 [3407940.001]
  • [Cites] Genetics. 1989 May;122(1):19-27 [2659436.001]
  • [Cites] Genes Dev. 1990 Dec;4(12B):2242-51 [2279698.001]
  • [Cites] Cell. 1991 Nov 29;67(5):955-67 [1720354.001]
  • [Cites] Development. 1992 Jan;114(1):221-32 [1576962.001]
  • [Cites] Cell. 1993 Nov 19;75(4):791-803 [8242750.001]
  • [Cites] Dev Dyn. 1994 Feb;199(2):103-15 [7515724.001]
  • [Cites] Cell. 1995 Mar 10;80(5):747-56 [7889568.001]
  • [Cites] Development. 1995 Sep;121(9):2937-47 [7555720.001]
  • [Cites] Development. 1997 Jun;124(12):2463-76 [9199372.001]
  • [Cites] Development. 1997 Sep;124(18):3651-62 [9342057.001]
  • [Cites] RNA. 1997 Dec;3(12):1421-33 [9404893.001]
  • [Cites] Development. 1998 Feb;125(4):679-90 [9435288.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 1997;62:25-34 [9598333.001]
  • [Cites] Mol Cell. 1998 May;1(6):863-72 [9660969.001]
  • [Cites] Cell. 1998 Jul 24;94(2):251-60 [9695953.001]
  • [Cites] Dev Biol. 1999 Aug 15;212(2):405-13 [10433830.001]
  • [Cites] Genetics. 1999 Sep;153(1):235-50 [10471709.001]
  • [Cites] J Biol Chem. 1999 Oct 1;274(40):28491-6 [10497212.001]
  • [Cites] Curr Biol. 2005 Jan 26;15(2):171-8 [15668175.001]
  • [Cites] Curr Biol. 2005 Jan 26;15(2):179-84 [15668176.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Jun;7(6):449-56 [16625152.001]
  • [Cites] Cell Res. 2007 Jan;17(1):15-25 [17199109.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):1925-30 [18272501.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Jun 9;106(23):9304-9 [19470484.001]
  • [Cites] Genetics. 2000 Aug;155(4):1809-19 [10924476.001]
  • (PMID = 20018853.001).
  • [ISSN] 1083-351X
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Drosophila Proteins; 0 / RNA-Binding Proteins; 0 / bam protein, Drosophila; 0 / pumilio protein, Drosophila; EC 3.6.4.- / DNA Helicases; EC 3.6.4.13 / bgcn protein, Drosophila
  • [Other-IDs] NLM/ PMC2836079
  •  go-up   go-down


69. Wang Y, Yang J, Gao Y, Zhao XL, Li HZ, Yao Z: [Relationship between raf kinase inhibitor protein and metastasis of ovarian carcinoma]. Zhonghua Fu Chan Ke Za Zhi; 2009 Jul;44(7):522-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Relationship between raf kinase inhibitor protein and metastasis of ovarian carcinoma].
  • OBJECTIVE: To investigate the relationship between raf kinase inhibitor protein (RKIP), a novel metastasis suppressor gene, and metastasis of ovarian carcinoma.
  • METHODS: Immunohistochemistry, RT-PCR, and western blot analysis were performed to examine the expression of RKIP in clinical samples of ovarian tumors and five human ovarian carcinoma cell lines.
  • Stable cell lines over-expressed or deleted of RKIP were cloned to investigate the function of RKIP in ovarian cancer cells.
  • The recombinant plasmids expressing sense (ss) or antisense (as) RKIP cDNA or empty vector was transfected into ovarian cancer cell line SKOV3 by lipofectamine.
  • The expression level of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK) and extracellular signal-regulated kinase (ERK) in ovarian cancer cells were detected by western blot analysis.
  • (1) The expression levels of RKIP protein in ovarian carcinoma tissues from patients were found to be reduced than those in ovarian benign tumor and borderline tumor.
  • SKOV3 clones stably expressing full-length recombinant ssRKIP, asRKIP, and their respective empty vector were obtained. (2) RKIP was able to block basal levels of MEK and ERK in ovarian cancer cells.
  • CONCLUSION: RKIP could inhibits the metastasis, but also the growth of ovarian cancer cells. patients were found to be reduced than those in ovarian benign tumor and borderline tumor.
  • SKOV3 clones stably expressing full-length recombinant ssRKIP, asRKIP, and their respective empty vector were obtained. (2) RKIP was able to block basal levels of MEK and ERK in ovarian cancer cells.
  • CONCLUSION: RKIP could inhibits the metastasis, but also the growth of ovarian cancer cells.
  • [MeSH-major] Extracellular Signal-Regulated MAP Kinases / metabolism. Mitogen-Activated Protein Kinase Kinases / metabolism. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology. Phosphatidylethanolamine Binding Protein / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Cell Line, Tumor. Cell Proliferation. Female. Genes, Tumor Suppressor. Genetic Vectors. Humans. Immunohistochemistry. Middle Aged. Neoplasm Invasiveness. Neoplasm Metastasis. Phosphorylation. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Transfection. Young Adult

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19957553.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Phosphatidylethanolamine Binding Protein; 0 / RNA, Messenger; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 2.7.12.2 / Mitogen-Activated Protein Kinase Kinases
  •  go-up   go-down


70. Abbott KL, Lim JM, Wells L, Benigno BB, McDonald JF, Pierce M: Identification of candidate biomarkers with cancer-specific glycosylation in the tissue and serum of endometrioid ovarian cancer patients by glycoproteomic analysis. Proteomics; 2010 Feb;10(3):470-81
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of candidate biomarkers with cancer-specific glycosylation in the tissue and serum of endometrioid ovarian cancer patients by glycoproteomic analysis.
  • Epithelial ovarian cancer is diagnosed less than 25% of the time when the cancer is confined to the ovary, leading to 5-year survival rates of less than 30%.
  • Therefore, there is an urgent need for early diagnostics for ovarian cancer.
  • Our study using glycotranscriptome comparative analysis of endometrioid ovarian cancer tissue and normal ovarian tissue led to the identification of distinct differences in the transcripts of a restricted set of glycosyltransferases involved in N-linked glycosylation.
  • In this study, we have extended our observations by the use of selected lectins to perform a targeted glycoproteomic analysis of ovarian cancer and normal ovarian tissues.
  • Our results have identified several glycoproteins that display tumor-specific glycosylation changes.
  • The glycoproteins that were verified were then analyzed further using existing microarray data obtained from benign ovarian adenomas, borderline ovarian adenocarcinomas, and malignant ovarian adenocarcinomas.
  • The verified glycoproteins found to be expressed above control levels in the microarray data sets were then screened for tumor-specific glycan modifications in serum from ovarian cancer patients.
  • Results obtained from two of these glycoprotein markers, periostin and thrombospondin, have confirmed that tumor-specific glycan changes can be used to distinguish ovarian cancer patient serum from normal serum.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 2000 May;156(5):1549-56 [10793066.001]
  • [Cites] Environ Health Perspect. 2009 Jul;117(7):1116-23 [19654922.001]
  • [Cites] J Immunol. 2000 Oct 1;165(7):3898-906 [11034397.001]
  • [Cites] Biochim Biophys Acta. 2000 Oct 18;1482(1-2):298-307 [11058770.001]
  • [Cites] Annu Rev Physiol. 2001;63:521-54 [11181966.001]
  • [Cites] J Immunol. 2001 May 1;166(9):5792-800 [11313423.001]
  • [Cites] J Biol Chem. 2001 May 18;276(20):17507-14 [11278670.001]
  • [Cites] Immunol Rev. 2001 Apr;180:5-15 [11414363.001]
  • [Cites] Mol Immunol. 2001 Aug;38(2-3):175-87 [11532279.001]
  • [Cites] J Immunol. 2001 Oct 15;167(8):4141-5 [11591733.001]
  • [Cites] J Immunol. 2002 Mar 1;168(5):2560-7 [11859152.001]
  • [Cites] Inhal Toxicol. 2002 May;14(5):459-86 [12028803.001]
  • [Cites] J Biol Chem. 2002 Nov 8;277(45):42821-9 [12215441.001]
  • [Cites] Nucleic Acids Res. 2003 Oct 15;31(20):e122 [14530455.001]
  • [Cites] Inhal Toxicol. 2003 Nov;15(13):1309-25 [14569495.001]
  • [Cites] J Allergy Clin Immunol. 2003 Nov;112(5):905-14 [14610479.001]
  • [Cites] J Biol Chem. 2003 Dec 12;278(50):50781-90 [14522998.001]
  • [Cites] Clin Immunol. 2003 Dec;109(3):250-65 [14697739.001]
  • [Cites] Lancet. 2004 Jan 10;363(9403):119-25 [14726165.001]
  • [Cites] Science. 2004 Jun 11;304(5677):1678-82 [15192232.001]
  • [Cites] Physiol Genomics. 2004 Aug 11;18(3):261-72 [15173550.001]
  • [Cites] J Proteome Res. 2009 Apr;8(4):1631-8 [19714806.001]
  • [Cites] J Immunol. 2000 Jul 1;165(1):108-13 [10861042.001]
  • [Cites] Ann Surg. 1978 Dec;188(6):809-16 [736659.001]
  • [Cites] FEBS Lett. 1992 Dec 21;314(3):386-8 [1281792.001]
  • [Cites] J Immunol. 1996 Jun 15;156(12):4807-14 [8648128.001]
  • [Cites] J Immunol. 1997 Mar 1;158(5):2406-13 [9036991.001]
  • [Cites] J Exp Med. 1998 May 4;187(9):1537-42 [9565645.001]
  • [Cites] Genomics. 1998 Dec 1;54(2):316-22 [9828134.001]
  • [Cites] Methods Mol Biol. 1999;112:99-103 [10027233.001]
  • [Cites] J Allergy Clin Immunol. 2004 Nov;114(5):1116-23 [15536419.001]
  • [Cites] Electrophoresis. 2005 Jan;26(1):280-92 [15624150.001]
  • [Cites] Science. 2005 May 6;308(5723):804-6 [15879201.001]
  • [Cites] Electrophoresis. 2005 Jun;26(11):2092-108 [15880549.001]
  • [Cites] Immunol Rev. 2005 Aug;206:32-63 [16048541.001]
  • [Cites] Immunol Rev. 2005 Aug;206:83-99 [16048543.001]
  • [Cites] J Allergy Clin Immunol. 2006 Aug;118(2):455-65 [16890772.001]
  • [Cites] Clin Immunol. 2006 Nov;121(2):227-35 [16979384.001]
  • [Cites] J Radiat Res. 2007 Jan;48(1):39-44 [17229997.001]
  • [Cites] Inhal Toxicol. 2007;19 Suppl 1:117-26 [17886059.001]
  • [Cites] Proteomics. 2007 Nov;7(21):3906-18 [17922515.001]
  • [Cites] Am J Respir Cell Mol Biol. 2007 Dec;37(6):706-19 [17630318.001]
  • [Cites] Arch Med Res. 2008 Aug;39(6):560-6 [18662586.001]
  • [Cites] J Hum Genet. 2008;53(8):728-38 [18566738.001]
  • [Cites] Clin Exp Allergy. 2008 Dec;38(12):1901-10 [19037965.001]
  • [Cites] Clin Immunol. 2009 Feb;130(2):186-98 [18955015.001]
  • [Cites] Yonsei Med J. 2009 Feb 28;50(1):22-30 [19259344.001]
  • [Cites] Annu Rev Physiol. 2009;71:489-507 [19575684.001]
  • [Cites] Hum Gene Ther. 2009 Dec;20(12):1597-606 [19548841.001]
  • (PMID = 19953551.001).
  • [ISSN] 1615-9861
  • [Journal-full-title] Proteomics
  • [ISO-abbreviation] Proteomics
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / P41RR018502; United States / NCI NIH HHS / CA / R01 CA064462; United States / NCRR NIH HHS / RR / P41 RR018502; United States / NCI NIH HHS / CA / U01 CA128454; United States / NCI NIH HHS / CA / UO1CA128454; United States / NCI NIH HHS / CA / R01CA064462
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glycoproteins; 0 / Neoplasm Proteins; 0 / Proteome
  • [Other-IDs] NLM/ NIHMS793820; NLM/ PMC4932840
  •  go-up   go-down


71. Thomas CM, Boss EA, Boonstra H, van Tienoven D, Sweep CG, Massuger LF: Gonadotropins and female sex steroid hormones in cyst fluid and serum from patients with ovarian tumors. Eur J Gynaecol Oncol; 2008;29(5):468-72
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gonadotropins and female sex steroid hormones in cyst fluid and serum from patients with ovarian tumors.
  • The objective of the present study was to determine the concentrations of LH, FSH, 17beta-estradiol and progesterone in ovarian cyst fluid and serum from patients with benign and malignant ovarian tumors and to assess the correlation of the gonadotropin and female sex steroid hormone concentrations with menopausal and tumor status.
  • Ovarian cyst fluid and blood samples were prospectively collected from 103 patients with ovarian tumors.
  • Seventy-four of the patients had benign ovarian tumors while 29 patients had malignant ovarian tumors.
  • Malignant ovarian tumors showed significantly higher LH and FSH cyst fluid concentrations compared to concentrations from patients with benign tumors.
  • Furthermore, LH and FSH cyst fluid concentrations showed strong correlations (r > 0.62) with serum concentrations in case of malignant tumors, especially in postmenopausal women, but not in case of benign tumors.
  • The highest gonadotropin concentrations were observed in cyst fluid from malignant ovarian tumors.
  • Supportive evidence for such an increased vascular permeability is our previous finding of significantly higher VEGF concentrations in cyst fluid from malignant ovarian tumors.
  • The possibility of ectopic production of LH and FSH by malignant ovarian tissue cannot completely be ruled out.
  • [MeSH-major] Cyst Fluid / chemistry. Gonadal Steroid Hormones / analysis. Gonadotropins / analysis. Ovarian Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. PROGESTERONE .
  • Hazardous Substances Data Bank. MENOTROPINS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19051814.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Gonadal Steroid Hormones; 0 / Gonadotropins; 4G7DS2Q64Y / Progesterone; 4TI98Z838E / Estradiol; 9002-67-9 / Luteinizing Hormone; 9002-68-0 / Follicle Stimulating Hormone
  •  go-up   go-down


72. Han XY, Chen Y, Hou MM, Zhang J, Yang KX, Chen YY, Qie MR: [Expression of AIB1 protein in epithelial ovarian cancer cells and its impact on apoptosis]. Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Jul;39(4):619-22, 634
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of AIB1 protein in epithelial ovarian cancer cells and its impact on apoptosis].
  • OBJECTIVE: To investigate the expression of AIB1 (amplified in breast cancer 1) protein in epithelial ovarian cancer cells and to analyze the relationship between AIB1 protein and the apoptosis modulated proteins: P53 and Bcl-2.
  • METHODS: The expressions of AIB1, P53 and Bcl-2 proteins in 24 normal ovaries, 24 benign ovarian tumors, 18 borderline ovarian tumors and 69 epithelial ovarian cancers were examined with immunohistochemical method SP.
  • 1) The AIB1 protein expressed in 65.22% ovarian cancers, greater than in normal ovaries (8.33%), benign ovarian tumors (25.00%) and borderline ovarian tumors (38.89%).
  • The overexpression of AIB1 protein occurred in 36.23% ovarian cancers.
  • Ovarian cancers poorly-differentiated, at a late clinical stage and with lymph node involvement had higher AIB1 overexpression than those well-differentiated and moderately-differentiated, and those at an early clinical stage and without lymph node involvement.
  • 2) The expression of AIB1 was positively correlated with the expression of P53 (r = 0.342, P = 0.004) and Bcl-2 proteins (r = 0.311, P = 0.009) in the ovarian cancers.
  • CONCLUSION: AIB1 protein expression increases in ovarian cancers, which is associated with the higher malignant biological behavior.
  • The overexpression of AIB1 may be involved in the carcinogenesis and the development of epithelial ovarian cancers through a hormone independent pathway.
  • [MeSH-major] Apoptosis. Cystadenocarcinoma, Serous / pathology. Ovarian Neoplasms / pathology. Transcription Factors / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Immunohistochemistry. Middle Aged. Nuclear Receptor Coactivator 3. Proto-Oncogene Proteins c-bcl-2 / biosynthesis. Tumor Cells, Cultured. Tumor Suppressor Protein p53 / biosynthesis. Young Adult

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18798508.001).
  • [ISSN] 1672-173X
  • [Journal-full-title] Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
  • [ISO-abbreviation] Sichuan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Transcription Factors; 0 / Tumor Suppressor Protein p53; EC 2.3.1.48 / Nuclear Receptor Coactivator 3
  •  go-up   go-down


73. Mithieux F, Coriat R, De La Fouchardière C, Méeus P, Rivoire M: [Pseudo-Meigs syndrome: particular management of ovarian metastases in colorectal cancer]. Gastroenterol Clin Biol; 2008 Mar;32(3):261-4
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pseudo-Meigs syndrome: particular management of ovarian metastases in colorectal cancer].
  • [Transliterated title] Le pseudosyndrome de Meigs, particularité dans la prise en charge des métastases ovariennes de cancer colorectal.
  • Ascites and/or pleural effusion with ovarian metastases in colorectal cancer are usually related to peritoneal carcinomatosis.
  • Pseudo-Meigs syndrome is a characterized by non-malignant ascites and/or pleural effusion caused by pelvic tumors other than solid benign ovarian tumors.
  • After ovarian metastasis resection, ascites and pleural diffusion disappeared.
  • In the presence of acellular ascites with ovarian metastases from colorectal cancer, diagnosis of pseudo-Meigs syndrome may allow surgical treatment with curative intent.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / secondary. Colorectal Neoplasms / pathology. Meigs Syndrome / therapy. Ovarian Neoplasms / secondary

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18353585.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


74. Okamoto Y, Tanaka YO, Tsunoda H, Yoshikawa H, Minami M: Malignant or borderline mucinous cystic neoplasms have a larger number of loculi than mucinous cystadenoma: a retrospective study with MR. J Magn Reson Imaging; 2007 Jul;26(1):94-9
Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant or borderline mucinous cystic neoplasms have a larger number of loculi than mucinous cystadenoma: a retrospective study with MR.
  • PURPOSE: To determine whether there is any correlation between the number of loculi and the pathological grade of malignancy in mucinous cystic tumors of the ovary.
  • MATERIALS AND METHODS: We retrospectively studied MR images of 67 pathologically proven mucinous cystic tumors of the ovaries.
  • The mean maximum diameter of tumors was 13.0 cm in cystadenoma and 18.7 cm in malignant lesions.
  • The differences between the benign and malignant lesions were statistically significant in number (P = 0.001), maximum diameter (P = 0.011), and ratio (P = 0.002).
  • CONCLUSION: Ovarian mucinous neoplasm of borderline malignancy and mucinous adenocarcinomas had a larger number of loculi than adenomas.
  • [MeSH-major] Cystadenoma, Mucinous / pathology. Magnetic Resonance Imaging / methods. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Contrast Media. Female. Gadolinium DTPA. Humans. Middle Aged. Neoplasm Staging. Retrospective Studies

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 Wiley-Liss, Inc.
  • (PMID = 17659568.001).
  • [ISSN] 1053-1807
  • [Journal-full-title] Journal of magnetic resonance imaging : JMRI
  • [ISO-abbreviation] J Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


75. Knüsel PR, Kubik-Huch RA, Komminoth R, Siragusa A, Otto RCh: [Ovarian fibrothecoma: MR imaging findings and differential diagnosis]. Praxis (Bern 1994); 2006 Feb 22;95(8):283-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ovarian fibrothecoma: MR imaging findings and differential diagnosis].
  • [Transliterated title] Fibrothekom des Ovars: MR-bildgebung und Differentialdiagnose.
  • We report the preoperative MR imaging of a 70 year old woman with a large tumor of the lower abdomen.
  • The origin of this tumor was suspected to be either the left ovary or the uterus.
  • In the differential diagnosis a large subserous pedunculated leiomyoma or a low cellular, primarily benign ovarian tumor were considered.
  • [MeSH-major] Fibroma / diagnosis. Magnetic Resonance Imaging. Ovarian Neoplasms / diagnosis. Thecoma / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Hysterectomy. Leiomyoma / diagnosis. Neoplasms, Multiple Primary / diagnosis. Ovariectomy. Ovary / pathology. Uterine Neoplasms / diagnosis. Uterus / pathology

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16523993.001).
  • [ISSN] 1661-8157
  • [Journal-full-title] Praxis
  • [ISO-abbreviation] Praxis (Bern 1994)
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


76. Poncelet C, Fauvet R, Boccara J, Daraï E: Recurrence after cystectomy for borderline ovarian tumors: results of a French multicenter study. Ann Surg Oncol; 2006 Apr;13(4):565-71
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence after cystectomy for borderline ovarian tumors: results of a French multicenter study.
  • BACKGROUND: Fertility-sparing surgery for borderline ovarian tumors (BOT) is feasible and effective and does not seem to have a negative effect on survival.
  • Diagnosis and staging were based on International Federation of Gynecology and Obstetrics (1989) criteria.
  • RESULTS: After cystectomy, persistent BOT and benign ovarian cysts on the operated ovary were observed in 15% and 65% of patients, respectively.
  • [MeSH-major] Cystectomy. Intraoperative Complications. Neoplasm Recurrence, Local. Neoplasm Staging. Ovarian Neoplasms / surgery. Rupture, Spontaneous / surgery
  • [MeSH-minor] Adult. Disease-Free Survival. Female. France. Humans. Middle Aged. Ovarian Cysts. Ovariectomy. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16491337.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


77. Waalkes MP, Liu J, Ward JM, Powell DA, Diwan BA: Urogenital carcinogenesis in female CD1 mice induced by in utero arsenic exposure is exacerbated by postnatal diethylstilbestrol treatment. Cancer Res; 2006 Feb 1;66(3):1337-45
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Arsenic alone induced some urogenital system tumors, including mostly benign tumors of the ovary and uterus, and adrenal adenoma.
  • Diethylstilbestrol alone induced some tumors (primarily cervical) but when given after in utero arsenic, it greatly enhanced urogenital tumor incidence, multiplicity, and progression.
  • For instance, compared with the incidence of urogenital malignancies in the control (0%), arsenic alone (9%), and diethylstilbestrol alone (21%) groups, arsenic plus diethylstilbestrol acted synergistically, inducing a 48% incidence of malignant urogenital tumors.
  • Of the urogenital tumors induced by arsenic plus diethylstilbestrol, 80% were malignant, and 55% were multiple site.
  • Arsenic plus diethylstilbestrol increased ovarian, uterine, and vaginal tumors, and urinary bladder proliferative lesions, including three transitional cell carcinomas.
  • Tamoxifen alone did not increase urogenital tumors or affect arsenic-induced neoplasia but did increase arsenic-induced uroepithelial proliferative lesions.
  • [MeSH-major] Arsenic / toxicity. Diethylstilbestrol / toxicity. Genital Neoplasms, Female / chemically induced. Kidney Neoplasms / chemically induced. Prenatal Exposure Delayed Effects. Urinary Bladder Neoplasms / chemically induced

  • MedlinePlus Health Information. consumer health - Arsenic.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. DIETHYLSTILBESTROL .
  • Hazardous Substances Data Bank. ARSENIC, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16452187.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CO / N01 CO 12400; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogen Receptor alpha; 094ZI81Y45 / Tamoxifen; 731DCA35BT / Diethylstilbestrol; N712M78A8G / Arsenic
  •  go-up   go-down


78. Chang W, Oiseth SJ, Orentlicher R, Agarwal G, Yahr LJ, Cayten CG: Bilateral sclerosing stromal tumor of the ovaries in a premenarchal girl. Gynecol Oncol; 2006 May;101(2):342-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral sclerosing stromal tumor of the ovaries in a premenarchal girl.
  • BACKGROUND: Sclerosing stromal tumor of the ovary is a rare benign neoplasm that is usually unilateral in menstruating women with a mean age of 27.
  • CASE: An 11-year-old girl presented with asymptomatic bilateral sclerosing stromal tumor of the ovaries prior to menarche.
  • CONCLUSION: We herein report a unique case of bilateral sclerosing stromal tumor of the ovaries arising in a premenarchal girl.
  • [MeSH-major] Ovarian Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16403568.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Mukonoweshuro P, Oriowolo A: Stromal osseous metaplasia in a low-grade ovarian adenocarcinoma. Gynecol Oncol; 2005 Oct;99(1):222-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stromal osseous metaplasia in a low-grade ovarian adenocarcinoma.
  • BACKGROUND: Stromal osseous metaplasia is a rare and curious finding in tumors of the ovary.
  • CASE REPORT: The patient, a 66-year-old P3 G3 white female, had a past history of stage 1c left ovarian, well-differentiated endometrioid adenocarcinoma removed in 1981.
  • The tumor recurred 21 years later with prominent stromal osseous metaplasia that had not been present in the primary.
  • DISCUSSION: The pathogenesis of osseous metaplasia in epithelial tumors of the ovary is unclear; however, it is probable that a metaplastic process involving multipotential stromal stem cells results in bone formation.
  • CONCLUSION: Benign osseous metaplasia in ovarian tumors is rare and its histogenesis remains unclear.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Neoplasm Recurrence, Local / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16023183.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Byrne JA, Balleine RL, Schoenberg Fejzo M, Mercieca J, Chiew YE, Livnat Y, St Heaps L, Peters GB, Byth K, Karlan BY, Slamon DJ, Harnett P, Defazio A: Tumor protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancer. Int J Cancer; 2005 Dec 20;117(6):1049-54
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancer.
  • Recurrent chromosome 8q gain in ovarian carcinoma is likely to reflect the existence of multiple target loci, as the separate gain of chromosome bands 8q21 and 8q24 has been reported in independent studies.
  • Since tumor protein D52 (TPD52) has been identified as a chromosome 8q21 amplification target in breast and prostate carcinoma, we compared TPD52 expression in normal ovarian epithelium (n = 9), benign serous adenomas (n = 11), serous borderline tumors (n = 6) and invasive carcinomas of the major histologic subtypes (n = 57) using immunohistochemistry.
  • These analyses revealed that all normal ovarian epithelium samples and benign serous tumors were predominantly TPD52-negative, whereas TPD52 was overexpressed in most (44/57; 77%) ovarian carcinomas regardless of histologic subtype.
  • TPD52 therefore represents a novel molecular marker in ovarian cancer, which is broadly expressed across the different histologic subtypes and whose upregulation frequently reflects increased TPD52 copy number.
  • [MeSH-major] Gene Amplification / genetics. Gene Expression. Neoplasm Proteins / genetics. Ovarian Neoplasms / genetics
  • [MeSH-minor] Biomarkers, Tumor / analysis. CA-125 Antigen / blood. Chromosomes, Human, Pair 8. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Middle Aged. Ovary / chemistry

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc
  • (PMID = 15986428.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / Neoplasm Proteins; 0 / TPD52 protein, human
  •  go-up   go-down


81. Huddleston HG, Wong KK, Welch WR, Berkowitz RS, Mok SC: Clinical applications of microarray technology: creatine kinase B is an up-regulated gene in epithelial ovarian cancer and shows promise as a serum marker. Gynecol Oncol; 2005 Jan;96(1):77-83
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical applications of microarray technology: creatine kinase B is an up-regulated gene in epithelial ovarian cancer and shows promise as a serum marker.
  • OBJECTIVE:. (1) To identify and (2) validate genes that are up-regulated in ovarian cancer, and (3) to investigate whether the activity of a candidate gene, creatine kinase B (CKB) is elevated in pre-operative sera from ovarian cancer patients compared to patients with benign pelvic masses and normal controls.
  • METHODS: MICROMAX cDNA microarray system and RNA derived from pooled ovarian cancer cell lines and normal ovary surface epithelial cells (HOSE) were used to identify differentially expressed genes.
  • Using a commercially available enzyme assay, CKB activity was measured in pre-operative serum samples obtained from 45 ovarian cancer patients, 49 patients with a benign pelvic mass, as well as 37 normal controls.
  • RNA levels of CKB, measured by real-time PCR, were elevated a mean (and standard error) of 36-fold (8.4) in cancer cell lines compared with HOSE cells and 22.75-fold (10.45) in microdissected ovarian cancer epithelial cells compared with normal ovarian epithelial cells.
  • In serum, the mean (+/-standard error) of CKB enzyme activity in cancer cases was 24.7 U/L units (+/- 5.1) compared to 9.6 U/L (+/- 1.6) for benign mass cases (P = 0.0088) and to 8.5 U/L (1.7) for normal controls (P = 0.0096).
  • CONCLUSIONS: Microarray technology offers a method to identify tumor biomarkers with potential clinical usefulness.
  • Our data indicated that CKB gene expression is up-regulated in ovarian cancer cells in vitro and in vivo and that CKB enzyme activity is significantly elevated in sera from ovarian cancer patients, including those with stage I disease.
  • These findings suggest a potential role for CKB as a marker for early diagnosis.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Creatine Kinase / biosynthesis. Isoenzymes / biosynthesis. Oligonucleotide Array Sequence Analysis / methods. Ovarian Neoplasms / enzymology
  • [MeSH-minor] Adult. Creatine Kinase, BB Form. Female. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. Humans. Middle Aged. RNA, Neoplasm / biosynthesis. RNA, Neoplasm / genetics. Reverse Transcriptase Polymerase Chain Reaction. Up-Regulation

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15589584.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA86381; United States / NCI NIH HHS / CA / P50CA165009; United States / NCI NIH HHS / CA / R33CA103595
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Isoenzymes; 0 / RNA, Neoplasm; EC 2.7.3.2 / Creatine Kinase; EC 2.7.3.2 / Creatine Kinase, BB Form
  •  go-up   go-down


82. Winter LM, Sommer G, Bongartz G: High-field magnetic resonance imaging of the pelvis: uterus, ovary, and prostate gland. Top Magn Reson Imaging; 2010 Jun;21(3):177-88
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-field magnetic resonance imaging of the pelvis: uterus, ovary, and prostate gland.
  • It has given proof of its usefulness in the diagnosis of several benign and malignant disorders, and it is routinely used for the local staging of different tumors even when confined to specific parts of a pelvic organ.
  • Definition of high field seems fuzzy because of the availability of MRI machines with 3, 7 T, or higher; therefore, the general aspects of MRI of pelvic structures with emphasis on uterus, ovary, and prostate gland and attention to promising newer techniques such as 3 T, dynamic contrast imaging, and diffusion-weighted imaging are reviewed in this article.
  • [MeSH-major] Imaging, Three-Dimensional / methods. Magnetic Resonance Imaging / methods. Pelvic Neoplasms / diagnosis. Radiographic Image Enhancement
  • [MeSH-minor] Diffusion Magnetic Resonance Imaging / methods. Diffusion Magnetic Resonance Imaging / trends. Female. Forecasting. Humans. Male. Neoplasm Invasiveness / pathology. Neoplasm Staging. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / pathology. Prostatic Neoplasms / diagnosis. Prostatic Neoplasms / pathology. Radiation Effects. Risk Assessment. Sensitivity and Specificity. Signal-To-Noise Ratio. Uterine Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21847037.001).
  • [ISSN] 1536-1004
  • [Journal-full-title] Topics in magnetic resonance imaging : TMRI
  • [ISO-abbreviation] Top Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


83. He Y, Yang KX, Jiang W, Wang DQ, Li L: Sclerosing stromal tumor of the ovary in a 4-year-old girl with characteristics of an ovarian signet-ring stromal tumor. Pathol Res Pract; 2010 May 15;206(5):338-41
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sclerosing stromal tumor of the ovary in a 4-year-old girl with characteristics of an ovarian signet-ring stromal tumor.
  • Ovarian sclerosing stromal tumor (OSST) is an extremely rare neoplasm that primarily affects young women.
  • Signet-ring stromal tumor is another rare non-functioning benign ovarian stromal neoplasm.
  • We report a case of a right OSST with prominent characteristics of signet-ring stromal tumor in a 4-year-old girl with symptoms of premature thelarche.
  • The presence of non-mucin/non-lipid obvious signet-ring-like cells in this case suggests a possible relationship between OSST and signet-ring stromal tumor of the ovary.
  • [MeSH-major] Carcinoma, Signet Ring Cell / pathology. Ovarian Neoplasms / pathology. Sex Cord-Gonadal Stromal Tumors / pathology. Stromal Cells / pathology
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Child, Preschool. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Sclerosis / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009. Published by Elsevier GmbH. All rights reserved.
  • (PMID = 19604650.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


84. Cuatrecasas M, Catasus L, Palacios J, Prat J: Transitional cell tumors of the ovary: a comparative clinicopathologic, immunohistochemical, and molecular genetic analysis of Brenner tumors and transitional cell carcinomas. Am J Surg Pathol; 2009 Apr;33(4):556-67
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transitional cell tumors of the ovary: a comparative clinicopathologic, immunohistochemical, and molecular genetic analysis of Brenner tumors and transitional cell carcinomas.
  • Transitional cell tumors of the ovary include 2 distinct clinicopathologic categories: Brenner tumors and transitional cell carcinomas (TCCs).
  • We have performed a clinicopathologic, immunohistochemical, and molecular genetic analysis of 19 transitional cell tumors including 13 Brenner tumors (5 benign, 7 borderline, and 1 malignant) and 6 TCCs.
  • Six borderline Brenner tumors were stage IA and 1 stage IIA.
  • The malignant Brenner tumor was stage IA.
  • Two patients who had borderline Brenner tumors were alive and well at 3 and 10.9 years.
  • The patient who had a malignant Brenner tumor died of pulmonary thromboembolism shortly postoperatively, and 2 patients with TCCs died of tumor 1.8 and 13 years, postoperatively.
  • Brenner tumors and TCCs differed mainly in the expression of EGFR, p16, and p53.
  • Benign Brenner tumors showed a low immunoexpression for all markers.
  • Borderline Brenner tumors failed to immunoreact for p16, Rb, and p53; and showed weak immunostaining for Cyclin D1, moderate for Ras, and strong for EGFR.
  • The malignant Brenner tumor was also negative for p16, Rb, and p53, and strongly positive for Cyclin D1, Ras, and EGFR.
  • Our results suggest that Brenner tumors and TCCs follow different tumorigenic pathways, whereas borderline and malignant Brenner tumors are low-grade neoplasms with activation of the PI3K/AKT pathway through EGFR, TCCs are high-grade tumors that have p53 mutations and p16 and p53 protein overexpression.
  • [MeSH-major] Brenner Tumor / pathology. Carcinoma, Transitional Cell / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. DNA Mutational Analysis. DNA, Neoplasm / analysis. Female. Fluorescent Antibody Technique, Direct. Gene Dosage. Genes, erbB-1 / genetics. Humans. Immunoenzyme Techniques. In Situ Hybridization, Fluorescence. Middle Aged. Neoplasm Staging. Ovariectomy. Tissue Array Analysis. Treatment Outcome


85. Denkert C, Dietel M: Borderline tumors of the ovary and peritoneal implants. Verh Dtsch Ges Pathol; 2005;89:84-91
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Borderline tumors of the ovary and peritoneal implants.
  • The new WHO series on Pathology and Genetics of Tumours of the Breast and Female Genital Organs (33) defined to name the group of epithelial ovarian tumors with a dignity between benign and malignant exclusively as Borderline Tumors of the Ovary (BOT) and to skip the term "... of low malignant potential".
  • Further, the term "atypical proliferative tumour" was not recommended by the WHO.
  • During a Consensus Meeting on Borderline Tumors of the Ovary held at Bethesda on August 27-28, 2003 (2) the expert panel also recommended to use the BOT terminology.
  • However the term "tumour of low malignant potential" and--less favourable--"atypical proliferative tumour" may be used as synonym.
  • Both groups agreed unanimously that the name carcinoma should not be included in the diagnosis.
  • The group of borderline ovarian tumors is heterogeneous.
  • 80 to 90% of the cases have a very favourable prognosis while 10-20% exhibit a recurrent clinical course with peritoneal implants and very rarely death from the tumor within 10 years.
  • The morphological criteria and supporting methods for recognizing unfavorable BOT and for distinguishing them from highly differentiated ovarian carcinomas are summarized.
  • The presented data focus on serous tumors since this is by far the most common variant.
  • [MeSH-major] Ovarian Neoplasms / pathology. Peritoneal Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Disease-Free Survival. Female. Humans. Meta-Analysis as Topic. Neoplasm Invasiveness. Neoplasm Staging. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18035677.001).
  • [ISSN] 0070-4113
  • [Journal-full-title] Verhandlungen der Deutschen Gesellschaft für Pathologie
  • [ISO-abbreviation] Verh Dtsch Ges Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


86. Kushida Y, Haba R, Kadota K, Doi T, Ishikawa M, Hirakawa E, Kira M: Composite mucinous and granulosa cell tumor of the ovary. Pathol Int; 2005 Dec;55(12):797-801
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Composite mucinous and granulosa cell tumor of the ovary.
  • A composite mucinous and granulosa cell tumor of the ovary in a 76-year-old woman is herein reported.
  • At laparotomy this tumor proved to be a solid and cystic mass measuring 10 cm in greatest diameter.
  • Many of the cysts were lined with a benign mucinous epithelium of the endocervical type, and solid areas contained a proliferation of granulosa cells.
  • The coexistence of mucinous and granulosa cell tumor is extremely rare and only four such cases have previously been reported in the literature, and the histogenesis of this tumor has not yet been elucidated.
  • In the present case it is suggested that the granulosa cell element commenced as a reactive stromal hyperplasia in the wall of the pre-existing mucinous neoplasm and thereafter progressed to the point of producing a tumor-like mass or neoplastic changes.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Granulosa Cell Tumor / pathology. Ovarian Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16287496.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


87. Giordano G, D'Adda T, Gnetti L, Merisio C, Raboni S: Transitional cell carcinoma of the endometrium associated with benign ovarian brenner tumor: a case report with immunohistochemistry molecular analysis and a review of the literature. Int J Gynecol Pathol; 2007 Jul;26(3):298-304
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transitional cell carcinoma of the endometrium associated with benign ovarian brenner tumor: a case report with immunohistochemistry molecular analysis and a review of the literature.
  • This neoplasm is very rare, with only 13 cases reported in the international literature.
  • In this paper, a new case of TCCE associated with benign ovarian Brenner tumor is described.
  • Moreover, immunohistochemical and molecular studies are carried out in the effort to establish the phenotype and etiology of this rare neoplasm.
  • The molecular study, by polymerase chain reaction (PCR) failing to reveal the presence of HPV DNA, demonstrates that neither the TCCE nor the ovarian Brenner tumor is caused by an HPV infection.
  • The association of TCCE with benign ovarian Brenner tumor could be a coincidental event.
  • Conversely, this finding could be the manifestation of a multicentric metaplastic process (neometaplasia), involving both the coelomic epithelium of the ovary and the Mullerian epithelium of the uterus, or the evidence of "field effect" that manifests differently at different anatomical sites.
  • In our view, other cases of TCCE associated with ovarian Brenner tumor should be reported to confirm the last 2 hypotheses.
  • [MeSH-major] Brenner Tumor / pathology. Carcinoma, Transitional Cell / pathology. Endometrial Neoplasms / pathology
  • [MeSH-minor] DNA, Neoplasm / chemistry. DNA, Neoplasm / genetics. Female. Humans. Immunohistochemistry. Middle Aged. Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17581415.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


88. Wright JD, Powell MA, Mutch DG, Rader JS, Gibb RK, Gao F, Herzog TJ: Relationship of ovarian neoplasms and body mass index. J Reprod Med; 2005 Aug;50(8):595-602
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship of ovarian neoplasms and body mass index.
  • OBJECTIVE: To describe the distribution of benign and malignant ovarian neoplasms among overweight and obese women.
  • STUDY DESIGN: A review of patients who presented with a preoperative diagnosis of a pelvic mass between 1996 and 2001 was performed; 1,096 patients were identified.
  • Women with normal body mass indices were more likely to have malignant ovarian tumors (35.2%) than were the overweight (23.9%) and obese (25.8%) women.
  • Conversely, borderline ovarian tumors were less frequent in women with body mass indices of <25 (5.7%) than in the overweight (13.1%) and obese (10.9%) patients.
  • Benign ovarian neoplasms occurred in 20-25% of the women.
  • CONCLUSION: Significant differences exist in the distribution of ovarian neoplasms among women with different body mass indices.
  • Obese women are more likely to have ovarian tumors of low malignant potential, while women with normal body mass indices more commonly have invasive ovarian tumors.
  • [MeSH-major] Body Mass Index. Obesity / complications. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Body Weight / physiology. Child. Cohort Studies. Female. Humans. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Ovarian Cysts / diagnosis. Ovarian Cysts / pathology. Retrospective Studies. Risk Factors

  • MedlinePlus Health Information. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Obesity in Children.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16220765.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Ye S, Hao X, Zhou T, Wu M, Wei J, Wang Y, Zhou L, Jiang X, Ji L, Chen Y, You L, Zhang Y, Xu G, Zhou J, Ma D, Wang S: Plexin-B1 silencing inhibits ovarian cancer cell migration and invasion. BMC Cancer; 2010;10:611
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plexin-B1 silencing inhibits ovarian cancer cell migration and invasion.
  • However, whether or not Plexin-B1 expression is involved in human ovarian tumors remains unclear.
  • In the present study, Plexin-B1 expression was explored in benign and malignant human ovarian tumor tissues.
  • In addition, the impact of Plexin-B1 expression on ovarian cancer cell proliferation, migration and invasion were investigated in vitro.
  • METHODS: Plexin-B1 expression was analyzed in normal and benign ovarian tissues and serous ovarian tumors (both borderline and malignant) by immunohistochemical staining, as well as in four human ovarian cancer cell lines (A2780, C13*, SKOV3, and OV2008) by RT-PCR and western blot analyses.
  • RESULTS: Expression levels of Plexin-B1 protein were significantly higher in serous ovarian carcinomas than in normal ovaries or benign ovarian neoplasms, and in the former, Plexin-B1 expression was positively correlated with lymphatic metastasis, and the membrane and cytoplasm of cancer cells stained positively.
  • SKOV3 cells displayed the highest Plexin-B1 expression at both the mRNA and protein levels among the four tested human ovarian cancer cell lines and was selected as a cell model for further in vitro experiments.
  • CONCLUSION: Plexin-B1 expression correlates with malignant phenotypes of serous ovarian tumors, probably via phosphorylation of AKT at Ser473, suggesting that Plexin-B1 might be a useful biomarker and/or a novel therapeutic target.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Gene Silencing. Nerve Tissue Proteins / genetics. Ovarian Neoplasms / genetics. Receptors, Cell Surface / genetics
  • [MeSH-minor] Adult. Aged. Cell Line, Tumor. Cell Movement. Cell Proliferation. Female. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Invasiveness. Proto-Oncogene Proteins c-akt / metabolism

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12457-62 [11035813.001]
  • [Cites] Mol Cancer. 2009;8:26 [19386116.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3498-504 [11369643.001]
  • [Cites] Trends Immunol. 2001 Dec;22(12):670-6 [11738997.001]
  • [Cites] Sci STKE. 2002 Apr 16;2002(128):re4 [11972358.001]
  • [Cites] Nat Cell Biol. 2002 Sep;4(9):720-4 [12198496.001]
  • [Cites] Ann Hematol. 2002;81 Suppl 2:S74 [12611086.001]
  • [Cites] J Biol Chem. 2004 Jan 16;279(3):1885-91 [14559914.001]
  • [Cites] Dev Cell. 2004 Jul;7(1):107-16 [15239958.001]
  • [Cites] Mol Endocrinol. 2004 Oct;18(10):2570-82 [15243131.001]
  • [Cites] Neuron. 1995 Jun;14(6):1189-99 [7605632.001]
  • [Cites] Nature. 1996 Oct 10;383(6600):525-8 [8849723.001]
  • [Cites] Cell Oncol. 2009;31(6):423-36 [19940359.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11780-5 [8876214.001]
  • [Cites] Cancer Res. 1998 Mar 15;58(6):1238-44 [9515811.001]
  • [Cites] J Cell Biol. 1999 Mar 22;144(6):1235-44 [10087266.001]
  • [Cites] Curr Opin Immunol. 1999 Aug;11(4):387-91 [10448143.001]
  • [Cites] Cell. 1999 Oct 1;99(1):71-80 [10520995.001]
  • [Cites] Blood. 2005 Jun 1;105(11):4321-9 [15632204.001]
  • [Cites] Cell Mol Life Sci. 2005 Jun;62(12):1363-71 [15818466.001]
  • [Cites] Cytokine Growth Factor Rev. 2005 Aug-Oct;16(4-5):535-48 [15979925.001]
  • [Cites] Mol Cell Biol. 2005 Aug;25(16):6889-98 [16055703.001]
  • [Cites] Cancer. 2000 Mar 15;88(6):1378-83 [10717620.001]
  • [Cites] Mech Dev. 2000 Oct;97(1-2):35-45 [11025205.001]
  • [Cites] Biochem J. 2005 Aug 15;390(Pt 1):125-36 [15839837.001]
  • [Cites] Dev Dyn. 2005 Oct;234(2):393-403 [16145665.001]
  • [Cites] Fertil Steril. 2005 Oct;84 Suppl 2:1210-9 [16210013.001]
  • [Cites] Biochem J. 2006 Mar 1;394(Pt 2):459-64 [16187944.001]
  • [Cites] Endothelium. 2006 Mar-Apr;13(2):81-91 [16728327.001]
  • [Cites] Nat Cell Biol. 2006 Jun;8(6):615-22 [16715077.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9017-22 [16754882.001]
  • [Cites] EMBO Rep. 2006 Jul;7(7):704-9 [16799460.001]
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1115-22 [17317819.001]
  • [Cites] OMICS. 2007 Spring;11(1):41-57 [17411395.001]
  • [Cites] Annu Rev Cell Dev Biol. 2007;23:263-92 [17539753.001]
  • [Cites] J Biol Chem. 2007 Nov 30;282(48):34888-95 [17855350.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Nov 27;104(48):19040-5 [18024597.001]
  • [Cites] J Biol Chem. 2008 Jan 25;283(4):1893-901 [18025083.001]
  • [Cites] Oncology. 2007;72(3-4):172-80 [18097168.001]
  • [Cites] Transl Res. 2008 Mar;151(3):134-40 [18279812.001]
  • [Cites] Protein Sci. 2008 Jun;17(6):1003-14 [18411422.001]
  • [Cites] Am J Pathol. 2008 Aug;173(2):545-60 [18599607.001]
  • [Cites] Mol Biol Cell. 2009 Mar;20(6):1728-36 [19158377.001]
  • [Cites] PLoS One. 2009;4(4):e5052 [19337377.001]
  • [Cites] Curr Biol. 2001 Mar 6;11(5):339-44 [11267870.001]
  • (PMID = 21059203.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Nerve Tissue Proteins; 0 / PLXNB1 protein, human; 0 / Receptors, Cell Surface; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  • [Other-IDs] NLM/ PMC2991310
  •  go-up   go-down


90. Van Holsbeke C, Van Belle V, Leone FP, Guerriero S, Paladini D, Melis GB, Greggi S, Fischerova D, De Jonge E, Neven P, Bourne T, Valentin L, Van Huffel S, Timmerman D: Prospective external validation of the 'ovarian crescent sign' as a single ultrasound parameter to distinguish between benign and malignant adnexal pathology. Ultrasound Obstet Gynecol; 2010 Jul;36(1):81-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective external validation of the 'ovarian crescent sign' as a single ultrasound parameter to distinguish between benign and malignant adnexal pathology.
  • OBJECTIVE: To determine the sensitivity and specificity of the 'ovarian crescent sign' (OCS)-a rim of normal ovarian tissue seen adjacent to an ipsilateral adnexal mass-as a sonographic feature to discriminate between benign and malignant adnexal masses.
  • METHODS: The patients included were a subgroup of patients participating in the International Ovarian Tumor Analysis (IOTA) Phase 2 study, which is an international multicenter study.
  • The gold standard was the histological diagnosis of the adnexal mass.
  • The ability of the OCS to discriminate between borderline or invasively malignant vs. benign adnexal masses, as well as between invasively malignant vs. other (benign and borderline) tumors, was determined and compared with the performance of subjective evaluation of ultrasound findings by the ultrasound examiner.
  • RESULTS: The OCS was evaluated in 1377 adnexal masses from 12 centers, 938 (68%) masses being benign, 86 (6%) borderline, 305 (22%) primary invasive and 48 (3%) metastases.
  • The OCS was present in 398 (42%) of 938 benign masses, in 14 (16%) of 86 borderline tumors, in 18 (6%) of 305 primary invasive tumors (one malignant struma ovarii, one uterine clear cell adenocarcinoma and 16 epithelial carcinomas, i.e. four Stage I and 12 Stage II-IV) and in two (4%) of 48 ovarian metastases.
  • For discrimination between invasive vs. benign or borderline tumors, the sensitivity for absent OCS was 94%, the specificity was 40%, the LR+ was 1.58 and the LR- was 0.14.
  • However it is a poor discriminator between benign and malignant adnexal masses.
  • [MeSH-major] Ovarian Neoplasms / ultrasonography. Ovary / ultrasonography
  • [MeSH-minor] Adnexal Diseases / ultrasonography. Diagnosis, Differential. Female. Humans. Neoplasm Staging. Predictive Value of Tests. Prospective Studies. Sensitivity and Specificity. Ultrasonography, Doppler

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 ISUOG. Published by John Wiley & Sons, Ltd.
  • (PMID = 20217895.001).
  • [ISSN] 1469-0705
  • [Journal-full-title] Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
  • [ISO-abbreviation] Ultrasound Obstet Gynecol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] England
  •  go-up   go-down


91. Khunamornpong S, Lerwill MF, Siriaunkgul S, Suprasert P, Pojchamarnwiputh S, Chiangmai WN, Young RH: Carcinoma of extrahepatic bile ducts and gallbladder metastatic to the ovary: a report of 16 cases. Int J Gynecol Pathol; 2008 Jul;27(3):366-79
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoma of extrahepatic bile ducts and gallbladder metastatic to the ovary: a report of 16 cases.
  • Information on ovarian metastasis of carcinoma of the extrahepatic bile ducts and gallbladder is limited.
  • Sixteen examples are reported; 3 primary tumors were hilar cholangiocarcinomas, 5 common bile duct carcinomas, and 8 gallbladder carcinomas.
  • The patients ranged from 21 to 87 years (mean, 59 years); 7 presented to gynecologists with nonspecific pelvic symptoms similar to primary ovarian neoplasms.
  • The primary tumor was identified before the detection of the ovarian lesions in 5 cases, was simultaneously detected with the ovarian metastases in 9, and was diagnosed postoperatively in 2.
  • All but one case had bilateral ovarian involvement.
  • The thirty-one ovarian lesions included twenty-nine grossly abnormal ovaries that were enlarged (range, 3.0-16.5 cm, mean, 9.4 cm) and 2 ovaries with only microscopic involvement.
  • Microscopically, ovarian surface implants were seen in 66%, multinodular growth in 58%, and infiltrative stromal invasion in 81%.
  • Mucinous epithelial differentiation was seen in 81%, sometimes with foci of benign-like or borderline-like epithelium simulating primary ovarian mucinous neoplasia.
  • Signet ring cells were present in sufficient quantity for a diagnosis of Krukenberg tumor in four tumors.
  • Colloid-type carcinoma was observed at least focally in 3 tumors.
  • Although the diagnosis of a metastatic tumor to the ovary is possible in most of the cases based on standard diagnostic criteria, problems in the differential diagnosis may be posed by morphologic patterns that overlap strikingly with primary ovarian neoplasms, benign, borderline, and malignant, as discussed herein.
  • [MeSH-major] Adenocarcinoma / pathology. Bile Duct Neoplasms / pathology. Gallbladder Neoplasms / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18580314.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Jain D, Akhila L, Kawatra V, Aggarwal P, Khurana N: Psammocarcinoma of ovary with serous cystadenofibroma of contralateral ovary: a case report. J Med Case Rep; 2009;3:9330

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Psammocarcinoma of ovary with serous cystadenofibroma of contralateral ovary: a case report.
  • INTRODUCTION: Psammocarcinoma of ovary is a rare serous neoplasm characterized by extensive formation of psammoma bodies, invasion of ovarian stroma, peritoneum or intraperitoneal viscera, and moderate cytological atypia.
  • Extensive medlar search showed presence of only 28 cases of psammocarcinoma of ovary reported till date.
  • CASE PRESENTATION: We herein report a case of psammocarcinoma of ovary with serous cystadenofibroma of contralateral ovary in a 55 year old Asian Indian female.
  • CONCLUSION: To the best of author's knowledge, ours is the rare case describing coexistence of this very rare malignant serous epithelial tumor with a benign serous cystadenofibroma of contralateral ovary.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Comput Assist Tomogr. 2007 May-Jun;31(3):490-2 [17538302.001]
  • [Cites] Gynecol Oncol. 2007 Apr;105(1):248-51 [17222893.001]
  • [Cites] Arch Gynecol Obstet. 2009 Jun;279(6):931-6 [18982336.001]
  • [Cites] Gynecol Oncol. 2009 Jun;113(3):402-4 [19345402.001]
  • [Cites] Arch Gynecol Obstet. 2009 Aug;280(2):283-6 [19096859.001]
  • [Cites] Int J Gynecol Cancer. 2009 Jul;19(5):844-6 [19574771.001]
  • [Cites] J Pathol. 2004 Mar;202(3):336-40 [14991899.001]
  • [Cites] Int J Gynecol Pathol. 1990;9(2):110-21 [2332269.001]
  • [Cites] Gynecol Oncol. 1995 Nov;59(2):309-11 [7590493.001]
  • [Cites] Pathologe. 1997 Nov;18(6):463-6 [9451736.001]
  • [Cites] South Med J. 1998 May;91(5):477-80 [9598860.001]
  • [Cites] Obstet Gynecol. 1998 Oct;92(4 Pt 2):659-61 [9764653.001]
  • [Cites] Gynecol Oncol. 2005 Jan;96(1):259-62 [15589614.001]
  • [Cites] Clin Nucl Med. 2005 Jun;30(6):395-9 [15891291.001]
  • [Cites] Gynecol Oncol. 2005 Nov;99(2):510-1 [16051342.001]
  • [Cites] Cytojournal. 2008;5:7 [18416848.001]
  • (PMID = 20072673.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2806332
  •  go-up   go-down


93. Saba L, Guerriero S, Sulcis R, Virgilio B, Melis G, Mallarini G: Mature and immature ovarian teratomas: CT, US and MR imaging characteristics. Eur J Radiol; 2009 Dec;72(3):454-63
MedlinePlus Health Information. consumer health - Ultrasound.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mature and immature ovarian teratomas: CT, US and MR imaging characteristics.
  • Ovarian teratomas (OTs) are the most common germ cell neoplasm.
  • They include mature cystic teratomas, monodermal teratomas (neural tumors, struma ovarii, carcinoid tumors) and immature teratomas.
  • Teratomas are the most common benign ovarian neoplasms in women less than 45 years old.
  • [MeSH-major] Magnetic Resonance Imaging / methods. Ovarian Neoplasms / diagnosis. Teratoma / diagnosis. Tomography, X-Ray Computed / methods. Ultrasonography / methods

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18804932.001).
  • [ISSN] 1872-7727
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Number-of-references] 93
  •  go-up   go-down


94. de Moura JP Jr, Nicolau SM, Stávale JN, da Silva Pinhal MA, de Matos LL, Baracat EC, de Lima GR: Heparanase-2 expression in normal ovarian epithelium and in benign and malignant ovarian tumors. Int J Gynecol Cancer; 2009 Dec;19(9):1494-500
SciCrunch. OMIM: Data: Gene Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heparanase-2 expression in normal ovarian epithelium and in benign and malignant ovarian tumors.
  • Several papers have associated the expression of heparanase 1 with various malignant tumors.
  • OBJECTIVE: The aim of this study was to evaluate the expression of heparanase 2 in epithelial neoplasia of the ovaries and in samples of normal ovarian tissue.
  • METHODS: Seventy-five ovary specimens were analyzed and divided into 3 groups: 23 malignant and 35 benign epithelial ovarian neoplasia and 17 without ovarian disease.
  • RESULTS: In the quantitative analysis, we found positivity indices for heparanase 2 expression of 72.2% and 87.3% in the samples of benign and malignant neoplasias, respectively.
  • In these, the intensity of expression and the expression index were 147.2 and 121.2, respectively, for the benign neoplasia and 134.1 and 118.0 for the malignant neoplasia.
  • Qualitatively, its expression was strong or moderate in 44.2% of the benign and 78.2% of the malignant tumors; its expression in all of the nonneoplastic samples was negative, with the exception of one that was weakly positive.
  • Furthermore, there was no difference in its expression between benign and malignant ovarian epithelial neoplasia.
  • [MeSH-major] Carcinoma / metabolism. Epithelium / metabolism. Glucuronidase / metabolism. Ovarian Neoplasms / metabolism. Ovary / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cell Proliferation. Cell Transformation, Neoplastic / metabolism. Disease Progression. Female. Humans. Middle Aged. Neoplasm Staging. Young Adult

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19955924.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.2.1.- / heparanase; EC 3.2.1.31 / Glucuronidase
  •  go-up   go-down


95. Suh-Burgmann E: Long-term outcomes following conservative surgery for borderline tumor of the ovary: a large population-based study. Gynecol Oncol; 2006 Dec;103(3):841-7
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcomes following conservative surgery for borderline tumor of the ovary: a large population-based study.
  • OBJECTIVES: To examine outcomes in women treated with conservative surgery for borderline ovarian tumor in a large population-based cohort with long-term follow-up.
  • METHODS: Women treated by conservative surgery for borderline tumor of the ovary from 1982-2004 within a large HMO setting were identified using electronic and tumor registry data.
  • The indications for and outcomes from any subsequent gynecologic surgery and the risk of recurrent ovarian borderline and malignant tumor were determined.
  • Patients were followed with remaining ovarian tissue in situ for a mean of 6.9 years, with 59 women having 10 or more years of such observation.
  • There were 21 recurrences with borderline tumor (11%) with a median time to first recurrence of 4.7 years; women treated by cystectomy recurred three times more often compared to women treated by oophorectomy (23% versus 7%).
  • Two patients (1%) recurred with malignant disease involving remaining ovarian tissue, both within the first 3 years after surgery, with one death due to recurrence.
  • During long-term follow-up, 19% of patients eventually underwent complete removal of ovarian tissue: in 8%, the surgery was prophylactic, in 5%, surgery was done for benign pathology, and in 6% for recurrent disease.
  • CONCLUSIONS: In this population-based HMO setting, 11% of women treated with conservative surgery for borderline tumor recurred; however, half of these recurrences were successfully managed by repeat conservative surgery, with only 6% of women overall needing eventual complete removal of ovaries for recurrent disease.
  • [MeSH-major] Neoplasm Recurrence, Local / surgery. Ovarian Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. California / epidemiology. Child. Cohort Studies. Disease-Free Survival. Female. Fertility. Gynecologic Surgical Procedures / methods. Gynecologic Surgical Procedures / utilization. Health Maintenance Organizations. Humans. Medical Records. Middle Aged. Neoplasm Staging. Postoperative Complications. Registries. Retrospective Studies. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16793124.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


96. Sedláková I, Vávrová J, Tosner J, Hanousek L: Lysophosphatidic acid: an ovarian cancer marker. Eur J Gynaecol Oncol; 2008;29(5):511-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lysophosphatidic acid: an ovarian cancer marker.
  • OBJECTIVE: To determine whether lysophosphatidic acid (LPA) can serve as an ovarian cancer marker, we compared plasma LPA levels in ovarian cancer patients, in women with no ovarian pathology, and in women with benign ovarian tumors.
  • METHOD: Capillary electrophoresis with indirect ultraviolet detection was used to analyze the plasma LPA levels of 133 patients (60 patients with ovarian cancer, 43 women without ovarian pathologies and 30 patients with benign ovarian tumors) during a three-year period.
  • RESULTS: Patients with ovarian cancer had a significantly higher plasma LPA level (n=60, median (med) 16.99 micromnol/l, range 4.53-43.21 micromol/l) compared with controls with no ovarian pathology (n=43, med 2.92 micromol/l, range 0.94-22.93 micromnol/l) and patients with benign ovarian tumor (n=30, med 7.73 micromol/l, range 1.12-28.84 micromol/l) (p < 0.001).
  • We found that plasma LPA levels were associated with the International Federation of Gynecology and Obstetrics (FIGO) stage and ovarian cancer histological type.
  • Patients with endometrial ovarian cancer had significantly higher plasma LPA levels in comparison with other histological types of epithelial ovarian carcinoma.
  • CONCLUSION: The plasma LPA level can be a useful marker for ovarian cancer, particularly in the early stages of disease.
  • [MeSH-major] Biomarkers, Tumor / blood. Lysophospholipids / blood. Ovarian Neoplasms / blood

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19051824.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Lysophospholipids; 22002-87-5 / lysophosphatidic acid
  •  go-up   go-down


97. Agaba EI, Ekwempu CC, Ugoya SO, Echejoh GO: Meigs' syndrome presenting as haemorrhagic pleural effusion. West Afr J Med; 2007 Jul-Sep;26(3):253-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The association of a benign ovarian tumor with ascites and hydrothorax that resolve after tumor resection, known as Meigs syndrome is a rare clinical entity.
  • Rarer still is the haemorrhagic form of the syndrome OBJECTIVE: To describe a case of benign ovarian tumour associated with ascites and bloody pleural effusion.
  • RESULTS: The physical examination and a pelvic ultrasonographic scan revealed ascites in addition to a right sided ovarian mass.
  • The pleural effusion and ascites resolved spontaneously thus confirming the diagnosis of Meigs' syndrome.
  • CONCLUSION: Meigs' syndrome should be considered in the differential diagnosis in female patients with hemorrhagic pleural effusion.
  • [MeSH-major] Hemothorax / diagnosis. Meigs Syndrome / diagnosis. Pleural Effusion / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Fibroma / diagnosis. Fibroma / surgery. Hemorrhage / diagnosis. Hemorrhage / etiology. Hemorrhage / surgery. Humans. Ovarian Neoplasms / ultrasonography. Ovariectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18399347.001).
  • [ISSN] 0189-160X
  • [Journal-full-title] West African journal of medicine
  • [ISO-abbreviation] West Afr J Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


98. Nowak M, Glowacka E, Szpakowski M, Szyllo K, Malinowski A, Kulig A, Tchorzewski H, Wilczynski J: Proinflammatory and immunosuppressive serum, ascites and cyst fluid cytokines in patients with early and advanced ovarian cancer and benign ovarian tumors. Neuro Endocrinol Lett; 2010;31(3):375-83
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proinflammatory and immunosuppressive serum, ascites and cyst fluid cytokines in patients with early and advanced ovarian cancer and benign ovarian tumors.
  • OBJECTIVE: To analyze the profiles of interleukin-2 (IL-2), IL-6, IL-8, IL-10, tumor necrosis factor-alpha (TNF-alpha), transforming growth factor-beta1 (TGF-beta1) and interferon-gamma (IFN-gamma) in serum and the tumor microenvironment (cyst fluid, ascites) in women with ovarian cancer or benign ovarian tumors to find the differences in their immunological status.
  • We also estimated serum cytokines as biomarkers to distinguish preoperatively between malignant or benign character of tumors.
  • POPULATION: 51 women with epithelial ovarian cancer, 26 with benign ovarian tumors of epithelial origin and 21 healthy controls.
  • RESULTS: We did not found differences in the levels of IFN-gamma, TNF-alpha and IL-2 in all fluids isolated from patients with malignant or benign tumors.
  • Women with advanced cancer had significantly higher serum IL-6, IL-10 and TGF-beta1 levels than women with early stages or benign tumors.
  • The concentrations of IL-6 and IL-8 were higher in ascites of cancer patients than in ascites of women with benign tumors.
  • CONCLUSIONS: Our results indicate on intensified inflammatory process in women with ovarian cancer (accompanied by their immunosuppression).
  • Preoperative analysis of serum IL-6, IL-10 and IL-8 may improve the differential diagnosis of ovarian tumors.
  • [MeSH-major] Ascites / metabolism. Cyst Fluid / metabolism. Cytokines / metabolism. Ovarian Neoplasms / immunology
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Middle Aged

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20588232.001).
  • [ISSN] 0172-780X
  • [Journal-full-title] Neuro endocrinology letters
  • [ISO-abbreviation] Neuro Endocrinol. Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / Cytokines
  •  go-up   go-down


99. Marchesini AC, Magrio FA, Berezowski AT, Neto OB, Nogueira AA, Candido dos Reis FJ: A critical analysis of Doppler velocimetry in the differential diagnosis of malignant and benign ovarian masses. J Womens Health (Larchmt); 2008 Jan-Feb;17(1):97-102
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A critical analysis of Doppler velocimetry in the differential diagnosis of malignant and benign ovarian masses.
  • OBJECTIVES: To evaluate the intratumoral reliability of color Doppler parameters and the contribution of Doppler sonography to the gray-scale differential diagnosis of ovarian masses.
  • METHODS: An observational study was performed including 67 patients, 15 (22.4%) with malignant ovarian neoplasm and 52 (77.6%) with benign ovarian diseases.
  • CONCLUSIONS: Gynecologists must be careful in interpreting results from Doppler evaluation of ovarian masses because PSV and EDV present poor intratumoral reliability.
  • The lower RI value, evaluated in at least two distinct sites of the tumor, was able to improve the performance of gray-scale ultrasound in differential diagnosis of ovarian masses.
  • [MeSH-major] Laser-Doppler Flowmetry. Ovarian Diseases / ultrasonography. Ovary / blood supply
  • [MeSH-minor] Blood Flow Velocity. Diagnosis, Differential. Female. Humans. Neovascularization, Pathologic / ultrasonography. Ovarian Neoplasms / ultrasonography. Reproducibility of Results. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Ovarian Disorders.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18240986.001).
  • [ISSN] 1540-9996
  • [Journal-full-title] Journal of women's health (2002)
  • [ISO-abbreviation] J Womens Health (Larchmt)
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


100. Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, Steinhoff M, Messerlian G, DiSilvestro P, Granai CO, Bast RC Jr: The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol; 2008 Feb;108(2):402-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass.
  • OBJECTIVES: The CA125 tumor marker is used to help predict the presence of ovarian cancer in patients with an adnexal mass.
  • Because elevated CA125 levels occur in many benign gynecologic conditions, we set out to identify other novel biomarkers that would increase the sensitivity and specificity of CA125.
  • Of these, 233 patients were eligible for analysis with 67 invasive epithelial ovarian cancers and 166 benign ovarian neoplasms.
  • Mean values for all marker levels except Her2 differed significantly between patients with benign masses and cancer.
  • CONCLUSIONS: As a single tumor marker, HE4 had the highest sensitivity for detecting ovarian cancer, especially Stage I disease.
  • [MeSH-major] Biomarkers, Tumor / blood. Biomarkers, Tumor / urine. Ovarian Neoplasms / blood. Ovarian Neoplasms / urine. Pelvic Neoplasms / blood. Pelvic Neoplasms / urine






Advertisement